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Background: Brachial artery flow-mediated dilatation (FMD) and carotid artery intima-media 
thickness (IMT) are measures of vascular endothelial function and subclinical atherosclerosis 
respectively. Both endothelial dysfunction and subclinical atherosclerosis have been linked with HIV 
and antiretroviral therapy (ART) in the developed world. Furthermore, known biomarkers of 
inflammation and endothelial dysfunction can be measured to predict cardiovascular outcomes in HIV-
infected individuals. The exact link between endothelial dysfunction, atherosclerosis, HIV, ART and 
the biomarkers remains inconclusive, particularly in South African and Western Cape populations. 
Aims: To investigate the putative relationship between subclinical atherosclerosis, endothelial 
dysfunction, biomarkers of cardiovascular disease (CVD), and HIV-infection in a Western Cape study 
population. 
Methods: Two different epidemiological studies were performed: a cross-sectional main study (HIV-
infected, n= 204 of whom on ART n=188 and without ART n= 16; and HIV-free, n= 143), and a 
longitudinal sub-study to assess the 12-month temporal progression of selected CVD outcomes (HIV-
free, n= 57). For both studies, participants were recruited from health clinics in Cape Town and 
Worcester between 2017 and 2018. Lifestyle and health data were collected, and vascular (FMD% and 
IMT by ultrasound technology), anthropometric (body-mass-index [BMI]; waist circumference [WC]), 
cardiovascular (lipid profile; blood pressure [BP]; plasma glucose), renal (creatinine; urine albumin 
creatinine ratio [ACR]), liver (gamma-glutamyl-transferase [GGT]) and HIV-related (viral load; CD4, 
duration of HIV, duration of treatment) measures were obtained. Serum biomarkers were analyzed 
using Luminex technology, including C-reactive protein (CRP), tumour necrosis factor-alpha (TNF-α), 
vascular endothelial growth factor (VEGF), plasminogen activator inhibitor-1 (PAI-1) and adhesion 
molecules (intercellular adhesion molecule-1 [ICAM-1], vascular cellular adhesion molecule-1 
[VCAM-1], e-selectin, p-selectin).  
Results: In the longitudinal study (mean age: 45 years), WC, plasma glucose, BP, and hypertension, 
increased at 12-months follow-up. In the cross-sectional study (mean age: 41 years), the HIV-infected 
group showed a lower BMI, WC, BP, hypertension and PAI-1 versus the HIV-free group (p<0.05), 
whereas anaemia, ACR, creatinine, GGT and VCAM-1 were increased in the HIV-infected group 
(p<0.05). Additionally, viral load and VCAM-1 levels were higher in the HIV-infected without ART 
group versus the ART treated group (p<0.05). CD4 count, total cholesterol, HDL, LDL, hemoglobin, 
GGT, creatinine levels were higher in the ART group compared to the ART naïve group (p<0.05). Flow 
mediated dilatation (FMD) was higher and IMT was lower in the ART group versus ART naïve group 
(p<0.05). Furthermore, no significant correlations were found between biomarkers and FMD and IMT. 





IMT (p<0.001), while in the HIV-free group, age, high systolic BP, obesity and LDL cholesterol 
positively associated with IMT (p<0.05). In the HIV-infected group, ART positively associated, while 
viral load inversely associated with FMD%. In the HIV-free group, creatinine inversely associated with 
FMD% (p<0.05). 
Discussion and conclusion: Overall, our study showed a higher presence and progression of 
cardiovascular risk parameters in the HIV-free population. In the HIV context, ART showed a more 
cardioprotective and immune-protective effect, where it was associated with reduced subclinical 
atherosclerosis and improved endothelial function. Our study confirmed that age is an independent 









Agtergrond: Bragiale arterie vloei-gemedieerde dilatasie (FMD) en karotis arterie intima-media dikte 
(IMD) verteenwoordig die meting van vaskulêre endoteelfunksie en subkliniese aterosklerose 
onderskeidelik. Voorheen het studies in ontwikkelde lande aangetoon. Daar is voorheen tudies in 
ontwikkelde lande aangetoon dat beide endoteeldisfunksie en subkliniese aterosklerose ‘n verband met 
MIV en antiretrovirale terapie (ART) toon. Verder kan verskeie inflammatoriese en endoteeldisfunksie 
biomerkers gemeet word om kardiovaskulêre uitkomste in MIV-geïnfekteerde populasies te voorspel. 
Die presiese verband tussen endoteeldisfunksie, aterosklerose, MIV, ART en die biomerkers is nog nie 
heeltemal verklaar of duidelik nie nie, veral nie in Suid-Afrikaanse en Wes-Kaapse bevolkings nie. 
Doelstelling: Om die potensiele vermoedelike verband tussen subkliniese aterosklerose, 
endoteeldisfunksie, kardiovaskulêre biomerkers en MIV-infeksie in ‘n Wes-Kaapse studiebevolking te 
ondersoek. 
Metodiek: Twee verskillende epidemiologiese studies was onderneem: ‘n deuranit hoofstudie (MIV-
geïnfekteer, n= 204 waarvan n=188 op ART was, en n=16 ART sonder;  MIV negatief is, n= 143), en 
‘n longitudinale sub-studie om die 12-maande progressie van geselekteerde kardiovaskulêre uitkomste 
te ondersoek (MIV negatief, n= 57). Deelnemers was by gesondheidsklinieke in Kaapstad en Worcester 
tussen 2017 en 2018 gewerf. Lewenstyl- en gesondheidsinligting was ingesamel, asook vaskulêre (FMD 
en IMD met behulp van ultraklank tegnologie), antropometriese (liggaamsmassa-indeks [LMI]; 
middelomtrek [MO]), kardiovaskulêre (lipiedprofiel; bloeddruk [BP]; plasma glukose), nier (kreatinien; 
urien albumien-kreatinienverhouding [ACR]), lewer (gamma glutamieltransferase [GGT]) en MIV-
verwante (virale lading; CD4, duur van MIV-infeksie, duur van behandeling) metings was ingesamel. 
Serum biomerkers was met behulp van Luminex tegnologie geanaliseer, insluitende C-reaktiewe 
proteïen (CRP), tumor nekrose faktor-alfa (TNF-α), vaskulêre endoteel groeifaktor (VEGF), 
plasminogeen-aktiveerder- inhibeerder-1 (PAI-1), en aanhegtingsmolekules (intersellulêre 
adhesiemolekule-1 [ICAM-1], vaskulêre sellulêre adhesiemolekule-1 [VCAM-1], e-selektien, p-
selektien). 
Resultate: In die longitudinale studie (gemiddelde ouderdom: 45 jaar), het WC, plasma glukose, BP, 
en hipertensie toegeneem na 12 maande. In die deursnitstudie (gemiddelde ouderdom: 41 jaar), was 
BMI, WC, BP, hipertensie en PAI-1 laer in die MIV-geïnfekteerde groep in vergelyking met die geen 
MIV groep (p<0.05), terwyl anemie, ACR, kreatinien, GGT and VCAM-1 verhoog was in die MIV- 
geïnfekteerde groep (p<0.05). Verder was die virale lading en VCAM-1 vlakke hoër in die 
onbehandelde MIV-geïnfekteerde groep in vergelyking met die ART groep (p<0.05). CD4 telling, 
totale cholesterol, HDL, LDL, hemoglobien, GGT en kreatinien vlakke was hoër in die ART groep 
(p<0.05 vs onbehandeld). FMD was hoër en IMT laer in die ART groep (p<0.05 vs. onbehandeld). 





Wat onafhanklike assosiasies betref, het ouderdom positief geassosieer met IMT in die MIV-
geïnfekteerde groep (p<0.001), terwyl ouderdom, hoë sistoliese bloeddruk, vetsug en LDL cholesterol 
positief met IMT geassosieer was in die kontrole groep (p<0.05). In die MIV-geïnfekteerde groep het 
ART positief geassosieer met FMD%, terwyl virale lading omgekeerd geassosieer met FMD%. In die 
geen MIV groep, was kreatinien omgekeerd geassosieer met FMD% (p<0.05). 
Bespreking en gevolgtrekking: Oor die algemeen het ons studie ‘n hoër teenwoordigheid en progressie 
van kardiovaskulêre risikofaktore in die geen MIV groep getoon. In die geval van die MIV-
geïnfekteerde deelnemers, het ART behandeling meer kardio- en immuunbeskermende effekte getoon, 
waar dit met verlaagde subkliniese atereosklerose en beter endoteelfunksie geassosieer was. Die studie 
het ook bevestig dat ouderdom ‘n onfhanklike voorspeller van subkliniese aterosklerose is, terwyl virale 
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Chapter 1: Introduction 
 
1.1 Context of the PhD study  
This PhD study is embedded in a larger multinational parent study named EndoAfrica, which is led by 
Prof Hans Strijdom (PhD supervisor).  The overarching aim of the EndoAfrica parent study is to assess, 
in a longitudinal fashion, whether there is a link between HIV, antiretroviral therapy (ART) and 
cardiovascular risk factors, as well as endothelial structure and function, in South Africa. In addition to 
the Stellenbosch University group, the EndoAfrica research consortium consists of partners and 
collaborators from the Medical University of Graz (Austria), Prof Nandu Goswami (co-supervisor), 
Hasselt University (Belgium), Prof Tim S. Nawrot, and the University of Antwerp, (Belgium), Prof 
Patrick De Boever (co-supervisor). The PhD supervisor (Prof Hans Strijdom) is the national and 
international project coordinator and the leader of the EndoAfrica consortium.  
 
1.2 Significance of the PhD study  
Currently, South Africa is faced with a double burden of disease, with communicable diseases such as 
HIV on the one hand, and non-communicable diseases such as cardiovascular diseases (CVD) on the 
other. The underlying pathophysiological origin of many CVD is atherosclerosis and endothelial 
dysfunction, which can clinically and non-invasively be measured using validated gold standard 
techniques such as carotid artery intima-media thickness (IMT) and brachial artery flow-mediated 
dilatation (FMD), respectively. Both atherosclerosis and endothelial dysfunction can potentially be 
prevented, and endothelial dysfunction has been shown to be a predictor of future CVD in patients, 
especially if detected early in preclinical stage.  
Interestingly, Today, CVD has become a major cause of death in the HIV population, partially due to 
increased lifespan of these individuals with the success of ART, as well as due to direct effects of the 
ART drugs. There is a lack of data from studies assessing cardiovascular risk factors in HIV infected 
individuals in low income countries, including in South Africa. A large body of research on this topic 
exists in the more affluent countries in Europe and North America, highlighting a gap in research on 
this topic in South Africa. Additionally, very few studies have investigated the association between 
HIV/ ART and, endothelial dysfunction and atherosclerosis in South Africa. The interaction between 
factors linked with CVD and HIV, especially with ART addition is vastly complex and their overall 
impact on the cardiovascular system warrants further investigation. Furthermore, there are circulating 
biomarkers that are associated with endothelial dysfunction and atherosclerosis, which can be screened 
and measured to predict cardiovascular outcomes in the HIV population. Hence the current study aims 
to address this gap in research especially in the South African context, where the country is known to 





the putative relationship between subclinical atherosclerosis, endothelial dysfunction, biomarkers of 
cardiovascular disease, and HIV-infection in a South African population from the Western Cape 
Province. 
 
1.3 Overarching aim of this PhD study 
The main aim of the PhD study is to contribute in a novel and innovative way, to the scientific research 
body both at a national and international level in the fields of HIV and CVD. More specifically, the 
study aims to explore the important interaction between HIV, endothelial function and markers of 
subclinical atherosclerosis by shedding light on specific questions regarding HIV-associated 
cardiovascular risk and disease in a study cohort of adult volunteer participants living in Western Cape, 
South Africa. The study has an epidemiological approach with a cross-sectional design. In addition, a 
longitudinal sub-study was performed to explore the progression of selected CVD outcomes. 
Furthermore, the PhD dissertation aims to explore the relevance of specific imaging techniques and 
biomarkers of CVD, novel in the context of the South African research environment, and their 
relationship with HIV in the study population.  
 
1.4 The structure of the dissertation 
The dissertation is divided into six chapters, including this chapter 1. Refer to figure 1.1, which 
provides a schematic representation of the structure of this dissertation. The literature review (chapter 
2) is divided into three sections; (i) section A, exploring CVD and underlying mechanisms, section B, 
focusing on HIV and its mechanisms, followed by (ii) a comprehensive literature analysis regarding the 
link between HIV and CVD, and (iii) concluding with a rationale as well as aims and objectives of this 
PhD study in section C. This is followed by the methodology applied in the study (chapter 3) and results 
(Chapter 4) which is divided into two sections, section A comprising of results of the main cross-
sectional study and section B, reporting on results from the longitudinal sub-study. The discussion 
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Chapter 2: Literature review 
 
2.1 Introduction 
This chapter serves to critically appraises the current literature pertaining to the relevant themes of the 
PhD study. The chapter is divided into three sections (refer to figure 2.1), and aims to systematically 
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Section A: Cardiovascular disease and its underlying mechanisms 
 
2.2 Cardiovascular disease 
2.2.1 Introduction and Epidemiology 
Cardiovascular disease (CVD) is a non- communicable disease (NCD) that largely represents ailments 
of the heart and blood vessels. At present, CVD is the leading cause of morbidity and mortality in the 
world. In fact, the United Nations, identified NCDs, including CVD, as a major global health concern 
which is increasingly hindering sustainable human development (Roth et al., 2017).  
Approximately 71% of all deaths globally is attributed to NCDs, with CVD representing the greatest 
contributor. The high CVD prevalence has been linked to increased socio-economic costs including 
disability, loss of productivity as well as increasing poverty and health inequality. The poor 
communities in the urban areas have the worst CVD outcomes, largely due to their inability to access 
or afford preventative services and chronic treatments (Cappuccio and Miller, 2016). The World Health 
Organization (WHO) reports approximately 18 million CVD related deaths annually, of which more 
than 75% occurs in low to middle income countries. The high-income countries are demonstrating a 
decline in CVD related mortality rates, possibly due to improved management strategies of CVD, 
including prevention and reducing risk factors pertaining to it (Cappuccio and Miller, 2016; Yusuf, 
Rangarajan et al., 2014). In contrast, the current global CVD burden of 80% originates from low to 
middle income countries (Cappuccio, Miller 2016, Yusuf, Rangarajan et al., 2014).  
The sub-Saharan Africa (SSA) region, consisting of low to middle income countries, is predicted to 
show an increase in NCDs, due to epidemiological and demographical transitions. Furthermore, this 
region also has a high incidence of CVD, which has developed into a major health concern due to its 
growing mortality and morbidity rates (Dalal et al., 2011). The World bank classifies South Africa as a 
middle-income country in the SSA region, where NCD related mortality rates have now exceeded the 
known burden of HIV/ AIDS and tuberculosis (infectious diseases), with CVD being the largest 
contributor (Schutte, 2019). In 2009, the WHO estimated that South Africa will have a two to three 
times higher burden of NCD (including CVDs) compared to the developed countries, with 
disproportionate effect on the poor in the urban settings (Mayosi et al., 2009). Additionally, it was 
predicted that there will be a 41% increase in CVD related mortality in South Africa between the year 
2000 and 2030 (Mpe 2010). Recently, the NCD Countdown 2030 (which is a collaboration between the 
WHO, The Lancet, NCD Alliance (a network of civil society organisations) and the Imperial College, 
London), further suggests that South Africa has a 51.9% probability of NCD related mortality (NCD 






2.2.2 Cardiovascular risk factors 
According to the WHO, a risk factor is any characteristic or exposure that increases the probability of 
developing a disease or injury in an individual (WHO, 2017). The Framingham Heart Study was one of 
the first studies to conceptualize risk factors pertaining to CVDs (Kannel et al., 1961). The World Health 
Federation further divided these CVD risk factors into modifiable and non-modifiable categories, which 
will be discussed below (World Heart Federation, 2017). A large portion of CVD risk can be attributed 
to modifiable risk factors such as hypertension, smoking, obesity, unhealthy diet, physical inactivity, 
dyslipidaemia, and diabetes mellitus, all of which account for 61% of global CVD related mortality 
worldwide (Cappuccio and Miller, 2016). Approximately 84% of the global burden of CVD that is 
caused by modifiable risk factors occur in low to middle income countries, including countries of SSA, 
where CVD risk factors are mostly similar in comparison to the rest of the world (Mensah, 2013). 
Studies indicate that eliminating these risk factors may improve the average global life expectancy by 
approximately five years (WHO, 2009). Refer to table 2.1 for a summary of modifiable and non-
modifiable risk factors. 
Table 2.1: Summary of modifiable and non-modifiable CVD risk factors (Balakumar, Maung-u and 
Jagadeesh, 2016). 
Modifiable Risk factors Non- modifiable Risk factors 
Hypertension Age 
Smoking Sex 
Obesity Family history of CVD 
Unhealthy diet Ethnic or Cultural factors 
Physical inactivity Socio economic factors 
Dyslipidaemia  
Type 2 Diabetes Mellitus  
Excessive use of alcohol  
Stress & Depression  
 
2.2.2.1 Modifiable risk factors: 
Hypertension 
Hypertension is regarded by many as the most common, modifiable, and independent CVD risk factor 
(WHO, 2016; Balakumar, Maung-u and Jagadeesh, 2016). It is defined as a systolic blood pressure 
reading of ≥ 140 mmHg and/or a diastolic blood pressure of ≥ 90 mmHg, following repeated 
examination (Seedat et. al., 2011; Unger et. al., 2020). Hypertension is known to be a major cause of 
premature death, due to its ‘silent’ (asymptomatic) nature. Typically, hypertension has a negative 





coronary heart disease (CHD). Furthermore, hypertension has been found to cause approximately half 
of all ischemic strokes and an increased risk of hemorrhagic stroke (Balakumar, Maung-u and 
Jagadeesh, 2016). There are many behavioural characteristics that can make individuals more 
susceptible to hypertension, these include unhealthy diets (high salt, saturated and trans-saturated fat, 
low dietary potassium through reduced consumption of fruits and vegetables), lack of physical exercise, 
obesity and excessive intake of alcohol and tobacco. Furthermore, a family history of hypertension, age 
over 65 years and comorbidities with diabetes and kidney disease can also increase the risk of 
hypertension. The WHO has found an increase in the global hypertension prevalence from 595 million 
in 1975 to approximately 1.13 billion in 2015. The increase was largely seen in low to middle income 
countries, probably due to increase in hypertension risk factors in those regions (WHO, 2019; Antignac 
et al., 2018). The SSA region has particularly noticed an increase in the burden of hypertension, 
especially due to the fact that the affected populations remain undiagnosed, untreated or inadequately 
treated, which, therefore leads to a higher morbidity and mortality risk (Ataklte et al., 2014). The Heart 
and Stroke Foundation estimates that more than a third of individuals are living with hypertension in 
South Africa, further contributing to the CVD epidemic in this country (Heart and Stroke Foundation 
South Africa, 2016).  
Tobacco use (smoking) 
After hypertension, smoking is found to be the second leading cause of CVD. Approximately 10% of 
all CVDs can be attributed to tobacco use. Globally, smoking (including second hand smoking) is 
thought to result in approximately 6 million deaths every year, which is further predicted to increase to 
8 million annually by 2030 (WHO, 2015; Balakumar, Maung-u and Jagadeesh, 2016). The use of 
tobacco has been shown to cause short term increases in blood pressure, reduced oxygen capacity of 
blood and increased clotting tendency of the blood, all of which could lead to a range of CVDs. 
Furthermore, smoking has been linked to increase blood triglycerides while decreasing HDL 
(Balakumar, Maung-u and Jagadeesh, 2016). Ultimately, smoking has been associated with an increased 
risk of atherosclerosis (discussed in section 2.2.3). Globally, approximately 1.1 billion people smoked 
tobacco in 2015 (WHO, 2015). The WHO reports that many countries today show a decline in smoking 
including in SSA, however, there still appears to be an increase in smoking in the Eastern Mediterranean 
and in some parts of African Region.  At present, SSA has a considerable variation in the smoking 
prevalence among countries, with 26.5% in Zambia, to 60% in Sierra Leone (Owusu-Dabo et al., 2009; 
Brathwaite et al., 2015; Murphy, Liu and Parascandola, 2018). However, due to limited data, these 
estimations cannot be conclusive. South Africa was reported to have approximately 20% prevalence of 








Obesity is a chronic disease affecting individuals of all ages and is sometimes referred to as ‘adiposity’, 
which refers to increased amounts of adipose (fat) tissue in the body. A benchmark for normal adiposity 
remains unknown, however, adiposity is essentially when there is an imbalance between the energy 
(calories) intake and energy (calories) used (Arboix, 2015).  Increased body fat has been linked to many 
other CVD risk factors, such as hypertension, dyslipidaemia, type 2 diabetes and vascular diseases. 
Body mass index (BMI) is a well-known measure of obesity and overweight. BMI is calculated as 
bodyweight in kilograms divided by height in meters squared (Piché et al., 2018). The WHO has 
classified BMI into various weight categories, refer to table 2.2 (WHO, 2016). Waist circumference 
and waist-to-hip ratio are commonly used to measure abdominal obesity, which in the South African 
context is clinically defined by waist circumference of more than or equal to 94 cm in males and 80 cm 
in females (Alberti et al., 2009; Seedat and Rayner, 2013). The development of many comorbidities is 
dependent on the BMI as well as the degree of obesity (Piché et al., 2018). Research suggests that obese 
individuals are at higher risk of developing CVD and manifestations thereof, especially CHD, angina, 
myocardial infarction, heart failure and sudden cardiac death (Piché et al., 2018). Studies have shown 
that visceral fat/ abdominal obesity is a strong risk factor for developing CVD and metabolic 
complications (Piché et al., 2018). According to the WHO, more than 1.9 billion adults were found to 
be overweight with 650 million obese (WHO, 2016). At present, obesity is linked with 2.8 million 
deaths annually. Traditionally, being overweight or obese was more prevalent in high-income countries, 
however the trend has greatly moved towards low to middle income countries, with females particularly 
affected, in urban settings of the SSA region (Scott et al., 2013). With regards to South Africa, there is 
an increased burden of obesity, in fact, South Africa is found to have the highest prevalence of obesity 
in the SSA region (Tugendhaft et al., 2016). 
Table 2.2: Classification of obesity according to BMI (Balakumar, Maung-u and Jagadeesh, 2016; 
WHO guidelines). 
BMI (kg/𝐦𝟐) Categories 
< 18.5 Underweight 
18.5–24.9 Normal weight 
25.0–29.9 Overweight 
30.0–34.9 Obesity (class I) 
35.0–39.9 Obesity (class II) 
≥ 40.0 Obesity (class III) 
≥ 50 Obesity (class IV) 






Poor intake of fruits and vegetables, and high intake of saturated and trans-fat as well increased salt 
intake have been linked with increased weight gain and CVD risk (Balakumar, Maung-u and Jagadeesh, 
2016). Reduced intake of fruits and vegetables may account for approximately 20% of CVD globally. 
(World Health Federation, 2018) According to the WHO, 1.7 million deaths globally are due to low 
fruit and vegetable consumption (WHO, 2018). High salt intake is an important determinant of 
hypertension and cardiovascular risk (Ha, 2018). Similarly increased consumption of saturated and 
trans-fat is linked with heart disease and stroke (Balakumar, Maung-u and Jagadeesh, 2016). With 
westernization, processed foods with elevated levels of salt and fat have slowly been infiltrating 
countries such as South Africa, ultimately contributing to CVD (Spires et al., 2016).  
Physical inactivity  
Insufficient physical activity is a major CVD risk factor and places individuals at risk for developing 
cardio-metabolic diseases such as diabetes mellitus (Balakumar, Maung-u and Jagadeesh, 2016). 
Physical inactivity is a term used to identify people who do not get the recommended level of regular 
physical activity or exercise. The American Heart Association recommends 30-60 minutes of aerobic 
exercise three to four times per week to promote cardiovascular fitness.  In general, individuals who 
achieve less than 30 minutes of moderate intensity physical activity per week are thought to be 
physically inactive (CDC and American Heart association, 2020). Overall, physical inactivity is thought 
to be amongst the top ten leading risk factors for death worldwide (World Health Federation, 2016).  
 Advantages of sufficient exercise include a reduction in CVD related mortality, increased exercise 
capacity as well as with enhanced quality of life (González and Fuentes, 2017). Furthermore, a study 
showed that total physical activity, running, weight training, and walking were each associated with 
reduced CHD risk (Tanasescu et al., 2002); while the WHO states that insufficient physical activity can 
increase the risk of mortality by 20 - 30% in comparison to individuals who are sufficiently active 
(WHO, 2018). According to the WHO, physical inactivity has led to approximately 3.2 million deaths 
worldwide (WHO, 2015) The United States of America and the Eastern Mediterranean areas are found 
to have the highest prevalence of physical inactivity, with males found to be more active than females 
in almost every country. In the African region, many countries have reported high prevalence of 
physical inactivity, such as Swaziland with 49.1% and Mauritania with 52.6% prevalence in adults. As 
with many developing countries, South Africa is undergoing nutritional, lifestyle and socioeconomic 
transitions, which may in some ways be unfavourable to the health of individuals. It is estimated that 






Dyslipidaemia is characterized by abnormal blood concentrations of one or more of the following: total 
cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and 
triglycerides (Arboix, 2015; Noubiap et al., 2018). Dyslipidaemia is one of the leading contributors to 
CVD and mortality worldwide (Noubiap et al., 2018).  Important risk factors for CVD and stroke is 
high levels of LDL cholesterol and triglycerides (Tanne et al., 2001). Approximately one third of 
ischemic heart disease is attributed to dyslipidaemia (Balakumar, Maung-u and Jagadeesh, 2016). Many 
studies demonstrate a decreased risk of heart disease when dyslipidaemia is controlled. High LDL 
cholesterol levels play a pivotal role in the initiation and progression of atherosclerosis (as described in 
section 2.2.3), thus directly contributing to CVD (Hansson, 2017; Pasquel and Gregg, 2019). Elevated 
triglyceride levels are also known to contribute to CVD. In contrast, HDL cholesterol is found to have 
protective characteristics in atherosclerosis and thus has an inverse relation with the development of 
CHD ( Robert et al., 2016). Overall low HDL has been associated with increased risk of developing 
CVD. In 2016, elevated total cholesterol levels were associated with 4.4 million deaths (Noubiap, 
Bigna, Nansseu, Nyaga, Balti, Justin B. Echouffo-Tcheugui, et al., 2018). In 2011, approximately 25% 
of adults from low-income countries and more than 50% of adults from high-income countries reported 
elevated total cholesterol (Balakumar, Maung-u and Jagadeesh, 2016). In South Africa, diabetes as well 
as HIV and anti-retroviral therapies (ART) have been found to drive dyslipidaemia (Burren and 
Hattersley, 2004; Dave et al., 2016; Ntusi, 2018). The effects of some classes of ART drugs on lipid 
metabolism have been described in literature and will be further explored in section B of this chapter.  
Diabetes Mellitus 
Diabetes Mellitus is a well-known risk factor for CVD (World Heart Federation, 2017). Many studies 
have shown that individuals with type 2 diabetes have a higher CVD related mortality and morbidity in 
comparison to individuals without Diabetes (Matheus et al., 2013). In fact, CVD is the leading cause of 
mortality in diabetic populations (World Heart Federation, 2017). Particularly, diabetes has been 
associated with higher risk of CHD, stroke, and heart failure (Leon, 2015). It is well established that 
elevated glucose levels contribute to endothelial dysfunction (discussed later in section 2.2.4) in the 
arteries and atherosclerosis (Martín-Timón, 2014). Furthermore, diabetic (particularly type 2) 
individuals,  often present with several other risk factors such as obesity, hypertension, and 
dyslipidaemia (Leon, 2015). In addition, evidence from literature shows that diabetic individuals often 
have elevated oxidative stress, vascular damage and dysfunction and a pro-clotting profile (Matheus et 
al., 2013; Leon, 2015). All of this collectively can increase the risk of developing major CVDs such as 







Other modifiable risk factors (excessive use of alcohol, stress and depression) 
Excessive use of alcohol as well psychosocial conditions such as depression, stress and anxiety are 
found to be associated with increased CVD risk (Balakumar, Maung-u and Jagadeesh, 2016). Chronic, 
heavy alcohol consumption has been linked with increased risk of stroke, whilst light to moderate intake 
has been found to reduce the risk of stroke (Arboix, 2015). Alcohol has also been associated with 
myocardial injury and increased risk of cardiac arrhythmias (World Heart Federation, 2017). Some 
studies also link alcohol abuse to increased blood pressure,  acute myocardial infarction, and CHD 
(Piano, 2017). According to WHO, alcohol abuse results in 3 million deaths annually which represents 
5.3 % of all deaths worldwide (WHO, 2018). With regards to depression, some studies have 
demonstrated that depression may be an independent risk factor for certain CVDs (Fiedorowicz, 2014). 
The underlying mechanisms are related to modifications in sympathetic stimulation and alteration in 
lipid metabolism (Lichtman et al., 2014). Depression has also been thought to indirectly contribute to 
CVD when it occurs concurrently with stress, physical inactivity, and medication non-adherence. 
According to the WHO, more than 264 million people of all ages suffer from depression, which is a 
major contributor to the overall global burden of disease (WHO, 2020). 
 
2.2.2.2 Non modifiable Risk Factors 
Age 
It is well known in research that age is an independent risk factor for CVDs (Dhingra and Vasan, 2012). 
Age has been associated with arterial stiffness, and alteration of lipid profiles, all of which can 
contribute to the development of CVD. With increasing age, functional and structural modification can 
occur in the vascular wall, such as thickening of the arterial wall and stiffness. These changes could 
also contribute to the development of systolic hypertension and left ventricular hypertrophy 
(Westerman, Engberding and Wenger, 2015). Furthermore, age has been linked with elevated pro-
inflammatory cytokines such as interleukin (IL)-1, IL-6, IL_8, IL-13, IL-18, as well as C-reactive 
protein (CRP), interferons α and β, transforming growth factor β, tumour necrosis factor alpha (TNF)-
α, its soluble receptors (TNF-R1 and TNF-R2), and serum amyloid, all of which play a role in the 
development of atherosclerosis, further contributing to CVD (Chia, Egan and Ferrucci, 2018).  Due to 
medical advances globally, the longevity of the population is increasing, however the presence of CVD 









Differences in CVD between males and females are more prominent at a younger age. The prevalence 
of CVD in younger people appears to be higher in males than females; studies have attributed part of 
this effect on reproductive hormones (Wakabayashi, 2017). As females age, the prevalence of CVD 
rises almost to the level of males (Wakabayashi, 2017). In fact, females have been reported to have a 
more unfavourable cardiovascular risk profile, especially with regards to CHD and diabetes mellitus ( 
Westerman, Engberding and Wenger, 2015; Balakumar, Maung-u and Jagadeesh, 2016; Wakabayashi, 
2017). Although males and females do share all traditional risk factors, the impact of these factors are 
different in the two gender groups (Gao et al., 2019). For example, some researchers have noted that 
age, hypertension and total cholesterol and LDL-cholesterol have a higher influence on males; while 
smoking, diabetes and triglycerides and HDL-cholesterol levels have a higher effect on women (Galiuto 
and Locorotondo, 2015; Gao et al., 2019). When considering females, there are certain sex-specific 
factors that may influence CVD (Gao et al., 2019). For instance, it is noted that pregnancy related 
cardiovascular complications such as preeclampsia, gestational hypertension, gestational diabetes 
mellitus, menopause-related hormonal changes and autoimmune diseases can also play a role 
(Balakumar, Maung-u and Jagadeesh, 2016; Westerman, Engberding and Wenger, 2015). Menopause 
specifically may impact body fat and the lipid profiles of the females, especially HDL levels as 
oestrogen levels significantly deplete with hormonal changes, all of which is found to independently 
impact HDL and body fat of females (Westerman, Engberding and Wenger, 2015). 
Family history of CVD 
Literature also points towards family history of CVD, and socioeconomic factors to play a part in the 
development of CVD. Family history of CVD can aid in predicting future CVD events in individuals 
(World Heart Federation, 2017). The CVD risk is dependent on the number and age of CVD affected 
first degree families. Studies have found that siblings of patients with CVD have approximately 40% 
increased risk in comparison to the siblings of individuals without CVD (Murabito et al., 2005). 
Additionally, CVD risk increases to approximately 60-75% if the one is the offspring of parents with 
premature CVD (Feinleib et al., 1975; Kolber, 2014). The development of CVD is not entirely 
dependent on family history, however, as a range of environmental and other risk factors play a role 









Other non-modifiable risk factors  
Literature has also reported on genetic (e.g. ancestry), cultural and socio-economic factors that may be 
associated with CVD risk. Cultural factors that could increase CVD risk include dietary choices and 
habits (BeLue et al., 2009). The so-called Western lifestyle that includes a diet high in fat and sugar, 
may influence metabolic and vascular function across populations (Kopp, 2019). Another study that 
looked at the role of ancestry showed that South Asians have a higher CVD related mortality than 
Europeans (Forouhi and Sattar, 2006). Lastly, socio-economic status, generally measured through 
education and income of an individual, is also found to be a predictor of CVD and related deaths 
(Rawshani et al., 2015). Particularly, in high-income countries, low socioeconomic status has been 
shown to associate with an increased risk of CVD and mortality (Stringhini et al., 2017; Antignac et 
al., 2018; Rosengren et al., 2019). Levels of education and income can impact decision making and 
access to healthcare which can indirectly increase the risk of CVD.  
 
2.2.2.3 The interaction of CVD risk factors 
Often the risk factors discussed above interact with each other and create a chain of mechanisms, which 













2.2.3 Atherosclerosis  
A major underlying pathophysiological mechanism of the two most common CVDs, viz. CHD and 
cerebrovascular disease (stroke), is atherosclerosis (Frostegård, 2013) . The major risk factors that play 
a role in the development of atherosclerosis are shown in figure 2.3. This chronic condition is 
characterized by plaque build-up, which ultimately cause a hardening of the arterial walls (Bergheanu, 






Figure 2.3: Some of the major risk factors of atherosclerosis. Figure designed by the author of this 
dissertation. 
 
The pathophysiology of atherosclerosis is initiated by elevated levels of plasma cholesterol 
(hypercholesterolemia) that lead to alteration in the arterial endothelial permeability. The arterial 
endothelial permeability refers to structural and functional changes in the entire vessel wall which acts 
as the passage for macromolecules, fluids, and cells into the intima (Mundi et al., 2018). This increase 
in endothelial permeability is primarily due to changes/ dysfunction in endothelial barrier function 
(main function is to regulate the exchange of biological molecules and maintain a low and selective 
permeability to fluid and solutes under normal physiological conditions) (Mundi et al., 2018). 
Subsequent increase in endothelial permeability permits migration of cholesterol rich fractions of the 
blood (low density lipoproteins (LDL)) into the arterial wall (Sakakura, Nakano et al., 2013, Naseem 
2005). Endothelial cells that express adhesion molecules such as such as vascular adhesion molecule-1 
(VCAM-1) and selectins, permit circulating monocytes to migrate via diapedesis in the subendothelial 
space. In this space, the monocytes acquire macrophage characteristics and change into foamy 
macrophages (Bergheanu, Bodde and Jukema, 2017). The accumulation, alteration and oxidation of 
LDL cholesterol in the subendothelial space convert them into strong chemo-attractants, which results 
in secretion of chemotactic protein 1 (MCP-1), selectins, intercellular adhesion molecules (ICAMs), 
vascular cell adhesion molecules (VCAMs), platelet and endothelial cell adhesion molecules 
(PECAMs) and junctional adhesion molecules (JAMs) in endothelial cells, all of which facilitate 
monocyte rolling and attachment of cholesterol to the endothelium (Braunersreuthe, Mach 2006, 
Montecucco, Mach 2009, Naseem 2005). All of this ultimately leads to a cascade of vascular 











Figure 2.4: Vascular modification in atherosclerosis (Adapted from Bergheanu, Bodde and Jukema, 
2017). 
 
The surrounding inflammation leads to the release of soluble inflammatory mediators such as C-reactive 
protein (CRP), cytokines (interleukin 6 (IL-6) and tumour necrosis factor alpha (TNFα), interferon 
gamma and adipocytokines) endocannabinoids and hormones (Steffens, Montecucco and Mach, 2009; 
Hansson, 2017). All of these mediators further increase inflammation and activate immune and vascular 
cells. Smooth muscle cells then migrate to the intima and cause irreversible arterial remodelling which 
lead to arterial stenosis with calcium and collagen deposition. A rupture is possible when there is 
atherosclerotic plaque instability (which can be caused by toxic mediators from the vascular and 
immune cells). A rupture can essentially expose the blood flow to the intra-plaque pro-thombotic 
material which can result in the formation of thrombus. This can lead to a sudden occlusion of the artery, 
which can ultimately disrupt blood flow and result in ischaemia in the heart and brain (Montecucco, 
Mach 2009).   
 
2.2.4 Endothelial Function & Dysfunction 
2.2.4.1 The Vascular endothelium & its function 
Atherosclerosis begins in the blood vessels, more specifically in the endothelium located in the tunica 
intima of blood vessel walls; hence, the vascular endothelium and its function have a crucial role in the 
development or prevention of atherosclerosis (Zhao, Vanhoutte and Leung, 2015). The blood vessels 
are composed of three layers (refer to figure 2.5): an intimal monolayer of endothelial cells (ECs), 
which forms the vascular endothelium, medial vascular smooth muscle and the adventitia or tunica 
•Characterized by layers of smooth muscle cells  
(SMCs) and extracellular matrix. Commonly located 
in coronary artery, carotid artery, abdominal aorta, 
descending aorta, and iliac artery
Intimal Thickening
•Abundant macrophage foam cells mixed with SMCs 
and proteoglycan-rich intima
Fatty streak
•Layers of SMCs in proteoglycan-collagen matrix 
aggregated near the lumen
•Underlying lipid pool: acellular area rich in 







externa (Zhao, Vanhoutte and Leung, 2015). The ECs therefore represent the inner most interior surface 
of the blood vessels; and they cover the entire vascular tree from the heart to the capillaries.  
 
Figure 2.5: Structure of the arterial wall. Tunica intima is composed of ECs and internal elastic 
membrane; the smooth muscle cells (SMCs) and external elastic membrane form the tunica media; 
tunica externa is composed of adventitia. The inner layer of ECs forms the endothelium. Figure designed 
by the author of this dissertation based on content from (Zhao, Vanhoutte and Leung, 2015). 
The endothelium has the most important role in regulating vascular homeostasis. It actively controls the 
vascular tone and permeability and regulates the exchange of molecules in response to extracellular and 
intracellular signals (Flammer and Luscher, 2011). One of the main outcomes of a healthy endothelium 
is its ability to maintain a balance between coagulation and fibrinolysis, inflammatory activity, and cell 
proliferation. In terms of atherogenesis, the endothelium prevents the adhesion of immune cells and 
infiltration of monocytes into the sub-endothelial space of lesion-prone areas, thus interfering and 
preventing the development of atherosclerotic plaques (Daiber et al., 2017). Overall, a healthy 
endothelium is critical in preventing thrombotic events and further exerts anticoagulant, antiplatelet, 






Figure 2.6: Atheroprotective effects of the endothelium. Figure designed by the author of this 
dissertation based on contents from (Favero et al., 2014). 
The ECs have the ability to sense mechanical stimuli such as pressure and shear stress through its 
mechanosensors. In addition, they have receptors for ligands such as hormones and other vasoactive 
substances, to which the endothelium responds to by releasing agents that regulate vasomotor function, 
trigger inflammatory processes, and affect homeostasis (Endemann and Schiffrin 2004, Limaye and 
Vadas 2007). The endothelium is able to achieve most of its functions by releasing endothelium-derived 
relaxing factors (EDRF) and endothelium-derived constricting factors (EDCF), refer to table 2.3 for a 
summary of EDRFs and EDCFs. At optimal function, the endothelium maintains a balance between 






Table 2.3: Summary of relevant endothelial derived factors and their function. 
Endothelium derived relaxing factors 
 Description Function 
Nitric Oxide  
(NO) 
The most important EDRF, produced by endothelial nitric 
oxide synthase (eNOS) in response to shear stress (Flammer 
and Lüscher, 2010). Described in detail under section 2.2.4.2 
Key function is the induction of a vasodilatory effect on the 
vasculature (Davignon and Ganz, 2004). Other functions 
include inhibition of smooth muscle cell proliferation, 
prevention of platelet adhesion and aggregation, as well as 
leukocyte adhesion and migration into the arterial wall 




Produced by cyclooxygenase-1 (COX-1) from arachidonic 
acid and increases cAMP in smooth muscle cells and in 
platelets. Released partly in response to shear stress and when 
there are disturbances in endothelial function (Flammer and 
Lüscher, 2010). 
Main function is to limit vasoconstriction. Also known to aid in 
the release of NO by endothelial cells and vice versa, the action 
of PGI2 in the vascular smooth muscle is also potentiated by 





Hydrogen sulphide is known to be a major EDHF.  Other 
EDHFs include K+, cytochrome P450 metabolites 
(epoxyeicosatrienoic acids- arachidonic acids) and hydrogen 
peroxide (Ozkor and Quyyumi, 2011) 
EDHFs are responsible for vascular smooth muscle 
hyperpolarisation and eventually vasodilation (Ozkor and 
Quyyumi, 2011). 





 Description Function 
Endothelin 1  
(ET-1) 
ET-1 is more dominant in the cardiovascular system and its 
production is stimulated by  Interleukin (IL-1ß), tumor 
necrosis factor (TNFα), transforming growth factor (TGFß), 
platelet derived growth factor (PDGF), vasopressin, hypoxia, 
and shear stress (Flammer and Lüscher, 2010; Haque, Welch 
and Loizidou, 2013). ET-1 is one of a family of three 
endothelins (ET-1, ET-2, ET3) (Haque, Welch and Loizidou, 
2013).   
ET-1 elicits its function by binding to two G-protein coupled 
receptors,  ETA and ETB. Main function is to exert opposite 
effects to NO and promote vasoconstriction. Binding to 
ETAreceptors in the vascular smooth muscle cells lead to 
vasoconstriction, meanwhile, binding to ETB.  in the 
endothelium reduces ET-1 production by promoting NO and 
prostacyclin production (Bourque, Davidge and Adams, 2011). 
Thromboxane A 
(TXA2) 
TXA2 is converted from prostaglandin H2 through TXA2 
synthase in the cyclooxygenase (COX) pathway (Chen, 2018). 
TXA_2 is a proatherogenic prostanoid that can induce 
vasoconstriction, platelet activation and adhesion. In the 
cardiovascular system, its main role is signalling endothelium 
dependent contractions in the arteries (Chen, 2018). 
Angiotensin II 
(Ang II) 
Ang II is a hormone, bioactive peptide of the renin-angiotensin 
system (RAS). The diverse actions of Ang II are mediated via 
AT1 and AT2 receptors, which couple to many signalling 
proteins, e.g. small G proteins, phospholipases, mitogen-
activated protein (MAP) kinases, phosphatases, tyrosine 
kinases, NADPH oxidase, and transcription factors (Cat & 
Touyz 2011). 
It is a potent vasoconstrictor that increases peripheral vascular 
resistance and elevates arterial blood pressure. It is known for 
its pathophysiological role in CVDs such as hypertension, heart 





2.2.4.2 Nitric oxide (NO)- the most important vasodilating factor 
NO is the most crucial EDRF in the vascular system. It is synthesized in the ECs by endothelial nitric oxide 
synthase (eNOS) during conversion from L-arginine to L-citruline (Sena, Pereira and Seiça, 2013). Refer to 
figure 2.7 for NO production and release description. The production of NO by eNOS requires cofactors such 
as tetrahydrobiopterin (BH4) and nicotinamide adenine dinucleotide phosphate (NADPH). Shear stress and 
vasodilatory agonists such as acetylcholine, activate eNOS to produce NO by increasing intracellular calcium 
by acting on specific receptors (muscarinic receptors) (Davignon and Ganz, 2004; Zhao, Vanhoutte and Leung, 
2015). This displaces caveolin and calcium then binds with calmodulin, activating eNOS to produce NO, hence 
the shear stress-induced synthesis of NO by eNOS is calcium-dependent. In contrast, NO can also be produced 
via a calcium independent pathway where eNOS is phosphorylated independent of calcium and ultimately 
leads to the production of NO (Zhao, Vanhoutte and Leung, 2015). Once NO is produced, it diffuses to the 
vascular smooth muscle cells (VSMCs) and activates soluble guanylate cyclase (sGC), elevating levels of 
cyclic guanosine-3,5-monophosphate (cGMP) and leading to relaxation of VSMCs (Davignon and Ganz, 2004; 
Zhao, Vanhoutte and Leung, 2015) (refer to figure 2.7). 
 
Figure 2.7: Production of nitric oxide (NO) by endothelial cells and relaxation of the vascular smooth muscle 
cells. Figure designed by the author of this dissertation based on content from (Davignon and Ganz, 2004; 
Toblli et al., 2012). eNOS, endothelial nitric oxide synthase; NO, nitric oxide; NADPH, reduced nicotinamide 
adenine dinucleotide phosphate; CaM, calmodulin; GTP, guanosine 5’-triphosphate; GC, guanylate cyclase; 
cGMP, cyclic guanosine monophosphate. 
The most important function of NO is its vasodilatory effect on the vasculature. NO mediates this vasodilation 





from vasodilation, NO can also exert anti-thrombotic and anti-inflammatory effects on the vasculature by 
inhibiting platelet adherence and aggregation, leukocyte adhesion/infiltration, and proliferation of vascular 
smooth muscle cells (Strijdom, Chamane and Lochner, 2009). Furthermore, NO is known to prevent oxidative 
modification of LDL- cholesterol which is found to be one of the crucial mechanisms in atherosclerosis 
(Davignon and Ganz, 2004). Apart from NO’s direct role, it can also modulate the release of other endothelium 
derived factors, for example, in many large arteries, EDHF dependent vasodilation only becomes prominent 
when NO is inhibited, also demonstrating NO’s gatekeeping abilities (Vanhoutte et al., 2017). Hence, overall, 
NO is the most important vasodilating factor in maintaining vascular homeostasis and endothelial function. 
 
2.2.4.3 Endothelial dysfunction 
Pathophysiological alterations to the endothelium towards reduced vasodilation and a pro-inflammatory and 
prothrombotic state collectively result in endothelial dysfunction  (Rajendran et al., 2013; Daiber et al., 2017). 
The hallmark of endothelial dysfunction is reduced NO bioavailability. Additionally, endothelial dysfunction 
is characterized by poor hemodynamic deregulation, impaired fibrinolytic ability, overproduction of growth 
factors, increased expression of adhesion molecules and inflammatory genes, excessive generation of ROS, 
increased oxidative stress, and enhanced permeability of the endothelium (Sena, Pereira and Seiça, 2013), 
collectively resulting in a loss of vascular homeostasis. Refer to table 2.4 for a summary of the major 
modifications associated with endothelial dysfunction. 
Table 2.4: Summary of characteristics associated with endothelial dysfunction ( Adapted from Sena, Pereira 
and Seiça, 2013). 
Major modifications associated with endothelial dysfunction 
•  vasodilation (NO, PGI2) 
• oxidative stress & uric acid 
• Pro-coagulant abilities (von Willebrand Factor (vWF), plasminogen activator inhibitor (PAI-1), P 
selectin) 
• Pro-inflammatory state (ICAM, VCAM, E-selectin, CRP, TNF-α, IL-6, MCP-1) 
•  damage of ECs &  repair of endothelial progenitor cells. 
 
 
The pathophysiology of endothelial dysfunction is characterized by impaired NO bioavailability which is 
largely in response to increased oxidative stress and inflammation (Simsek et al., 2010). Oxidative stress can 
be due to either an increase in oxidant production, or a reduction in antioxidant protection or a failure in 
repairing oxidative damage  (Simsek et al., 2010). Hyperglycaemia, insulin resistance, dyslipidaemia, 
inflammation, and cigarette smoking are some of the many cardiovascular risk factors associated with 





instead of NO (Endemann 2004, Van den Oever, Raterman et al., 2010) . ROS can induce EC damage, and 
free radicals are known to disrupt the balance of NO, which leaves the endothelium overtly permeable, 
allowing toxins and acute phase and pro-inflammatory proteins such as CRP to pass through the blood vessels 
and into adjacent tissues (Rajendran et al., 2013). Inflammation is additionally known to reduce NO 
bioavailability. When NO and its physiological actions are inhibited, endothelial signalling is impaired leading 
to endothelial dysfunction and, if not reversed, resulting in widespread pathophysiological consequences in 
the body.  One of the major sequelae of endothelial dysfunction is atherogenesis and thrombosis, largely due 
to the loss of endothelium’s protective abilities and for the induction of pro-atherothrombotic mechanisms 
(Sena, Pereira and Seiça, 2013). Additionally, apart from atherosclerosis, endothelial dysfunction is associated 
with the development of many other CVDs such as hypertension, and coronary artery disease, as well as 
metabolic conditions such as diabetes mellitus (Sena, Pereira and Seiça, 2013). 
 
2.2.5 Biomarkers of Atherosclerosis (inflammation) & Endothelial dysfunction 
A biomarker is defined as a measurable characteristic by which a physiological process or pathology can be 
identified (Group et al., 2001; Stoner et al., 2013). Generally, a biomarker should be quantifiable in samples 
such as blood, serum, urine or tissue and should be associated directly or indirectly with the represented disease 
(Stoner et al., 2013). As discussed in earlier sections, CVD pathogenesis includes the complex mechanisms of 
atherosclerosis and ED and hence there is not only one biomarker present to predict CVD, but several which 
can be implicated with the disease.  Additionally, it is imperative to note that not all biomarkers are equal with 
some similar in their function and offering a better prognostic information than others or some better suited to 
predict certain specific CVDs. For the purposes of this PhD dissertation, only known and major biomarkers of 
atherosclerosis and ED will be discussed. Refer to table 2.5 for some of the major circulating biomarkers of 
ED and atherosclerosis with their functions. 
 





VCAM-1 is expressed in blood vessels after the ECs are stimulated by cytokines. Its 
main function is to mediate rolling, adhesion and migration of leukocytes across the 
endothelial barrier (Stoner et al., 2013). VCAM-1 is up-regulated by cytokines in 
response to TNF-α and IL-1 and through stabilization of mRNA through the action 
of IL-4. Furthermore, VCAM-1 is known to promote monocyte chemotaxis 




ICAM-1 is expressed on the surface of ECs, leukocytes and SMCs in response to 
shear stress, bacterial toxins, pro-inflammatory cytokines and oxidants. ICAM-1 is 





their subsequent transmigration and accumulation in the arterial intima (Stoner et al., 
2013). ICAM-1 also participates in angiogenesis, and EC activation or damage 
(Goncharov et al., 2017). All these processes play a vital role in the development and 
progression of atherosclerosis. Hence measurement of circulating soluble ICAM-1 





PECAM-1 belongs to the immunoglobulin gene superfamily and is highly expressed 
(high density) in ECs and moderately (low density) on the surface of hematopoietic 
cells (Galkina and Ley, 2007; Stoner et al., 2013). Functions of PECAM-1 include 
involvement in angiogenesis, integrin regulation, apoptosis and transendothelial 
migration of monocytes. Importantly, it plays a role in plaque formation and 
thrombosis. Its role in the pathogenesis of atherosclerosis can be attributed to its 
ability to mediate leukocyte infiltration (Stoner et al., 2013; Goncharov et al., 2017). 
E-selectin E-selectin is one of the 3 members of the selectin family which includes P-selectin 
and L-selectin (Goncharov et al., 2017). E-selectin can serve as a surrogate marker 
of increased expression of cellular adhesion molecules such as VCAM and ICAM on 
vascular ECs, and reflect inflammation and activation of ECs (Stoner and Sabatier, 
2010; Goncharov et al., 2017).  
P-selectin P-selectin is a transmembrane adhesion protein that is upregulated in activated 
platelets and vascular ECs. P-selectin is known to mediate the initial interaction of 
circulating leukocytes with activated ECs which lead to a characteristic rolling of the 
leukocytes on the endothelium. Hence, it plays an important role at sites of 
inflammation and vascular injury by contributing to thrombus formation through 
leukocyte involvement (Goncharov et al., 2017).  
Interleukin- 6 (IL-
6) 
IL-6 is a pleiotropic cytokine, produced by a variety of cells, including ECs.   
The physiological effects of IL-6 are found in a variety of tissues and include cell 
growth, differentiation, and importantly angiogenesis, re-vascularization, and tissue 
healing (Goncharov et al., 2017).  
Tumour necrosis 
factor- alpha  
(TNF-α) 
TNF-α is a cytokine which is produced by macrophages, ECs and SMCs of 
atherosclerotic arteries (Stoner et al., 2013). It has a wide range of pro-inflammatory 
functions. It contributes to atherosclerotic processes by causing metabolic 
perturbations and increasing the expression of cellular adhesion molecules such as 
VCAM-1 and ICAM-1 (Meager, 1999). Furthermore, TNF-α is known to induce the 
expression of chemokines and enhance the production of other cytokines and growth 
factors (Stoner et al., 2013). Additionally, TNF-α also stimulates new vessel 
formation and induces the process of atheroma development (Hotamisligil and 







CRP is an acute phase protein. A growing body of literature points to CRP as a 
potential, crucial etiological factor in inflammation and atherosclerosis (Jialal, 
Devaraj and Venugopal, 2004). Liver and hepatocytes are the primary sites of CRP 
production. Production is usually in response to the stimulation by IL-6 and TNF-α 
from the inflammation site. CRP is also known to enhance the expression of adhesion 
molecules such as ICAM-1, VCAM-1, E-selectin, and P-selectin, as well as MCP-1 
in ECs, further promoting endothelial activation dysfunction and atherosclerosis 
(Pasceri et al., 2001; Stoner et al., 2013).  
Von Willebrand 
factor (vWF) 
vWF is a glycoprotein which plays a critical role in in blood coagulation. Both the 
expression and function of vWF is carefully regulated by protease ADAMTS-13. 
Another important function of vWF is the regulation of angiogenesis and any changes 
in its function can lead to can lead to thrombotic thrombocytopenic purpura 




MCP-1, a key chemokine, is produced either constitutively or after induction by 
oxidative stress, cytokines, or growth factors (Deshmane et al., 2009). Its main 
functions include regulations of migration and infiltration of monocytes and 




AGEs are products of non-enzymatic glycation and, oxidation of proteins and lipids 
in response to exposure to sugar. They accumulate in the vessel wall following 
oxidative stress (Basta, Schmidt and De Caterina, 2004). AGEs exert their pathogenic 
functions through activating their receptor for advanced glycation end products 
(RAGE) and macrophages in an NF-κB-dependent fashion. All of this leads to the 
induction of platelet-derived growth factor (PDGF), insulin-like growth factor (IGF)-
I, and pro-inflammatory cytokines, such as interleukin-1β (IL-1β) and TNF-α. AGEs 
binding with RAGE produces ROS by reducing the cellular antioxidant defence 
mechanisms. Elevated ROS further activates ECs and promotes expression of 
procoagulant tissue factors and adhesion molecules such as E-selectin, VCAM-1 and 




VEGF is a hypoxia inducible cell mitogen (Paulus, Jennewein and Zacharowski, 
2011). It stimulates endothelial cell migration along with vessel permeability (Dvorak 
et al., 1999) and promotes survival of the newly formed blood vessels. VEGF is 




PAI-1 belongs to the family of serine protease inhibitors (SERPINs) (Paulus, 
Jennewein and Zacharowski, 2011). They are known to be the principal inhibitors of 
the tissue-type and the urinary-type plasminogen activator (Cesari, Pahor and Incalzi, 
2010). Both plasminogen activators can activate plasminogen and fibrinolysis. PAI-





Under physiological conditions, PAI-1 is released into the circulation and the 
extracellular space by liver cells, smooth muscle cells, adipocytes, and platelets 
(Paulus, Jennewein and Zacharowski, 2011). 
Angiotensin II  
(ANG II) 
ANG II is a key player in the renin–angiotensin–aldosterone system (RAAS). Its main 
function is to maintain blood pressure, salt and fluid volume homeostasis (Rautureau, 
Paradis and Schiffrin, 2011). It has vasoconstrictor and anti-natriuretic properties. 
ANG II can also induce production of ROS, and both production and expression of 
pro-inflammatory cytokines and adhesion molecules. Furthermore, it is known to 
promote the functional adhesion of monocytes to ECs and enhance expression of 




In literature many biomarkers have been identified that may represent the balance 
between free radical formation and protective antioxidants (Stafforini et al., 1997). 
Oxidative stress biomarkers include F2 isoprostane, lipoprotein-associated 
phospholipase A2 (LpPLA1), nitrotyrosine, and oxidized LDL. Important antioxidant 
biomarkers include coQ10, GSH, and SOD. Most of these biomarkers are pro-
atherogenic and play a role and correlate with atherosclerosis and CVD (Stoner et al., 
2013).  
 
Endothelial dysfunction is accompanied by inflammation, hence fragments of activated endothelium, 
endothelial microparticles, and as well as whole ECs are released into the circulation. These can typically be 
measured in the blood and their circulating levels are found to elevated in CVD (Halcox, 2012). The 
proinflammatory and procoagulant state of the ECs lead to endothelial activation in the lesion-prone regions 
of the vessels. This is characterized by an increase in leukocytes and is associated with early stages of 
atherosclerosis (Coker, 2017). Inflammatory makers associated with endothelial activation are some of the 
major known biomarkers of both endothelial dysfunction and atherosclerosis, refer to figure 2.8 for 







Figure 2.8: The role of the various inflammatory markers in endothelial activation.  Figure designed by the 
author of this dissertation based on content from (Gimbrone and García-Cardeña, 2016). IL-1,8, interleukin 1, 
8; IL-R, receptor for IL-1; TNF-R receptor for TNF; Ox-LDL-R, receptor for oxidized LDL; RAGE, receptor 
for AGE; TLRs, Toll-like receptors; VCAM-1, vascular cellular adhesion molecule-1; ICAM-1, intercellular 
cell adhesion molecule-1; ROS, reactive oxygen species; VWF, von Willebrand factor; MCP-1 monocyte 
chemoattractant-1; and PAI-1, Plasminogen activator inhibitor-1. 
 
Endothelial activation begins in the lesion-prone regions of the vessels where actions of proinflammatory 
agonists such as IL-1, TNF, and endotoxin, oxidized lipoproteins and advanced glycation end products (AGE), 
as well as biomechanical stimulation by disturbed blood flow take place (refer to figure 2.8) (Gimbrone and 
García-Cardeña, 2016). These factors and disturbed blood flow act largely through the pleiotropic transcription 
factor, nuclear factor-κB (NF-κB), and lead to cellular expression of adhesion molecules such as ICAM-1 and 
VCAM-1, as well as secreted and membrane-associated chemokines such as MCP-1, and prothrombotic 
mediators such as tissue factor (TF), vWF and PAI-1 (Pober et al., 1986; Gimbrone and García-Cardeña, 2016). 
This leads to selective monocyte and T lymphocytes recruitment which then relocate in the subendothelial 
space. The combined actions of activated ECs, SMCs, monocyte/macrophages and lymphocytes result in the 
production of a complex paracrine milieu/ environment of cytokines, growth factors, and ROS within the vessel 
wall, all of which promote chronic proinflammatory state and atherosclerotic progression (Gimbrone and 





In the activated state, endothelial cells have an increased expression of proinflammatory cytokines, enzymes 
and adhesion molecules (Baghai et al., 2018). Thus, it is highly possible that endothelial activation plays a 
crucial role in development of endothelial dysfunction. In many ways endothelial activation is an early step in 
the development of endothelial dysfunction (Daiber et al., 2017). Therefore, identification of endothelial cell-
derived inflammatory factors may serve as biomarkers of endothelial dysfunction (Sun et al., 2020). Refer to 
figure 2.9 for the link and role of endothelial activation and dysfunction in vascular disease. 
 
Figure 2.9: The role of endothelial activation and dysfunction in vascular disease. CVD risk factors such as 
hypercholesterolemia, smoking and oxidative stress, promote endothelial dysfunction; meanwhile 
proinflammatory cytokines, turbulent blood flow and advanced glycation end-products (AGEs) are important 
mediators of endothelial cell activation via the activation of the transcription factor, NF-κB. NO from eNOS 
or NO donors reduces endothelial cell activation through inhibition of NF-κB. Reduced or loss of NO leads to 





Both endothelial dysfunction and endothelial cell activation lead to atherosclerosis by increasing 
vasoconstriction, SMC proliferation, platelet aggregation, leukocyte adhesion, and LDL oxidation. Figure 
designed by the author of this dissertation based on contents from (Liao and Liao, 2013). NO, nitric oxide; 
LDL, low density lipoprotein; eNOS, endothelial nitric oxide synthase; SMC, smooth muscle cell; VCAM-1, 
vascular cellular adhesion molecule-1; ICAM-1, intercellular cell adhesion molecule-1; and AGE, advanced 
glycation end-products. 
 
2.2.6 The role of CVD risk factors, endothelial dysfunction, atherosclerosis and 
biomarkers in CVD 
Prolonged exposure to cardiovascular risk factors such as age, obesity, smoking, dyslipidaemia, hypertension 
and diabetes, among others, is known to impact the endothelium. Vascular endothelium can lose its defence 
mechanisms, resulting in endothelial activation and dysfunction (refer to figure 2.10). Endothelial dysfunction 
is known to be one of the major links between CVD risk factors and atherosclerosis (Mudau et al., 2012). The 
progression to atherosclerosis from cardiovascular risk factors is mediated by a range of mechanisms and 
inflammatory markers (refer to figure 2.10), however, endothelial dysfunction is a reversible step in the 
process of CVD and hence clinical screening, or measurement thereof can prove to be useful. Furthermore, 
there are established circulating biomarkers associated with endothelial dysfunction and atherosclerosis, which 
too can be screened and measured to predict cardiovascular outcome (Park and Park, 2015).  
Atherosclerosis exists along a continuum and begins with subclinical atherosclerosis which starts early with 
processes of ED and inflammation. The term “subclinical atherosclerosis” refers to early pro-atherosclerotic 
changes in blood vessels that are not detected by normal physical examination. It has no or minimal 
recognizable clinical findings and is often asymptomatic (Shiel 2018). Hence, subclinical atherosclerosis is 
defined as an early precursor of atherosclerosis. Subclinical atherosclerosis can remain clinically undetected 
throughout the life of the individual until an acute cardiovascular event transpires (refer to figure 2.10) (Singh 
et al., 2018). Hence, measuring subclinical atherosclerosis can prove to be an early indicator of atherosclerosis 






Figure 2.10: The progression from CVD risk factors to ED to atherosclerosis and ultimately CVD. Figure 





2.2.7 Measurement of Atherosclerosis and Endothelial function 
2.2.7.1 Measurement of Atherosclerosis 
As discussed in earlier sections, atherosclerosis is a chronic, progressive inflammatory disease which 
typically has a long asymptomatic phase. Eventually, atherosclerosis progression can lead to an acute 
cardiovascular event (Toth, 2008). However, while the disease is still in its subclinical phase, it can 
remain undetected until a symptom or acute event occurs. Hence the subclinical phase can be useful for 
measurement, particularly from the clinical perspective as changes in the arterial wall precede clinical 
signs and symptoms (Holewijn et al., 2010). Thus, measurement and quantification of subclinical 
atherosclerosis could serve as an early indicator of atherosclerotic burden and if detected in a timely 
fashion, it can slow or prevent the progression to CVD (Singh et al., 2018). Atherosclerosis 
measurement further represents the overall risk exposure and genetic susceptibility which may be 
beneficial in refining CVD risk stratification and therapeutic strategies (Singh et al., 2018).  
There are several invasive and non-invasive techniques available to measure subclinical atherosclerosis. 
These techniques can identify and measure distributions and parameters in the vasculature, such as 
luminal diameter, vessel wall thickness, and plaque volume (Toth, 2008). Currently there are many 
invasive techniques available that visualize the arterial system and measure the extent of atherosclerosis. 
These techniques include intravascular ultrasound and angiography. Less invasive techniques include 
computed tomography and magnetic resonance imaging. However, it is understood that these invasive 
techniques are not ideal for screening in the general population (Holewijn et al., 2010). Some of the 
techniques require injected detergents to optimize image quality and may also expose the individuals to 
radiation. Overall, these techniques are found to be expensive, and not widely available and applicable 
to everyone. Therefore, recently more non-invasive techniques have been developed that are both 
affordable and more widely available (Refer to table 2.6) (Holewijn et al., 2010). One such successful 
technique, which is also relevant to the current dissertation, is the measurement of carotid intima medial 













Table 2.6: Various techniques for the measurement of subclinical atherosclerosis 
Technique Brief description 
Coronary angiography A highly invasive technique using a catheter and detergents to localize 
plaque and reveal the degree of coronary luminal stenosis. A downfall 
of this technique is that it cannot identify specific lesions that are prone 
to rupture and hence can lead to acute coronary syndromes (ACS) 
(Little et al., 1988; Toth, 2008).  
Intravascular 
ultrasound (IVUS) 
IVUS is an invasive technique that relies on the miniaturisation of 
ultrasound transducers that are placed at the tip of a coronary catheter 
(Tabas, García-Cardeña and Owens, 2015). This technique can measure 
both the size and composition of the plaques along the vessel wall and 
provide information regarding the lesion location and plaque burden 
(Toth, 2008).  
Intima media thickness 
(IMT) measurement  
IMT is a validated successful non-invasive technique that measures the 
thickness of the inner most two layers (tunica intima and tunica media) 
of the arterial wall by means of ultrasound technology. Clinically, IMT 
is often conducted on the carotid artery of the individuals (Toth, 2008; 
Holewijn et al., 2010; Nezu et al., 2016). 
Magnetic resonance 
imaging (MRI) 
High resolution MRI can be used to measure of plaque burden and 
susceptibility to rupture. The technique generates images of the arteries 
to visualize stenosis, occlusions and aneurysms. MRI assesses plaque 
volume and composition, fibrous cap integrity, and lesion type (Chu et 
al., 2004; Toth, 2008).  
Electron beam computed 
tomography (EBCT) 
EBCT is clinically used to measure coronary artery calcification by 
means of rapid imaging technology and use of electron beam (gun). 
Plaque burden can be reflected through coronary calcium deposits as 
they are related to the lipid and apoptotic remnants of the plaque. Some 
studies point to coronary artery calcification as an independent 
cardiovascular risk factor, however, although EBCT can identify and 
measure the severity of coronary plaques within the coronary tree, it 
cannot predict plaque rupture (Toth, 2008). 
Pulse wave velocity 
(PWV) 
Clinically, PWV is a gold standard non-invasive method to measure 
arterial stiffness. It measures the velocity at which the blood pressure 
pulse circulates through the arteries. The technique records pulse 





the right carotid and the left femoral artery (Townsend et al., 2015).  As 
PWV increases as the arteries become stiffer with ageing and 
progression of atherosclerosis (Holewijn et al., 2010). 
 
2.2.7.1.1 Intima media thickness (IMT) measurement  
IMT measurement by ultrasound is a well-known non-invasive, sensitive, and reproducible technique. 
In the literature, it is an established marker of subclinical atherosclerosis (Holewijn et al., 2010; Kim 
and Youn, 2017). With aging and progression of atherosclerosis, the arterial wall thickens and the 
ultrasound IMT technique measures these structural changes in the arterial wall (Holewijn et al., 2010). 
To be more specific, carotid IMT measurements reflect the distance between the luminal border of the 
intima and the outer border of the media of the carotid artery far wall, which is represented as a double-
line pattern on a B-mode ultrasound image (refer to figure 2.11) (Stein et al., 2008; Kim and Youn, 
2017) . Reference values for IMT has been discussed in many studies, the most common guideline 
includes an IMT value of > 0.9 mm or the presence of plaque as a sign of damage (Naqvi, Lee and Iana, 
2015). There are four segments in the carotid artery, common carotid artery (CCA), bifurcation (bulb), 
external carotid artery and internal carotid artery (ICA). Although IMT can be measured at the bulb and 
ICA, the most common site of measurement as reported in the literature is the distal common carotid 
artery. This is largely due to the difficulty in obtaining images for measuring ICA IMT, whilst the CCA 
far wall IMT has been considered to have the best reproducibility and validated to display the true 





                                                        
Figure 2.11: Measurement of carotid IMT. The most distal 10 mm of the common carotid artery is 
measured. Normal intima-media complex is depicted; ECA, external carotid artery; ICA, internal 
carotid artery; and CCA, common carotid artery. Figure designed by the author of this dissertation based 
on contents from  (Holewijn et al., 2010).  
Although IMT data reported in the literature have been found to be generally consistent and 
reproducible, a measure of inter-study variability does exist, which could be ascribed to different 
protocols, ultrasound devices, sonography techniques, reading equipment, readers of the scans, and the 
thickness of the intima media complex (Holewijn et al., 2010). However, since the development of 
automatic devices and edge detection software programs, the variability has decreased substantially 





2.2.7.2 Measurement of Endothelial function 
Endothelial dysfunction is an early precursor of atherosclerosis and appears even before structural 
changes develop. If detected at an early stage, treatment and/ or lifestyle changes can potentially reverse 
the progression to atherosclerosis and CVD (Holewijn et al., 2010).  Clinically, endothelial dysfunction 
was first demonstrated in 1986 by intracoronary infusion of the NO-inducing agent, acetylcholine, and 
quantitative coronary angiography in atherosclerotic coronary arteries (Ludmer et al., 1986). Since then, 
many less invasive and non-invasive techniques have been developed to measure endothelial function 
(Refer to table 2.7 for techniques for the measurement of endothelial function). All these various 
techniques have their disadvantages and advantages; however, for clinical purposes, techniques that are 
non-invasive, reliable, reproducible and easily accessible are favoured as the ideal methods for the 
measurement of endothelial function (Deanfield, Halcox and Rabelink, 2007; Al-Qaisi et al., 2008; 
Flammer and Lüscher, 2010). The current gold standard measurement of endothelial function in clinical 
research is the technique of flow-mediated dilatation (FMD) of the brachial artery (Flammer and 
Lüscher, 2010). This method was also used in the current PhD study and explained further below.  
Table 2.7: Selected techniques for the measurement of endothelial function adapted from (Mudau et 





An invasive technique which involves intracoronary infusion of the 
endothelium-dependent vasodilator, acetylcholine, and subsequent 
measurement of the vasomotor response due to relaxing factors 
Flow mediated 
dilatation 
A gold standard, non-invasive technique which relies on endothelium-
dependent release of NO and other EDRF’s in response to reactive hyperaemia. 




Involves intra-brachial infusion of endothelial-dependent vasodilators such as 
acetylcholine, metacholine, substance P and bradykinin, with subsequent 
measurement of changes in endothelial function of forearm arterioles 
Finger 
plethysmography 
A non-invasive technique that measures changes of the pulse-wave amplitude 
during reactive hyperaemia. Low pulse-wave amplitudes are associated with 







2.2.7.2.1 Flow mediated Dilatation (FMD)  
Flow mediated dilatation (FMD) of the brachial artery was initially introduced in 1992. Since then it 
has become the gold standard non-invasive technique for the measurement of endothelial function 
(Flammer and Lüscher, 2010). FMD essentially measures transient changes in the brachial artery 
diameter in response to shear stress which is induced by reactive hyperaemia. To be more precise, an 
increase in blood flow in the brachial artery is achieved by rapid deflation of a pneumatic cuff which is 
placed on the forearm distal to the brachial artery (refer to figure 2.12) (Al-Qaisi et al., 2008). This 
pneumatic cuff is first hyper-inflated up to 200 mmHg (or 50mmHg above the individual’s supra 
systolic blood pressure) and deflated after 5 minutes. Upon deflation of the cuff, the blood flows back 
into the artery causing hyperaemia (increased flow), which induces shear stress and activation of eNOS. 
NO is released and diffuses to the smooth muscle cells causing them to relax (resulting in vasodilation) 
(Ghiadoni et al., 2015). FMD is measured as the percentage change in the brachial artery diameter in 
response to increased flow (refer to figure below 2.12) (Al-Qaisi et al., 2008). Although no 
standardized normal ranges have been determined yet, some studies in the literature have shown that 
normal FMD values in healthy populations range between 7-10%. Individuals with impaired 
cardiovascular function have lower or absent FMD value (Stout, 2009). The Framingham Heart Study 
further demonstrated mean FMD% values of ~3.3% in females and ~2.4% in males with ranges from 0 









Figure 2.12: Schematic representation of the assessment of FMD of the brachial artery. The image 
displays the position of the cuff on the forearm as well as the ultrasound probe on the arm. The timeline 
shows the FMD technique, where baseline measurement is for 1 minute, after which the cuff is inflated 
causing an occlusion, followed by deflation after 5 min which leads to reactive hyperaemia which 
induces shear stress and NO release.  Figure designed by the author of this dissertation based on contents 
from (Ghiadoni et al., 2015; Jarrete, Zanesco and Delbin, 2016). NO, nitric oxide. 
Flow mediated dilatation (FMD) is widely used in clinical research, however the application is found 
to be technically challenging and thus still requires standardization (Stout, 2009).  When using FMD, 
the effect of the environment and physiological influences as well technical (equipment) and operator 







Section B: Human Immunodeficiency virus and its underlying 
mechanisms 
 
2.3 Human immunodeficiency virus 
2.3.1 Introduction and Epidemiology  
Acquired immune deficiency syndrome (AIDS) was first identified as a new disease in 1981 (CDC 
report, 1981). Two years later, a retrovirus, termed human immunodeficiency virus (HIV) was 
confirmed to be the aetiological agent that causes AIDS. Initially, HIV infection rates were mistakenly 
believed to be on a slow rise; however, the number of people living with HIV grew to approximately 8 
million by 1990, reaching 30 million by the end of that decade, which demonstrated the devastating and 
widespread nature of the disease. The response to the HIV pandemic during the first two decades was 
poor and only began to improve in the mid-2000s largely due to the roll out of successful combination 
antiretroviral therapy (ART) (Delpech, 2013). Today, due to successful ART, the HIV epidemic has 
transformed from a rapidly terminal disease to a chronic and manageable condition with steady 
incremental improvements in life expectancy (Kaplan-lewis, Aberg and Lee, 2017).  
Since the start of the HIV epidemic, approximately 75 million people globally have been diagnosed 
with HIV-infection of whom approximately 32 million have died of the disease (WHO, 2018). 
Furthermore, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS), it is 
estimated that 37.9 million people were living with HIV by the end of 2018 (UNAIDS, 2019). 
According to the WHO, the burden of HIV/ AIDS varies considerably between countries and regions, 
with the sub-Saharan African region being affected most significantly, accounting for two-thirds of 
people living with HIV globally. It is estimated that 68% of the people living with HIV are from SSA 
with Eastern and Southern Africa accounting for 20.6 million HIV-infected people, and 800,000 new 
HIV infections in 2018 (UNAIDS, 2019). At present, South Africa has the highest number of people 
living with HIV, estimated to be 7.7 million at the end of 2018 (UNAIDS, 2019). In 2014, UNAIDS in 
partnership with their essential stakeholders, launched the so-called 90–90–90 targets with the aim to 
at least diagnose 90% of all HIV-positive individuals, provide ART for 90% of those diagnosed, and 
achieve viral suppression for 90% of those treated by 2020 (Bain, Nkoke and Noubiap, 2017). With 
regards to these goals, South Africa has made great progress in HIV testing rates and has subsequently 
achieved the first of the 90-90-90 target, with 90% of people living with HIV aware of their status in 
the country (UNAIDS AIDSinfo, 2019). Furthermore, till date, South Africa is home to the largest ART 







2.3.2 HIV pathophysiology  
HIV is subdivided into two types, HIV-type 1 (HIV-1) and HIV-type 2 (HIV-2) (Eberle and Gürtler, 
2012). HIV-1 is mainly responsible for AIDS and has been reported to have originated in the area 
around Kinshasa in Democratic Republic of Congo, from where it is believed to have spread through 
the transport networks to other areas in SSA, West Africa, Europe and the rest of the world (Bbosa, 
Kaleebu and Ssemwanga, 2019). HIV-2, on the other hand has been documented to be less infectious 
than HIV-1 (Gilbert et al., 2003) and is largely reported to be endemic to Western Africa, however 
recently HIV-2 infections have also been described in in Europe (Portugal and France), India and the 
United States of America (Bbosa, Kaleebu and Ssemwanga, 2019). Genetically, HIV belongs to the 
Lentivirus genus of the Retroviridae family (Tavassoli, 2011). The HIV genome is characterized by 
retroviral genes such as gag, pol and env which is bordered by long terminal repeats (LTRs), consisting 
of the viral promoter (Kirchhoff, 2016).  
The HI virus itself is spherical in structure with two identical copies of RNA strands at the core, tightly 
bound to nucleocapsid proteins (NC, also known as p7) (Refer to figure 2.13)  (Zhu et al., 2006; 
Tavassoli, 2011).  The two RNA strands are further enclosed by a conical capsid which is composed of 
the p24 capsid protein (CA). This capsid, further consists of enzymes and proteins which are essential 
to the virus and not available in the host, this include copies of the viral protease and the accessory Vif, 
Vpr, and Nef proteins, as well as some cellular factors, such as tRNAlys3 which is used as a primer for 
reverse transcription (Tavassoli, 2011; Kirchhoff, 2016). The integrity of the virus is maintained by the 
matrix protein which surrounds the capsid. The envelope that surrounds this matrix is composed of a 
lipid membrane which is derived from the host cell and contains cellular proteins, as well as about 7–
12 trimeric complexes of viral envelope Env protein. The Env protein consists of the external 
glycoprotein 120 (gp120) that mediates viral attachment and the transmembrane glycoprotein 41 (gp41) 
that is critical for viral fusion (Kirchhoff, 2016). All of these envelope proteins arrange into 












Figure 2.13: Structure of the HIV particle. Figure designed by the author of this dissertation based on 
content from (Fanales-Belasio, Raimondo et al. 2010; Tavassoli, 2011; Kirchhoff, 2016). 
 
2.3.3 HIV life cycle 
Refer to figure 2.14 for a schematic presentation of the HIV replication cycle. HIV is an obligate 
intracellular parasite and as with other viruses, it relies on host proteins to complete its life cycle 
(Ghimire, Rai and Gaur, 2018). The HIV life cycle is a highly complex and regulated process which 
recruits viral and cellular components to the plasma membrane for assembly into infectious particles 
(Mailler et al., 2016). The replication cycle begins with the virus entry into the host. This multistep 
process includes envelope protein gp41 which is attached to and extends away from the viral membrane, 
with its extracellular domain non covalently binding to protein gp120 (refer to figure 2.13 above) 
(Klimas, Koneru and Fletcher, 2008; Tavassoli, 2011). Both proteins associate into homotrimers that 
mediate binding and entry into the host cell (Tavassoli, 2011). Gp120 binds to the CD4 receptor which 
leads to a structural change in the virus envelope complex of gp120 and gp40 to expose a particular 
domain of gp120 which enables binding with a coreceptor CC chemokine receptor 5 (CCR5) or CX 
chemokine receptor 4 (CXCR4) that is located on the surface of the cell membrane (Kirchhoff, 2016; 
Ghimire, Rai and Gaur, 2018). Following the double binding to host (both to CD4 and chemokine 
receptor), gp120 further undergoes a conformational change that moves the gp41 hydrophobic region 
close to the host cell, leading to its insertion into the host cell’s membrane (Fanales-Belasio et al., 
2010)(Fanales-Belasio, Raimondo et al. 2010; Tavassoli, 2011; Kirchhoff, 2016). This penetration into 
the cell membrane leads to a conformational rearrangement of the heptad repeat regions (HR1 and HR2) 





the gp41 hydrophobic fusion peptide which is inserted into the host’s membrane. This leads to the 
formation of the fusion pore which permits the virus capsid to enter the cell (Tavassoli, 2011). 
 
Figure 2.14: HIV life cycle. Figure designed by the author of this dissertation based on content from 
(Fanales-Belasio, Raimondo et al. 2010; Tavassoli, 2011; Kirchhoff, 2016). 
Refer to figure 2.14. Following fusion, the HIV capsid accompanied by the genetic information of the 
virus is released into the host cell cytoplasm (Ghimire, Rai and Gaur, 2018). HIV contains its genetic 
information as two single stranded RNA, meanwhile the host cell uses DNA. Hence, the viral RNAs 
are transcribed into linear double- stranded DNAs through the process of reverse transcription which is 
mediated by the HIV reverse transcriptase enzyme (Tavassoli, 2011). This transcribed HIV DNA moves 





integration process essentially completes the HIV infection with the viral DNA incorporated into the 
host’s genome (Tavassoli, 2011). This integrated form of the virus, now termed ‘provirus’ can express 
viral proteins if the host’s cell is in an activated state (Klimas, Koneru and Fletcher, 2008). Following 
cell activation, the provirus DNA is transcribed into a messenger RNA (mRNA) that initially yields 
synthesis of regulatory HIV proteins Tat and Rev. The viral protein Tat plays a crucial role in up 
regulating transcription. Initially only a small number of transcripts are produced, leading to a build-up 
pf Tat which subsequently triggers the phosphorylation of RNA polymerase II which greatly increases 
transcription of the viral genome (Tavassoli, 2011).  
The complexity of the HIV genome leads to the possibility of more than 30 different viral mRNA 
species in the host cell (Tavassoli, 2011). The viral mRNA coding for long fragments migrates to the 
cytoplasm, this transport is promoted by the Rev protein (Kirchhoff, 2016). In the cytoplasm, the mRNA 
dominates the protein making apparatus of the cell and begins synthesizing structural proteins of the 
new virus through the process of translation (Klimas, Koneru and Fletcher, 2008). The sequence of the 
proteins of the mRNA molecules is translated into the RNA and proteins including the envelope and 
the core of the virus. The process of translation yields gene products which are much larger than those 
that are part of the final virus and thus they need to be spliced into smaller functional units (Klimas, 
Koneru and Fletcher, 2008). The viral protease, dominates the splicing process and cleaves large gp160 
precursor molecules into gp120 and 41. The Gag and Pol proteins are also derived from a large 160 kD 
precursor molecule, from which the HIV protease cleaves the p24, p17, p9 and p7 Gag final products 
and the Pol proteins (Miceli and Parnes, 1993; Fanales-Belasio et al., 2010). The cleavage of the 
precursor molecules by the HIV protease is necessary for the generation of infectious viral particles. In 
summary, the new viral particles are generated in a stepwise fashion. To begin with, the two viral RNA 
strands associate together with the replication enzymes while the core protein assemble over them to 
form the virus capsid (Fanales-Belasio, Raimondo et al., 2010). Following this, the immature particle 
migrates towards the cell surface. This entire process is enabled by the Gag protein (Tavassoli, 2011). 
At this stage, the large precursor molecules are then cleaved by the viral protease, resulting in new 
infectious viral particles. Following this the virus then ‘pinches’ off the cells and ‘buds’ off through the 
host cell membrane while obtaining a new envelope (Fanales-Belasio, Raimondo et al., 2010; Klimas, 
Koneru and Fletcher, 2008). The surface of this new HIV particle then acquires HIV glycoproteins that 
promote binding to CD4 cell co-receptors to infect other cells (Tavassoli, 2011). A single cell can 
generate thousands of infectious HIV particles either in a recurrent fashion, over a period of weeks or 






2.3.4 Antiretroviral therapy (ART) 
Initially, the clinical management of HIV largely consisted of prophylaxis against common 
opportunistic infections and managing AIDS related illnesses. The race for finding effective treatment 
was ongoing throughout the 1980s and 1990s with the first successful ART drugs rolled out in the mid-
1990s (Ghimire, Rai and Gaur, 2018).  Shortly after this, approval was given for monotherapy, and 
combination therapy based on highly active antiretroviral therapy (HAART), which transformed HIV 
from a progressive fatal illness to a chronic manageable disease (Arts and Hazuda, 2012). Although, 
HAART is not a cure for HIV, it substantially reduces viral load, maintains T cell counts and prevents 
opportunistic infections that may be fatal (Ghimire, Rai and Gaur, 2018). Overall, these successful 
advances in the ART space have led to significant reductions in morbidity and mortality in people living 
with HIV (Rana et al., 2020). 
ART predominantly acts on various stages of the HIV life cycle to inhibit key steps in viral replication 
(Refer to figure 2.15 for a schematic representation (Arts and Hazuda, 2012). Currently the ART drugs 
are divided into seven different classes based on their target in the HIV life cycle. The first class 
approved by the Food and Drug Administration was the nucleoside reverse transcriptase inhibitors 
(NRTIs). Drugs from this class block the HIV reverse transcriptase and inhibit reverse transcription of 
viral RNA into double stranded viral DNA and thus prevents HIV from replicating (Arts and Hazuda, 
2012; AIDSinfo, 2018 ). A few years after the discovery of NRTIs, non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) were introduced. NNRTIs act by non-competitively inhibiting reverse 
transcriptase by binding to their allosteric site, thus altering their activity and blocking the development 
of double stranded viral DNA from the viral RNA (Arts and Hazuda, 2012; AIDSinfo, 2018 ). The third 
class of ARTs are the protease inhibitors (PIs) which act by blocking the viral protease enzymes 
responsible to produce mature virions after budding from the membrane  (Arts and Hazuda, 2012). 
Drugs from this class specifically inhibit the cleavage of Gag and Gag-Pol precursor proteins 







Figure 2.15: Schematic representation of the HIV life cycle and the sites of action of the various classes 
of ART. Figure designed by the author of this dissertation based on content from (Fanales-Belasio, 
Raimondo et al., 2010; Tavassoli, 2011; Arts and Hazuda, 2012; Kirchhoff, 2016; AIDSinfo, 2018). 
The integrase inhibitors (INIs), target and competitively inhibit the viral enzyme integrase which is 
responsible for integration of viral DNA into the DNA of the infected cell. More recently, entry 
inhibitors were introduced, including fusion inhibitors that block the HIV envelope from merging with 
the host CD4 cell membrane (fusion) (Arts and Hazuda, 2012; AIDSinfo, 2018 ), hence preventing the 
virus from entering the CD4 cell. Similar to this class, there are chemokine receptor antagonists which 
particularly target the CCR5 and inhibit fusion between the cell membranes (Arts and Hazuda, 2012; 
AIDSinfo, 2018 ). The last and most recent class of ART is the post-attachment inhibitors, which act 
by binding to the CD4 receptor on a host CD4 cell while subsequently inhibiting the virus attachment 
to CCR5 and CXCR4 coreceptors and entering the cell (AIDSinfo, 2018). Refer to table 2.8 below for 























































Currently, international guidelines for clinical management of HIV recommend initiation of ART as 
soon as possible after diagnosis (Rana et al., 2020). For many patients, this translates into taking a single 
well-oriented, fixed dose combination tablet once daily. However clinical management of patients on 
ART is riddled with adherence challenges with a sizeable proportion of patients not achieving viral 
suppression and subsequently resulting in poorer patient outcomes (Gardner et al., 2011; Powers et al., 
2017; Rana et al., 2020). It is noteworthy that despite chronic use of ART, there is no cure of the disease. 
HIV is coupled with persistent viral reservoir that harbours integrated, replication-competent provirus 
within host cellular DNA. This reservoir is resistant to ART and to actions by the immune system of 
the host. If treatment is stopped, these reservoirs reactivate and HIV can begin replicating again, and 
transmission can occur.  ART does not eradicate viral reservoirs, hence one of the main challenges in 
the fight against HIV infection is to develop strategies that are able to eliminate these persistent viral 
reservoirs (Churchill et al., 2016; National Institute of Allergy and infectious diseases, 2018). Other 
challenges include drug toxicity over a long treatment period, high viral mutation rates leading to ARV 
resistance (Ghimire, Rai and Gaur, 2018).  
 
2.3.5 ART guidelines in South Africa 
Initially ART commencement was based on the individual’s CD4 cell count. Revised guidelines were 
issued in 2015 by WHO recommending the initiation of ART immediately after diagnosis (WHO, 
2016). In accordance with the international guidelines, the South African ART guidelines recommend 
that all people living with HIV commence with ART regardless of age, CD4 cell count and clinical 
stage. According to the 2019 ART Clinical guidelines developed by the South African National 
Department of Health, all adult patients without any contraindications are recommended to begin ART 
within 7 days of diagnosis or on the same day if possible (South African National Department of Health, 
2019).  
Refer to table 2.9 for South African approved relevant ART drugs and their side effects. In South 
Africa, the first line treatment is largely available as a triple drug fixed dose combination (FDC) regimen 
(Meintjes, Moorhouse et al. 2017). The FDC regimen lowers the inconvenience of having to ingest 
multiple pills daily and largely simplifies prescription, dispensing and stock management of drugs. 
Furthermore, FDCs have shown to improve treatment compliance in individuals (Meintjes, Moorhouse 
et al., 2017, Davies 2013). In line with international guidelines, South Africa recommends first line 
ART treatment containing two NRTIs and one NNRTI (tenofovir + emtricitabine (or lamivudine) + 
efavirenz (preferred). At the time of the PhD study and still largely today, the FDC ART largely 
comprises of tenofovir (T), emtricitabine (E) and efavirenz (E) (also known as TEE), which is available 
as Atripla™ or Odimune™ in South Africa (Deeks and Perry, 2010). In 2018, the WHO recommended 





HIV patients to a different combination, which contains dolutegravir (D) in place of efavirenz, thus 
comprising the first line FDC to be TLD, instead of TEE or TLE  (USAID, 2019; WHO, 2019). This 
further also included INIs in combination with NRTIs as first line treatment for HIV. In South Africa, 
the TLD transition has been on a slow rise and riddled with controversies around dolutegravir’s adverse 
impact (increased risk of neural tube defects in the foetus) on women of child bearing age, however the 
WHO has supported the safety of the drug based on recent data from two clinical trials from Africa 
which demonstrate a significantly lower risk for these women (South African National Department of 
Health, 2019; WHO, 2019). More recently, dolutegravir has also been associated with abnormal weight 
gain, further questioning its adverse effects on these patients (Menard et al., 2017; Bourgi et al., 2020) 
Clinical guidelines in South Africa recommend that patients who are overweight should receive lifestyle 
interventions (such as prudent eating and moderate exercising plan) accompanying the dolutegravir 
based treatment while obese patients should be rather be considered for the TEE or TLE treatments 
(South African National Department of Health, 2019). 
The second line treatment in South Africa includes a PI-containing combination (zidovudine + 
lamivudine + lopinavir booster with ritonavir (lopinavir/r)). Patients with anaemia and renal failure are 
recommended to switch to abacavir (an NRTI). TLD is also recommended for use as a second-line 
regimen for patients failing on efavirenz or nevirapine containing regimens or for those failing a non-
dolutegravir-containing first-line regimen (WHO, 2019). Currently, however, the most common 
second-line ART contains PIs, lopinavir/ ritonavir which is available as Aluvia™ in South Africa 
(Chandwani and Shuter, 2008). HIV patients who demonstrate confirmed failure to both first and second 
line ART, a virologic failure and ART resistance are recommended to receive third line ART treatment, 
which is based on the individual’s genotype resistance testing, managed by an expert panel (South 













Table 2.9: Relevant South African approved ART drugs and their side effects. Content from (Charania, 
2017; South African National Department of Health, 2019, AIDSinfo 2020). 
Drugs Side Effects 
Emtricitabine  Common side effects include headache, diarrhoea, nausea, fatigue, dizziness, 
depression, insomnia, abnormal dreams, rash, abdominal pain, asthenia, 
increased cough, and rhinitis. In paediatric patients, skin hyperpigmentation 




The most common side effects include nausea, vomiting, diarrhoea, and 
asthenia. Less frequent side effects include hepatotoxicity, abdominal pain, 
and flatulence. This drug has also been implicated in causing kidney toxicity, 
particularly at elevated concentrations.  
Efavirenz  Common side effects include diarrhoea, dizziness, drowsiness, headache, 
increased sweating, poor concentration, trouble sleeping, depression and skin 
rash. 
Lamivudine Common side effects included headache, nausea, malaise, fatigue, nasal signs 
and symptoms, respiratory tract infections, throat and tonsils discomfort, 
abdominal discomfort and pain, vomiting, diarrhoea, and cough. 
Abacavir Common side effects include diarrhoea, dizziness, drowsiness, and headache. 
Lopinavir 
 
Common side effects include an increase in serum cholesterol and 
triglycerides.  
Ritonavir Common side effects include asthenia, malaise, diarrhoea, nausea and 
vomiting, abdominal pain, dizziness, insomnia, sweating, taste abnormality, 
metabolic hypercholesterolemia, hypertriglyceridemia, elevated 
transaminases and elevated creatine phosphokinase (CPK).  
Dolutegravir Usually mild and self-limiting. Side-effects include insomnia, headache, 
central nervous system (CNS) effects, gastrointestinal effects, and abnormal 
weight gain. Dolutegravir may increase the risk of neural tube defects. 






Section C: The link between CVD & HIV and its underlying 
mechanisms 
 
2.4 Cardiovascular risk factors and disease in HIV infected individuals 
2.4.1 Introduction 
Advances in ART have been successful in transforming HIV/Aids from a life-threatening acute disease 
to a chronic disease condition, which can be managed with treatment (Estrada et al., 2020). In fact, 
recently, some studies suggest that individuals on ART have a life expectancy approaching that of HIV-
free individuals (Samji et al., 2013; Kaplan, Hanna and Kizer, 2016). However, currently, CVD has 
become one of the main causes of morbidity in the HIV-infected population (Shah et al., 2018; Estrada 
et al., 2020). This could be partially attributed to the increased lifespan of the HIV-infected individuals 
as well as direct effects of the ART drugs (de Gaetano Donati, Cauda and Iacoviello, 2010). From the 
time effective ART was introduced, there have been mounting concerns and questions about the 
potential effect of ART on the development of CVD in the HIV population. These concerns continue 
to persist, even as HIV treatment is refined with fewer adverse effects, better adherence, more 
convenience, and earlier initiation of therapy (Kaplan, Hanna and Kizer, 2016). Furthermore, several 
studies have observed a high prevalence of traditional cardiovascular risk factors in HIV-infected 
individuals (Beltrán et al., 2015). Within the HIV context, all factors such as the individual’s genetics, 
traditional cardiovascular risk factors, adverse effects of ART as well as the inflammatory state of HIV 
may be considered as potential risk factors for CVD (de Gaetano Donati, Cauda and Iacoviello, 2010; 
Beltrán et al., 2015) (Refer to figure 2.16 below).  
 
Figure 2.16: Risk factors of CVD in HIV. Cardiovascular risk in HIV-infected individuals can be 
attributed to the individual’s genetics, traditional risk factors, adverse effects from antiretroviral therapy 
as well as the inflammatory state associated with HIV itself. Figure designed by the author of this 





2.4.2 Traditional cardiovascular risk factors and HIV  
Many studies show that HIV infected individuals have a generally high prevalence of traditional 
cardiovascular risk factors, including smoking, dyslipidaemia, hypertension, and type 2 diabetes 
(Currier et al., 2008; Beltrán et al., 2015). Interestingly, studies that have controlled for traditional risk 
factors have largely demonstrated a significant effect of these factors on CVD events in the HIV 
population. Furthermore, many studies show that all these factors are strong predictors of CVD in the 
HIV population (Triant et al., 2007; de Gaetano Donati, Cauda and Iacoviello, 2010). However, it is 
important to note that both ART and HIV infection may, additionally, influence the induction of 
particular risk factors such as dyslipidaemia and diabetes (Beltrán et al., 2015).   
Hypertension 
Hypertension is found to be the leading risk factor for CVD in the HIV population, particularly in SSA 
(Okello et al., 2020). Studies suggest that HIV-infected individuals in this region experience a high 
incidence of new-onset of hypertension, especially in the first two years after initiation of ART (Okello 
et al., 2020). Additionally, data from around the world shows that 35% of all HIV-infected individuals 
on ART have hypertension in comparison to an estimated 30% of HIV-free individuals. Furthermore, 
50% of HIV-infected individuals (over the age of 50 years) on ART have hypertension (Xu, Chen and 
Wang, 2017; Fahme, Bloomfield and Peck, 2018). In fact, there is evidence that HIV-infected 
individuals with hypertension have a higher risk of CVD and related mortality in comparison to HIV- 
free individuals with hypertension or HIV-infected individuals with normal blood pressure (Nüesch et 
al., 2013; Fahme, Bloomfield and Peck, 2018). Although literature is clear on the growing concern of 
hypertension within the HIV context, the mechanism leading to hypertension in HIV remains unclear 
with many virus and treatment related factors implicated, including chronic inflammation, immune 
reconstitution, and lipodystrophy, all of which are suggested to uniquely influence common 
downstream pathways such as the sympathetic and renin–angiotensin–aldosterone systems 
(Maffongelli et al., 2016; Fahme, Bloomfield and Peck, 2018). With regards to the type of treatment, 
PIs have particularly been implicated in the pathogenesis of hypertension due to their mechanistic effect 
on RAAS activation, endothelial dysfunction, arterial stiffness, and dyslipidaemia (Fahme, Bloomfield 
and Peck, 2018).  
Smoking 
In SSA, it has been found that HIV infected individuals are more likely to smoke in comparison to the 
HIV-free individuals (Okello et al., 2020). A metanalysis has further demonstrated that there is a 47% 
higher risk of smoking amongst HIV-infected men and 87% higher risk of smoking in HIV-infected 
women (Mdege et al., 2017). Reasons for smoking in this population have been speculated to include 
self-treatment of the comorbid anxiety and depression as well as self-management of HIV-associated 





HIV infection to independently increase CVD risk, it remains unclear whether HIV-infected individuals 
have an increased susceptibility to smoking-associated CVD in comparison to HIV-free smokers 
(Okello et al., 2020). In terms of the pathophysiological effect of smoking on CVD in the HIV context, 
the effect is similar to that of in the HIV-free context, however, it appears that smoking works 
synergistically with ART, especially with PIs, to promote CVD (Rahmanian et al., 2011). Ultimately, 
smoking in this population provides unique and specific risks that promote more rapid development of 
cardiovascular and pulmonary disease (Cropsey, K et al., 2017). 
Obesity 
A paradoxically high prevalence of obesity has been demonstrated in many HIV-infected populations, 
remarkably transforming the ‘slim’ and ‘wasting’ body image which was initially associated with the 
disease (Serwadda et al., 1985; Okello et al., 2020). Many studies in the SSA region have shown an 
increased weight gain following ART initiation (Koethe et al., 2016). The PI class of ART has been 
proven to have adverse effects resulting in weight gain, visceral adiposity and eventually lipodystrophy 
that is further believed to drive subsequent dysglycemia (Price et al., 2015; Okello et al., 2020). 
Furthermore, the newer generation first-line ART drugs such as dolutegravir (integrase inhibitor) have 
also been demonstrated to significantly increase weight gain in comparison to the previously 
recommended first line ART (Bourgi et al., 2020). Literature also shows that HIV-infected women have 
a higher prevalence of obesity and overweight in comparison to men, this is further in line with the 
trends in the HIV-free population (Malaza et al., 2012). 
Dyslipidaemia 
A higher burden of dyslipidaemia has been found in the HIV infected population in comparison to the 
HIV-free population (Dillon et al., 2013; Okello et al., 2020). A metanalysis across Africa further 
demonstrated a 26.2% prevalence of elevated total cholesterol in HIV-infected populations in 
comparison to 25.5% prevalence in the HIV-free population. Furthermore, the analysis confirmed a 
more than two-fold higher prevalence for elevated LDL cholesterol in HIV-infected (45.6%) versus 
HIV-free (21.4%) study populations (Noubiap et al., 2018). Additionally, studies have observed a 
decrease in total, HDL and LDL cholesterol, but an increase in triglyceride levels, in untreated HIV 
individuals (Riddler et al., 2003; Hemkens and Bucher, 2014). The HI virus itself is implicated in 
inducing these effects through persistent inflammation and immune activation as well as through its 
increased thrombotic activity (Hemkens and Bucher, 2014; Beltrán et al., 2015). It is now well known 
that several types of ART also increase total cholesterol, LDL-cholesterol, and triglycerides while 
keeping the HDL-cholesterol low (Hemkens and Bucher, 2014). The extent of lipid changes differs 
between antiretroviral drugs and drug classes. For instance, ART (e.g. indinavir, lopinavir vs. 





and triglycerides, whereas ART(e.g. efavirenz)  from the NRTI class  are found to increase total and 
LDL-cholesterol compared with newer PIs (Sax et al., 2009; Hemkens and Bucher, 2014). 
Diabetes 
Impaired glucose regulation associated with HIV and ART can lead to a rise in type 2 diabetes (Okello 
et al., 2020). Some studies suggest up to a four-fold higher risk of diabetes in HIV-infected individuals 
on ART in comparison to HIV-free individuals (Maganga et al., 2015). Furthermore, studies from 
Western countries showed that the positive association between HIV and diabetes, in fact correlated 
with traditional risk factors such as age and obesity, suggesting that these factors, and not the ART, 
may play a role in the progression to diabetes in the HIV-infected population (Tripathi et al., 2014). 
ART induced risk of diabetes has been associated with the use of drugs belonging to the PI class and 
the older thymidine analogue reverse transcriptase inhibitor family, which are implicated in 
mitochondrial toxicity (Hemkens and Bucher, 2014). However, today in many settings, these drugs 
have mostly been replaced (Hemkens and Bucher, 2014; Okello et al., 2020). Mitochondrial toxicity 
has been shown to lead to impaired insulin sensitivity and in vitro models suggest that PIs block glucose 
transporter (GLUT4) and may also affect glucose-sensing-cells, both causing impaired glucose 
sensitivity (Koster et al., 2003; Hemkens and Bucher, 2014). Furthermore, recently, the integrase strand 
inhibitor, dolutegravir, has been under speculation for its association with insulin resistance and 
diabetes (McLaughlin, Walsh and Galvin, 2018). It has been hypothesized that dolutegravir may have 
the ability to chemically bond with magnesium which in turn may affect the glucose transport via GLUT 
4 receptor and gluconeogenesis leading to insulin resistance (Kamal and Sharma, 2019). Other factors 
that may be associated with an increased risk of diabetes within the HIV context are high-sensitivity C-
reactive protein and tumour necrosis factors 1 and 2 (Brown et al., 2010). 
Age 
Due to the success of ART, the proportion of HIV-infected individuals over the age of 50 has 
significantly increased since the early days of the epidemic (Kirk and Goetz, 2009; de Gaetano Donati, 
Cauda and Iacoviello, 2010). Furthermore, the incidence and prevalence of HIV is rising in older adults. 
It also seems that the older adults with HIV have an accelerated decline in immune function and are 
more likely to be diagnosed later in comparison to younger adults (Önen et al., 2010). Although ART 
is likely to improve prognosis in older adults as well, a higher risk of co-morbidity remains (De et al., 
2013). Furthermore, it is speculated that the increased rate of CVD may also be due to the acceleration 
of biological aging which can be promoted by both the HI virus itself and/ or ART, suggesting that 
premature aging is in fact associated with HIV-infection. This in turn can influence development of 






Literature from developed countries suggests that HIV-infected women have an approximately 2 to 4 
times higher risk of myocardial infarction, stroke, and heart failure in comparison to HIV-free women 
(Chow et al., 2012; Janjua et al., 2017). The reasons for this could be elevated levels of systemic 
inflammation and interaction with reproductive hormones, as well as increased behavioural and 
psychosocial risk factors as compared to the general population (Zanni et al., 2019; Okello et al., 2020). 
Furthermore, generally many studies, especially from the SSA region, have observed a higher 
prevalence of increased risk factors such as obesity, dyslipidaemia and hypertension in both HIV-
infected and HIV-free women in comparison to HIV-infected and HIV-free men, respectively (Gaziano 
et al., 2017; Magodoro et al., 2019). Additionally, several studies measuring IMT as a surrogate marker 
to assess the prevalence of CVD have demonstrated mixed results when comparing HIV-infected 
women to HIV-infected men (Schoffelen et al., 2015; Okello et al., 2020). Future large-scale studies 
are warranted to further understand the CVD risk between men and women and their mechanism 
associated with HIV and ART (Okello et al., 2020).  
 
2.4.3 HIV, ART, endothelial dysfunction, and biomarkers of endothelial 
injury 
Endothelial dysfunction is the first step in atherogenesis (Kearns et al., 2017). A large body of literature 
provides evidence that endothelial dysfunction can progress to atherosclerosis and predict future 
cardiovascular events in many populations. In the HIV context, both the virus and certain types of ART 
drugs are found to be associated with endothelial dysfunction (Torriani et al., 2008; Wang, Yi, Green, 
et al., 2015). Refer to figure 2.17 for an overview of endothelial dysfunction in the HIV context. The 
ability of the HI virus to infect ECs can directly lead to endothelial dysfunction. HIV can enter ECs 
through chemokine receptors 3 and 4 (CCR-3 and CCR-4), cluster of differentiation 4 (CD4) or 
galactosyl-ceramide receptors (Skowyra et al., 2012). Furthermore, HIV can penetrate ECs with the 
assistance of its viral proteins such as GP120, tat and Nef (Anand, Rachel and Parthasarathy, 2018).  
Many studies have suggested that GP120 has a crucial role in the pathogenesis of endothelial 
dysfunction (Anand et al., 2009; Anand, Rachel and Parthasarathy, 2018). GP120 has been associated 
with apoptosis, adhesion molecule expression, pro-inflammatory cytokine production, and endothelial 
cell permeability (Fiala et al., 2004; Anand, Rachel and Parthasarathy, 2018). Additionally, GP120 is 
found to be responsible for the stimulation of macrophages to produce excessive amounts of NO, which 
can progress to direct endothelial damage (Wang, Yi et al., 2015). Furthermore, studies confirm that 
GP120 is directly involved in the upregulation of pro-inflammatory cytokines such as IL-6 and IL-8 in 
primary ECs (Yang et al., 2009; Anand, Rachel and Parthasarathy, 2018). In addition, the HIV TAT 
protein can activate inflammatory pathways via mononuclear cells that are known to produce TNF-α 
and the pro-inflammatory transcription factor, nuclear factor kappa-light-chain-enhancer of activated B 





of adhesion molecules E-selectin, VCAM-1 and ICAM-1, all of  which alter endothelial permeability 
and ultimately impact negatively on endothelial function (Anand, Rachel and Parthasarathy, 2018). Like 
GP120 and Tat, Nef has also been associated with several aspects of HIV-induced endothelial 
dysfunction (Anand, Rachel and Parthasarathy, 2018). A study has shown that Nef is involved in 
upregulation of ERK kinase mediated ICAM-1 in vascular ECs (Fan et al., 2010). Additionally, Nef 
can activate macrophages and produce foam cells, which is suggested to contribute to endothelial 
dysfunction and facilitate development of atherosclerosis (Anand, Rachel and Parthasarathy, 2018). 
Moreover, apart from these direct effects on endothelial function, HIV can also infect and decrease 
circulating endothelial progenitor cells especially the colony forming unit endothelial cells, which are 
essential for endothelial damage repair (Teofili, Iachininoto et al., 2010, Wang, Yi et al., 2015). 
Numerous studies have investigated the relationship between HIV and endothelial function (measured 
by the non-invasive method of FMD) in clinical settings (Margaritis, 2019). HIV-infected individuals 
with an elevated viral load are found to have an inverse association with FMD (Blum et al., 2005; 
Margaritis, 2019). Additionally, another study of 75 HIV-infected participants and 223 HIV-free 
participants showed that FMD was significantly lower in the HIV-infected group compared to HIV-free 
group. Furthermore, this study showed that viral load was an independent predictor of the degree of 
reduction in FMD (Solages et al., 2006; Margaritis, 2019). In addition, another study has shown that 
endothelial dysfunction is more pronounced when HIV infection is severe and more advanced (Wang, 
Yi et al., 2015, Subbarao, Lowe et al., 2011). 
In addition to the HI virus itself, ART can contribute to endothelial dysfunction in many ways (Skowyra 
et al., 2012). Refer to figure 2.17 for an overview of endothelial dysfunction in the context of HIV and 
ART. Particularly drugs from the PI class have been shown to directly induce endothelial dysfunction. 
They are thought to be responsible for mitochondrial DNA damage in ECs which can lead to destruction 
of the endothelium independent of the individual’s lipid profile (Zhong, et al., 2002, Skowyra et al., 
2012). Furthermore, it has been found that HIV-infected individuals receiving PIs have significantly 
lower endothelium-dependent vasodilatation measurements as assessed by the FMD protocol (Stein, 
Klein et al., 2001, O'Leary, Polak et al., 1999, Ogata, Yasaka et al., 2005, Bots, Hoes et al., 1999). 
However, other studies demonstrate contradicting findings. For instance, significant endothelial 
impairment was found with the drug indinavir, whereas the newer generation PI drugs such as lopinavir 
and ritonavir have not been confirmed to induce endothelial dysfunction in HIV-infected individuals 
(Dube, Shen et al., 2008, Grubb, Dejam et al., 2006, Skowyra, Zdziechowicz et al., 2012).  
With regards to biomarker analysis, it has been established that HIV infected individuals have higher 
levels of biomarkers of endothelial dysfunction such as cellular adhesion molecules compared to HIV-
free individuals (Francisci, Giannini et al., 2009, Wang, Melancon et al., 2013).  HIV is also associated 





Furthermore, all these inflammatory biomarkers have shown contradictory results in the presence of 
ART. Some studies have reported lower levels of biomarkers of inflammation and endothelial 
dysfunction in HIV-infected individuals on ART, whereas other studies demonstrate that these 
biomarkers remain elevated even in the presence of ART (Skowyra et al., 2012; Beltrán et al., 2015). 
For instance, a study has showed elevated P-selectin, tissue plasminogen activator and plasminogen 
activator inhibitor levels in treated HIV individuals when compared to the ART naive group (de Gaetano 




Figure 2.17: Overview of endothelial dysfunction in the context of HIV and ART. Figure designed by 
the author of this dissertation based on content from (Titanji et al., 2020). Viral proteins, inflammatory 
cytokines, and ART all lead to increase in ROS. Oxidative stress induces eNOS uncoupling leading to 
decrease NO availability. These mechanisms trigger endothelial dysfunction, which is characterized by 
decreased endothelial tight junction proteins, increased vascular adhesion molecules and 
vasoconstriction. ART, antiretroviral therapy; ROS, reactive oxygen species; eNOS; endothelial nitric 





intercellular adhesion molecule 1; IL-1, IL6, Il-8, interleukins-1, 6, 8; TNF-α, tumour necrosis factor- 
alpha. 
 
2.4.4 CVD risk, HIV, ART, and inflammatory biomarkers 
Many studies have demonstrated that CVD risk is higher in the HIV infected population in comparison 
to HIV-free population, even after adjusting for traditional risk factors such as hypertension, 
hyperlipidaemia, smoking and diabetes (Yoshimura, 2017). In fact, data from the Veterans Aging 
Cohort Study, Virtual Cohort (longitudinal study of HIV-positive, vs. age, ethnicity, and clinical site 
matched uninfected veterans) further demonstrated that HIV infection is associated with a 50% higher 
risk of acute myocardial infarction (Freiberg et al., 2013). Furthermore, there are many more studies 
that demonstrate increased risk of CVD, both in the absence and in the presence of ART (Grunfeld et 
al., 2009; Wang, Yi, Ann, et al., 2015).  However, despite increased availability of data in this field, 
the higher risk of CVD in HIV infected individuals remains incompletely understood. 
It is debatable as to which one of HIV-infection or ART poses a higher risk to CVD in HIV-infected 
individuals. Both the virus itself and ART have been implicated in the development of CVD.  Refer to 
table 2.10 for a list of mechanisms by which HIV may increase the risk of CVD. 
Table 2.10: List of mechanisms by which HIV may increase the risk of CVD (Beltrán et al., 2015). 
 
Refer to figure 2.18 for the role of HIV in the development of atherosclerosis. The HI virus is known 
to activate many inflammatory pathways which release cytokines and induce endothelial adhesion 
molecule expression. Both molecules facilitate leukocyte adhesion and transmigration and play a role 
in endothelial dysfunction which is discussed further in section 2.4.4 (Fisher, Miller and Lipshultz, 
2006; Beltrán et al., 2015). The persistent inflammation is accompanied by immune activation where 
several activation markers such as sCD163, sCD14, and CD14+/CD16+ monocyte expansion are 
elevated on monocytes/ macrophages (Beltrán et al., 2015). These monocytes/ macrophages play a 
crucial role in the development of atherosclerosis wherein macrophages phagocytize modified 
lipoproteins, which promotes proinflammatory and chemotactic cytokine secretion, and mediate 
cholesterol efflux from the arterial wall. Furthermore, the HI virus increases the proportion of 
CD14+/CD16+ monocytes, as it exhibits an activated phenotype with increased secretion of 
Mechanisms  
• Persistent inflammation and immune activation 
• Endothelial damage 
• Increased thrombotic activity 
• Higher oxidative stress 





proinflammatory cytokines (Beltrán et al., 2015). In addition, the virus suppresses the reverse 
cholesterol transport from arterial wall macrophages to HDL particles by blocking the adenosine 
triphosphate-binding cassette transporter A1 (ABCA-1) pathway (Mujawar et al., 2006). This 
ultimately promotes the accumulation of foam macrophages within atherosclerotic plaques (Anand, 
Rachel and Parthasarathy, 2018). In addition, both HIV induced inflammation and immune activation 
have been found to increase thrombotic activity by increasing biomarkers such as von Willebrand factor 
(Funderburg, 2014). Furthermore, HIV is known to increase oxidative stress by promoting oxidative 
lesions and damaging DNA repair mechanisms (Aukrust et al., 2005). Moreover, HIV promotes 
atherogenesis through its metabolic effects, mainly by decreasing HDL-cholesterol and apoA1, 
decreasing LDL particle clearance, as well as by increasing triglycerides and very low LDL cholesterol 
(Beltrán et al., 2015). All these HIV mechanisms of inflammation, immune activation and a 
prothrombotic state participate in the development of atherosclerosis and ultimately CVD.  
Refer to figure 2.18 for the role of ART in the development of atherosclerosis. In addition to the HI 
virus, a large body of evidence suggests that ART poses an increased CVD risk in HIV-infected 
individuals (Beltrán et al., 2015; Wang, Yi, Ann, et al., 2015). ART-induced hyperlipidaemia and 
hypercholesterolemia are known to promote the development and progression of atherosclerosis 
(Brown and Glesby, 2012). Furthermore, ART has been suggested to also promote the development of 
insulin resistance and type 2 diabetes (Colleen Hadigan et al., 2001; Beltrán et al., 2015). These 
alterations may occur either independently or as part of other disorders, such as metabolic syndrome or 
lipodystrophy (Beltrán et al., 2015). With regards to the type of ART, drugs from the PI class have been 
largely reported to cause dyslipidaemia and contribute to the increased CVD risk in the HIV-infected 
population (Wang, Yi, Ann, et al., 2015). In general, new generations of ART have substantially 
lowered adverse effects, however initiation of ART is usually  associated with increased weight gain, 
triglycerides, total cholesterol and LDL cholesterol (Lazzaretti et al., 2012; Beltrán et al., 2015). Hence 









Figure 2.18: Role of HIV and ART in the pathogenesis of atherosclerosis. Figure designed by the author 
of this dissertation based on content from (Kearns et al., 2017; Spadaro, Cecchetti and Fantuzzi, 2017). 
Both HIV and ART can induce dyslipidaemia and inflammation. This leads to accumulation and 
oxidation of LDL by ROS within the artery wall, which is followed by recruitment/infiltration of 
monocytes and their differentiation into macrophages, which become foam cells on uptake of oxidized 
LDL and then finally foam cell coalescence into a lipid necrotic core leading to plaque development.  
ART, antiretroviral therapy; LDL, low-density lipoprotein; ROS, reactive oxygen species; IL-6, 
interleukin-6; TNF-α, tumour necrosis factor- alpha; CRP, C reactive protein. 
A growing body of evidence suggests that multiple biomarkers can be measured to assess the role of 
inflammation and immune activation in the development of CVD in the HIV-infected population 
(Kearns et al., 2017). Biomarkers include inflammatory mediators and adhesion molecules that have 
been shown to be elevated in HIV –infection, such as high sensitivity (hs) CRP, IL-6, TNF-R, VCAM-
1, ICAM-1, and asymmetric dimethylarginine (ADMA) (Kurz et al., 2009; Neuhaus et al., 2010; 
Hileman et al., 2013). Particularly, increased hs CRP and IL-6 levels are found to be strong predictors 
of future cardiovascular events and overall mortality in both ART naïve and ART treated HIV infected 
patients, and are therefore regarded as useful biomarkers in this context (Kuller, Tracy et al., 2008, 
Wang, Yi et al., 2015). Furthermore, TNF-R has been associated with non-HIV related morbid events 
which includes CVD (Tenorio et al., 2014). Additionally, numerous studies have demonstrated that the 





to an increased prevalence of elevated biomarkers of inflammation, altered coagulation, and monocyte 
activation, independent of the effects of comorbid conditions (Sandler, Wand et al., 2011, Wang, Yi et 
al., 2015). 
Levels of inflammatory and immune activation biomarkers in HIV-infected individuals can be affected 
by the type of ART being used (Laurence, Elhadad and Ahamed, 2018). Furthermore, the effect of ART 
on biomarker levels have been contradictory so far, with some studies suggesting that ART may impose 
protective effect on CVD in HIV-infected population (Kurz et al., 2012; Beltrán et al., 2015). For 
instance, it has been reported that ART is associated with lower levels of certain biomarkers of 
inflammation, particularly, reduced levels of VCAM-1, ICAM-1 and CRP were reported in a study of 
115 HIV-infected individuals after 2 months and 14 months of ART (Duprez et al., 2012). Furthermore, 
another study showed that TNFR-II, VCAM-1, ICAM-1, and IL-6 plasma levels were significantly 
decreased after 24 weeks and 96 weeks of ART (McComsey et al., 2012). 
However, it is noteworthy that none of the studies suggest that ART completely reverses inflammation 
and immune activation in HIV patients (Beltrán et al., 2015). In fact, a few studies such as the Second 
Manifestations of ArTerial disease (SMART) study, Multi-Ethnic Study of Atherosclerosis (MESA) 
study, and Coronary Artery Development In young Adults (CARDIA) study, observed that virologically 
suppressed HIV-infected individuals on ART have elevated CRP and IL-6 levels amongst a few other 
biomarkers, in comparison to HIV-free individuals (Neuhaus et al., 2010). Additionally, similar results 
were found in a case-control study where the presence of ART was found to have lowered VCAM-1, 
CRP and TNFR-II levels, however, the levels remained elevated in comparison to HIV-free individuals 
(Beltrán et al., 2014). This further suggests that even in the presence of  ART, HIV may induce many 
inflammatory pathways which release biomarkers that  may contribute to CVD risk and development 
(Kearns et al., 2017).  
 
2.4.5 HIV, ART, subclinical atherosclerosis, and biomarkers of 
inflammation 
Carotid artery intima-media thickness (IMT) is a measure of sub-clinical atherosclerosis that is known 
to predict future CVD events in many populations (Hanna et al., 2016). Assessment of the carotid artery 
IMT via ultrasound, for evidence of subclinical atherosclerosis has previously been investigated in cross 
sectional and prospective studies as a marker of CVD risk in a HIV-infected population (Sarfo et al., 
2019). Many studies suggest that HIV-infected individuals have increased IMT in comparison to HIV-
free individuals. For example, a study demonstrated that HIV infection was associated with premature 
atherosclerosis even with extreme low levels of viremia, overt immunodeficiency, and exposure to ART 
and this appeared to be independent of traditional cardiovascular risk factors (Hsue, Hunt et al., 2009). 





disease rather than viral load or CD4+ T cell count (Hsue, Hunt et al., 2009). Another study compared 
carotid artery IMT in HIV-infected individuals with age and sex-matched controls with similar risk 
factors and patients with established coronary artery disease (CAD) and found that HIV-infected 
individuals had similar carotid artery IMT values in comparison with CAD patients. They further 
concluded that carotid artery IMT values in these groups were higher than those in the control group 
(Lekakis, Tsiodras et al., 2008). Furthermore, a large case control study with 1500 participants showed 
that both HIV and ART are independent predictors of early carotid atherosclerosis as measured by IMT 
(Lorenz et al., 2008; Margaritis, 2019).  
It has also been found that IMT progression is more rapid in HIV-infected individuals.  One study found 
faster progression among HIV-infected individuals on PI therapy compared to those on NNRTI-based 
regimens (Baker, Henry et al., 2009). The same study showed that HIV infected individuals on PIs have 
a significantly higher IMT (Baker, Henry and Neaton, 2010). However, other studies investigating 
newer generation PI drugs such as lopinavir and ritonavir could not demonstrate changes in IMT (Dube, 
Shen et al., 2008, Grubb, Dejam et al., 2006, Skowyra, Zdziechowicz et al., 2012). Interestingly, an 
increase in IMT was also found in HIV-infected individuals after initiation of ART, especially with 
tenofovir based therapy (Delaney, Scherzer et al., 2010). Overall, there are many studies that conclude 
that HIV infection is independently associated with increased IMT (Ross, Armentrout et al., 2008). In 
fact, a metanalysis of 20 studies, further confirms that both HIV and ART play a role in the progression 
of IMT (Msoka et al., 2019). 
From the literature, it is evident that inflammation, endothelial activation and endothelial dysfunction 
all have a major role in the development of plaque and atherosclerosis in the general population. In the 
non-HIV context, many studies have shown that increased levels of the proinflammatory cytokines, IL-
6 and CRP, are associated with subclinical atherosclerosis (Amar, Fauvel et al., 2006). In addition, CRP 
and IL-6 are independently predictive of future cardiovascular events (Amar, Fauvel et al., 2006, Ross 
et al., 2008). Furthermore, TNF-α has been implicated in myocardial dysfunction after acute coronary 
syndromes. Higher levels of TNF-α have been found in patients at baseline who experience recurrent 
myocardial infarctions or cardiac death. Moreover, it is interesting to note that there are not many 
studies that have observed the relationship between inflammatory markers, endothelial activation and 
subclinical atherosclerosis as measured by IMT in the non-HIV context. There is one study that found 
an association between IMT and inflammatory markers; however, the results are inconsistent with other 
studies (Thakore, Guo et al., 2007). 
The role of these biomarkers of inflammation and endothelial dysfunction in the HIV context has been 
explained previously under section 3.4.3 and 3.4.4. As discussed earlier, elevated levels of 
inflammatory markers, and endothelial dysfunction are evident in HIV infected individuals. This could 





Tabib, Leroux et al., 2000). However, it is interesting to note that there are not many studies that have 
observed the relationship between inflammatory markers, endothelial activation and subclinical 
atherosclerosis as measured by IMT in the HIV-infected population. A study from the USA that 
investigated the relationship between inflammatory markers, endothelial activation markers and IMT 
in an HIV-infected population, observed a significantly higher IMT, IL-6, VCAM, CRP and TNFα 
levels in the HIV-infected group compared to the HIV-free group. Overall, the study concluded that 
there was enhanced endothelial activation and inflammation in the HIV-infected individuals on ART 
with inflammatory markers being associated with endothelial activation, and both were associated with 
carotid artery IMT (Ross et al., 2008). Another study, also from the USA, investigated the association 
of biomarkers, including biomarkers of inflammation (CRP, IL-6, TNF-R1 and 2) and endothelial 
dysfunction (ICAM-1) with subclinical carotid atherosclerosis amongst male HIV-infected and HIV-
free study populations. This study suggested that levels of biomarkers of inflammation, and endothelial 
dysfunction were significantly elevated among HIV-infected men however no significant association 
was found between biomarkers of inflammation, and endothelial dysfunction and IMT in the HIV 
infected population (Subramanya et al., 2019).  
 
2.4.6 Rationale and problem statement 
From the literature, it is evident that most studies investigating cardiovascular risk factors in HIV are 
performed in Western countries (Mashinya et al., 2015a). Relatively few studies have investigated this 
topic in low-income countries (Mashinya et al., 2015a). However, HIV-infected individuals in SSA are 
expected to be at a particular risk of CVD, especially as life expectancy rises with a widespread scale 
up of ART programs (Ssinabulya et al., 2014; Schoffelen et al., 2015). Furthermore, there is a paucity 
of studies on cardiovascular risk factors in the HIV context of South Africa (Malaza et al., 2012; Fourie 
et al., 2015; Mashinya et al., 2015b; Roozen et al., 2020). Additionally, lifestyle, socio-economic 
factors as well as healthcare services vary across different regions of South Africa with widespread 
rapid urbanization present countrywide. People have become less physically active, while dietary fat 
and sugar consumption has increased (Roozen et al., 2020). Moreover, the burden of HIV remains high 
in the country. 
There are very few studies evaluating cardiovascular risk in the HIV-infected population in South 
Africa. A study from the Mpumalanga province of South Africa suggested an association between ART 
and CVD risk in rural HIV-infected individuals, however the use of ART was self-reported in the study 
and according to the authors, the cardiovascular risk may have been underestimated due to the stigma 
associated with HIV (Clark, Gómez-Olivé et al., 2015). Another study from the Limpopo province 
demonstrated that the CVD risk factors were common in the HIV-infected study group on ART, 
however, the risk score equation used was not developed particularly for the African context (Mashinya 





Moreover, very few studies have investigated the association between HIV, ART, and endothelial 
dysfunction in the South African context. The relationship between inflammatory pathways and the 
pathogenesis of HIV related endothelial activation is unclear. The interaction between factors linked 
with CVD and HIV, especially with ART addition is vastly complex and their overall impact on the 
vasculature warrants further investigation (Fourie, Schutte et al., 2015). As discussed in the earlier 
sections, there are two studies from the USA that have investigated the association between HIV, ART, 
biomarkers and sub-clinical atherosclerosis which may be of relevance to this PhD study. The  study by 
Ross et al., 2009b in the USA demonstrated increased inflammation, endothelial activation as well as 
increased IMT in their HIV-infected study population, and significant associations were also found 
between inflammatory markers and endothelial function, both of which were associated with IMT 
(Ross, Rizk et al., 2009b). However, the study comprised of a relatively small sample size (n= 73 HIV-
infected; n= 21 HIV-free participants), failed to control for important confounders such as smoking, 
blood pressure and clinical markers of overweight / obesity (e.g. waist hip ratio), all of which have been 
identified in literature to be linked with higher IMT (Ross, Rizk et al., 2009b). The study by Subramanya 
et al., 2019, demonstrated that levels of biomarkers of inflammation, and endothelial dysfunction were 
significantly elevated among HIV-infected men; however, no significant association was found between 
biomarkers of inflammation and endothelial dysfunction, and IMT in the HIV infected population 
(Subramanya et al., 2019). However, this study comprised of only male participants, which may 
preclude the generalizability of their findings to females. Additionally, the authors suggest that they 
may have over adjusted their statistical models, which may have weakened the observed biomarker 
associations with their endpoints. Furthermore, the study evaluated the associations between multiple 
biomarkers and markers of subclinical carotid atherosclerosis, and it is possible some findings were 
significant solely due to chance (Subramanya et al., 2019). 
Moreover, it is noteworthy that HIV-infected populations in European and North American countries 
differ vastly from their counterparts in African countries, in terms of their genetic makeup, socio-
economic and demographic profile and prevalence of traditional risk factors (Schoffelen et al., 2015). 
Furthermore, the predominant HIV-1 subtype in North America (subtype B) differs from that found in 
South Africa (subtype C), and the ART treatment guidelines are also different. 
Within the South African context, very few studies were found in the literature that may be of relevance 
to the current PhD study. A 2015 study from Limpopo showed an association between IMT and CVD 
risk factors and not HIV related factors; however, their study lacked an HIV negative control group 
which makes it impossible to conclude the true effect of HIV on IMT (Schoffelen et al., 2015). 
Furthermore, no investigations on serum biomarkers were performed, and secondary clinical markers 
of vascular function such as FMD or pulse wave velocity were not included  (Schoffelen et al., 2015). 
A study by Fourie et al., 2015 from the Northwest Province confirmed a link between endothelial 





measured by carotid IMT) could not be demonstrated (Fourie et al., 2015). A study from the Eastern 
Cape province, by Awotedu et al., 2015 demonstrated that arterial stiffness, cardiometabolic risk, age, 
and low CD4 count are associated with HIV-infected individuals in South Africa (Awotedu et al., 2015). 
However, no measurements of IMT and FMD were conduced to measure endothelial function or 
subclinical atherosclerosis. The most recent study by Roozen et al., 2020 assessed IMT and its 
determinants in two groups of HIV-infected individuals from different settings in South Africa. This 
study observed that CVD risk factors were the main drivers of IMT and the association of these 
traditional risk factors was increased with age (Roozen et al., 2020).  However, it is important to note 
that this study did not compare the HIV-infected group with a control, HIV-free group. Hence the true 
effect of HIV on IMT cannot be concluded. Furthermore, apart from the use of the IMT technique in 
the HIV population, no investigations on biomarkers and endothelial function were conducted.  
Overall, there is a paucity of data from South Africa on a putative link between biochemical and clinical 
markers of early vascular injury in the context of treated and untreated HIV-infected individuals. While 
we wait for data from the ongoing EndoAfrica parent study, to date, no South African studies have 
incorporated the gold standard of endothelial function measurement in clinical research, namely FMD. 
And finally, no studies have incorporated both the measures of endothelial function (FMD) and sub 
clinical atherosclerosis (with IMT) in the South African HIV context.  Furthermore, none of the studies 
discussed above assessed the HIV population of Western Cape, which is where the current study was 
conducted. Additionally, it is important to note that most studies found in literature were of the cross-
sectional nature and no studies have evaluated the role of these biomarkers of inflammation and 
endothelial function in a longitudinal fashion to validate their results from the cross-sectional study. 
Especially considering the participants are recruited in the same manner as the cross-sectional study 
and belong to the same setting. Furthermore, no studies have evaluated the association between 
biomarkers, IMT and FMD even in the non-HIV context of South Africa. This PhD study aims to 











2.4.7 Aims and objectives 
The overarching aim of the PhD study is to investigate the relationship between subclinical 
atherosclerosis and serum biomarkers of endothelial dysfunction and vascular inflammation in HIV-
infected (with or without ART) and HIV-free participants living in the Western Cape Province of South 
Africa. The PhD study incorporated two different epidemiological study designs with the main study 
comprising of a cross-sectional design and an exploratory sub-study being longitudinal in nature.  
2.4.7.1 Objectives: 
Specific objectives for the main cross-sectional study 
o To identify and assess the cardiovascular risk profile (dyslipidaemia, hypertension, obesity, 
diabetes mellitus and smoking) in HIV-infected and HIV-free participants, using data generated 
from comprehensive health questionnaires, anthropometric measurements, and biochemical 
blood analyses. 
o To measure the carotid IMT in the HIV-infected (with and without ART) and HIV-free groups. 
o To investigate possible associations between HIV-status, cardiovascular risk factors and carotid 
IMT measurements. 
o To measure and analyse known serum biomarkers of vascular endothelial dysfunction and 
vascular inflammation such as adhesion molecules (VCAM-1; ICAM-1); e-selectin; p-selectin; 
TNF-α, high sensitivity CRP and PAI-1 in all the study groups.  
o To investigate possible associations between HIV-status, serum biomarkers and carotid IMT 
measurements. 
o To measure vascular endothelial function in all the study groups by non-invasive flow-mediated 
dilation (FMD) of the brachial artery and investigate whether there is an association with carotid 
IMT and serum biomarkers. 
o To investigate possible associations between endothelial dysfunction (FMD), subclinical 
atherosclerosis (IMT), serum biomarkers, and the duration of HIV infection and ART, viral 
load, and CD4 count in the HIV-infected study group. 
 
Specific objectives for the exploratory longitudinal sub-study in HIV-free participants: 
o To measure and analyse temporal progression over 12 months of IMT. 
o To measure and analyse differences in IMT, FMD, serum biomarkers, and CVD risk factors at 







Chapter 3: Methodology 
3.1 Introduction 
This chapter describes the experimental design, methods and techniques used for this PhD study. The 
study consists of a cross-sectional main study and a longitudinal sub-study, refer to figure 3.1 for an 
overview of the two types of studies. The methods and techniques used are largely shared amongst the 
two studies. Where relevant, specific approach and design pertaining to the studies will be described 
separately in this chapter.  
 







3.2 Ethics and ethical considerations 
The study received ethical clearance from the Health Research Ethics Committee of Stellenbosch 
University (HREC; Ethics Reference Number: N13/05/064B; N12/12/086) and conforms to the 
principles of the Declaration of Helsinki.  Additionally, ethical clearance was renewed annually in 
line with HREC protocols. South African Good Clinical practice (GCP) guidelines were adhered to 
throughout the study. As part of the recruitment protocol, all eligible participants were briefed verbally 
as well as requested to read and sign the informed consent document prior to participating in the study. 
This process was conducted with utmost confidentiality and in the participant’s home language or 
language of choice. Additionally, participants were encouraged to ask any questions to clarify any 
uncertainties that they had about the study. Furthermore, the participants were informed clearly that 
their enrolment in the study is strictly voluntary and they could withdraw from the study at any point if 
they wished to do so.  
To maintain anonymity, a unique participant identification code (e.g. EA142) was assigned to each 
participant upon recruitment, and the code was used for all future study purposes. All data collected 
from the study was stored on a secure online database, Research Electronic Data Capture application 
(REDCapTM), with password protection. Any data in hard copies / paper were stored in a lockable 
cupboard and office with strictly controlled access in the Division of Medical Physiology, Stellenbosch 
University. The methodology used in this study was largely non-invasive, except for blood collection. 
Blood test results were accessible to participants upon requests. Furthermore, any health concerns 
observed during the study assessments, were immediately escalated to the research nurse, who informed 
and referred the participants for treatment. HIV testing for participants with unknown status was 
managed with utmost confidentiality and pre and post-test counselling.  
 
3.3 Study design and setting  
The PhD study consists of a main study and an exploratory sub-study, both imbedded within an 
overarching parent study (EndoAfrica) (Strijdom et al., 2017). The main study is cross-sectional in 
design and the exploratory sub-study is longitudinal in nature where the participants were assessed at 
baseline time point and again at 12-month period (refer to figure 3.1). Both studies are observational 
in design and were conducted in the Western Cape Province of South Africa. Participants for both 
studies were recruited at primary healthcare clinics in the northern suburbs of Cape Town, i.e. Bishop 
Lavis, Elsies river, Fisantekraal and Ravensmead, as well as in Worcester, a town approximately 120 
km north east of Cape Town. Once recruited, the participants were transported to the Tygerberg campus, 
Fisan building, Division of Medical physiology, where the assessments were conducted. The 






3.4 Study inclusion, exclusion criteria and study groups 
The main cross-sectional study had two groups of participants, HIV-infected (with or without ART) 
and HIV-free individuals that met the inclusion criteria, refer to figure 3.2. The longitudinal sub-study 
included a group of HIV-free participants who met the study inclusion criteria as described in figure 
3.2. The sub-study participants were assessed at baseline and after 12-month time period.  
Inclusion Criteria 
Main cross-sectional study Longitudinal sub-study 
✓ Participants ≥18 years of age  
✓ Not pregnant 
✓ ≥ 3 months’ post-partum 
✓ HIV-infected individuals 
(with or without ART) 
✓ HIV-free individuals  
✓ Participants ≥18 years of age  
✓ Not pregnant 
✓ ≥ 3 months’ post-partum 
✓ HIV-free individuals 
✓ Available for assessment at 
baseline and 12-month 
follow-up  








Figure 3.2: Inclusion criteria and study groups for both the main cross-sectional study and longitudinal 
sub-study. Figure designed by the author of this dissertation. 
 
For both the studies, individuals below the age of 18, those terminally ill, with active tuberculosis as 
well as females who were pregnant (confirmed with pregnancy test) and less than three months post-
partum were excluded from the study. Furthermore, for the longitudinal sub-study, HIV-infected 




















3.5 Participant recruitment 
Participants were recruited for both studies by experienced South African Nurses council (SANC) 
registered research nurses based on the inclusion criteria (refer figure 3.2). Volunteering participants 
with unknown HIV status were counselled and screened for HIV with a rapid HIV test (SD Bioline HIV 
1/2 3.0 immunochromatographic test kit; Standard Diagnostics, Republic of Korea) by the qualified 
research nurses. The participants were also pre and post counselled by the research nurse who had 
training in HIV counselling. Female participants underwent a pregnancy test and were requested to 
report on their last normal menstruation date. For the main study, HIV-free participants were recruited 
in the same manner as the HIV-infected participants, and care was taken to ensure that all participants 
were from the same geographical areas and of similar socio-economic and demographic backgrounds 
as far as possible. The HIV-free participants were generally healthy individuals which the research 
nurse had access to either due those individuals residing in the same community/ geographical location 
or through them attending the clinic for other acute treatments for themselves and/or their family 
members. 
The longitudinal sub-study comprised of a separate group of HIV-free participants who underwent 
baseline and 12-month follow-up assessments in a different arm of the parent EndoAfrica study cohort. 
No additional recruitment strategies were applied in the selection of these participants, except the sub-
study inclusion/ exclusion criteria as shown in figure 3.2. Furthermore, it should be noted that although 
no participants were shared amongst the main PhD study and the PhD sub-study, both cohorts shared 
similar demographic and socio-economic profiles.  
Following recruitment, verbal and written informed consent were obtained from all volunteering 
participants in the language of their preference. After which the participants were officially enrolled in 
the study and assigned a unique participant identification code. All medical samples and data received 
from the participants were labelled with bar codes linked to the participant’s identification code. 
Appointments for clinical investigations were made in advance and participants were requested to fast 
for at least 10 hours prior to the appointment. They were further requested to refrain from doing physical 
exercises, smoking, and drinking coffee for 4- 6 hours prior to the assessments. For the longitudinal 
sub-study, participant assessments were performed at baseline and after 12-month follow up period. 
 
3.6  General demographic, medical background, and lifestyle questionnaire  
Demographic, medical history and lifestyle related data were collected from all participants by means 
of an interview and questionnaire on the assessment day (including at both times points for the 
longitudinal sub-study). Refer to appendix A for the questionnaires used in this study. General 
demographic data included age, gender, and ethnicity (self-reported). Medical background data 





problems. HIV status, type of ART and duration of disease and ART was also recorded. This 
information was further validated by the patient’s clinic file, which was accessible to the investigator 
and/ or the research nurse. Family planning and menstrual date information was also collected from 
female participants. Additionally, any medication use by all participants was also recorded. Lifestyle 
data included smoking and alcohol consumption status as well as the frequency of smoking and alcohol 
consumption. Furthermore, socio-economic data such as employment status and monthly income were 
also recorded. For data collection, the participants were asked the questions objectively in the language 
of their preference. 
 
3.7 Anthropometric measurements 
All anthropometric measurements were completed in accordance with international guidelines (Marfell-
Jones, Stewart and De Ridder, 2012). Anthropometric measurements were conducted on the day of the 
assessment (including at both times points for the longitudinal sub-study). Measurements included body 
mass index (BMI), waist and hip circumference and wait-hip ratio. For the BMI calculation, body mass 
was recorded in kilograms (kg) using a digital electronic scale, height was measured using a stadiometer 
in centimetres (cm) to the nearest 0.1cm. BMI was calculated by division of body mass by the height in 
meters (m) squared. BMI was further categorised as per the guidelines shown in table 3.1. Waist and 
hip circumference were measured using a measuring tape in cm to the nearest 0.1cm. Waist-hip ratio 
was calculated by dividing waist circumference by hip circumference. Waist circumference and waist 
hip ratio was further categorized according to the guidelines shown in table 3.2. 
Table 3.1: BMI categories according to the WHO guidelines. 
Categories BMI (kg/m^2) 
Underweight < 18.5 
Normal weight 18.5–24.9 
Overweight 25.0–29.9 
Obese > 30.0 
 
Table 3.2: Waist hip ratio categories according to the WHO guidelines and waist circumference 
threshold according to Alberti et. al., 2009. 
Waist-hip ratio 
Categories  Females Males 
Low ≥ 0.80   ≥ 0.95  





High > 0.86  > 1.0  
Waist circumference (cm) 
Categories  Females Males 
High ≥ 80 ≥ 94 
 
3.8 Blood pressure and heart rate measurements 
Systolic blood pressure, diastolic blood pressure (SBP, SDP) and heart rate were measured using an 
Omron M6 automatic digital blood pressure monitor (Omron Healthcare, Kyoto, Japan). The blood 
pressure measurements were expressed in mmHg, were taken on the left arm in triplicate at 5-minute 
intervals and expressed as the mean value of the three measurements. The heart rate was measured in 
beats per minute (bpm). Blood pressure was further categorised according to guidelines shown in table 
3.3 below. 







Low < 120 < 80 
normal 120- 129 80- 84 
elevated 130- 139 85- 89 
High ≥ 140 ≥ 90 
 
 
3.9 Biochemical analyses 
3.9.1 Introduction 
Study participants were requested to fast from 22h00 the night before the assessment day. Qualified 
research nurses collected the fasting whole blood samples from the left arm of the participants in blood 
collection tubes (SGVac, The Scientific Group (Pty) Ltd.; Milnerton, Western Cape, SA) (Refer to 
figure 3.3). Mid-stream urine samples were also collected in urine containers (Refer to figure 3.3).  
All blood and urine samples were sent to the National Health Laboratory Service (NHLS), which is a 
South African National Accreditation System (SANAS) accredited laboratory, located at Tygerberg 
Hospital in Cape Town. The samples were prepared according to standardized methods and transported 
as soon as possible, following SANS 10231 regulations. The following parameters were analysed by 
the NHLS: Serum C-reactive protein (CRP), triglycerides, high density lipoprotein (HDL), low density 
lipoproteins (LDL), and total cholesterol; whole blood fasting glucose, glycated haemoglobin (HbA1c), 





microalbuminuria and urine albumin-creatinine ratio. Refer to figure 3.3 G for a photograph of the 
NHLS packet and tubes. 
 
Figure 3.3: Blood and urine sample collection tubes used for the study. Samples collected in each tube 
for various analysis A) Purple top (3 x 5 ml) tube which contains ethylenediamine tetra-acetic acid 
(EDTA; strong anticoagulant), used for haemoglobin (Hb), haemoglobin A1c (HbA1c), HIV viral load 
and CD4 count analysis; B) Yellow top (1 x 7 ml) tube which is serum separator tube which contains a 
clot activator (acid citrate dextrose solution), used for total cholesterol, HDL, LDL, triglyceride, blood 
creatinine and GGT analysis; C) Grey top (1 x 5 ml) tube which contains a potassium oxalate 
(anticoagulant) and sodium fluoride (preservative), used for fasting glucose analysis; D) Red top (1 x 3 
ml) serum blood collection tube which contains a lithium heparin (clot activator), used for serum 
preparation; E) Pink Eppendorf microcentrifuge tube (2 x  1.5 ml) used to aliquot 250 μl of serum from 
the red top tube for hsCRP analysis and vascular endothelial dysfunction biomarker analysis; F) (1 X 
5ml) urine container, used creatinine and microalbuminuria levels analysis; G) Photograph of  packet 
and tubes sent to NHLS for analysis. Photographs taken by researchers of the EndoAfrica team. Consent 
received for inclusion in this dissertation. Figure designed by the author of this dissertation. 
Fasting serum samples were prepared by centrifuging the red top tube for 10 minutes at 2000 g or 43 
revolutions per minutes (rpm) using a DM0412 clinical centrifuge from DLAD Scientific, Beijing, 
China. After centrifugation, 250 μl serum was extracted and aliquoted in 1.5 ml Eppendorf 
microcentrifuge tubes and stored at -80 °C. Serum biomarker analysis was conducted in collaboration 
with the Division of Molecular Biology and Human Genetics, University of Stellenbosch. Samples were 
selected by randomization and sent for evaluation for the following markers: TNF-α, adhesion 
molecules (VCAM-1 and ICAM-1), PAI-1, e-selectin, and p-selectin. Detailed biomarker analysis 






3.9.2 Blood chemistry analyses 
The selection of the blood chemistry parameters was based on comprehensive literature analysis and 
relevance to the current PhD study. Refer to table 3.4 for a summary of these parameters and reasons 
motivating their selection.   
Table 3.4: Summary of the blood chemistry parameters measured in this PhD study and motivation 
behind their selection.  
Parameter Measured Motivation 
Total Cholesterol, HDL, 
LDL and triglycerides 
Dyslipidaemia is characterized by abnormal blood concentrations of 
one or more of the following: total cholesterol, LDL, triglyceride 
levels and / or low HDL levels (Arboix, 2015). In literature 
dyslipidaemia is a well-known cardiovascular risk factor in the 
general population (Noubiap, Bigna, Nansseu, Nyaga, Balti, Justin B 
Echouffo-Tcheugui, et al., 2018) . Furthermore, both HIV and ART 
have been found to associate with dyslipidaemia in the literature 
(Okello et al., 2020). Hence, these parameters were particularly 
selected to measure the lipid profile of the study participants and 
observe the prevalence of dyslipidaemia as well as its associations 
with the study’s end points. For this PhD study, the criteria for 
dyslipidaemia include total cholesterol level of more than 5.1 mmol/l, 
or LDL level of more than 3 mmol/l, or triglyceride level of more 
than or equal to 1.7 mmol/l, or HDL level less than 1 mmol/l for 
males and less than  1.2 mmol/l for females (Seedat and Rayner, 
2011; Alberti et al 2009 ). 
High-sensitivity C-Reactive 
Protein (hsCRP) 
Literature suggests that hsCRP is a marker of systemic inflammation 
and a predictor of cardiovascular risk in the general population. 
Within the HIV context, increased hsCRP is found to be a strong 
predictor of future cardiovascular events and overall mortality in both 
ART naïve and ART treated HIV-infected patients (Kurz et al., 
2009). Thus, it can be regarded as a useful biomarker of measurement 
in the HIV context (Wang, Yi, Green, et al., 2015). For this PhD 
study, elevated hsCRP is defined as levels of more than 3 mg/L in the 
HIV-free population based on previous studies (Ridker et al., 2000) 
; and more than 3.3. mg/L in the HIV-infected population as 
suggested by literature (De et al., 2013; Vishwanath, Quaiser and 





Fasting glucose levels and 
HbA1c 
Fasting glucose levels and HbA1c are known markers of 
cardiovascular risk in both the HIV-free and HIV-infected 
populations (Okello et al., 2020; World Heart Federation, 2017). For 
the purposes of this study, elevated fasting glucose is considered as 
5.6 mmol/L or more (Heart and Stroke foundation, South Africa, 
2020). Elevated HbA1c levels is considered when above 5.9% and 
6.5 % HbA1c or above suitable for the diagnosis of Diabetes (Heart 
and Stroke foundation, South Africa, 2020).  
Haemoglobin levels (Hb) Low Hb level has been associated with increased cardiovascular risk 
in the HIV-free population (Kim et al., 2013). In the HIV context, 
persistent anaemia in HIV-infected individuals is associated with 
decreased survival and can be used as a measurement/ predictive 
indicator of the progression of HIV/AIDS (Obirikorang and Yeboah, 
2009). For the purposes of this PhD study, anaemia is defined as less 
than or equal to 12 g/dl for females and 13 g/dl for males (WHO, 
2019) 
Albuminuria, serum and 
urine creatinine, urine 
albumin-to-creatinine ratio 
(ACR) and eGFR 
Microalbuminuria is a well-known recognized early marker of renal 
dysfunction which is expressed by urine albumin to creatinine ratio 
(Glassock, 2010) . Elevated ACR has been associated with increased 
CVD risk in both HIV-free and HIV-infected populations (Pirro et 
al., 2016). Decreased estimated glomerular filtration rates (eGFR) 
has been associated with CVD and HIV. For the purposes of this 
study, elevated ACR is considered to be 3 mg/mmol or higher and 




Elevated GGT levels have been associated with increased 
cardiovascular risk (Ndrepepa and Kastrati, 2016). Furthermore, both 
HIV and ART have been associated with increased GGT levels 
(Osakunor et al., 2015). Additionally, elevated GGT levels have also 
been demonstrated in individuals with high alcohol consumption. For 
this PhD, criteria for elevated GGT level is 60 U/L or more for males 
and 40 U/L or more for females (NHLS, South Africa). 
CD4 count and viral load CD4 count and viral load are well known markers of HIV/ AIDS 
progression. For the purposes of this PhD study, immunological 





unsuccessful viral suppression at viral load above 1000 copies 
mRNA/ml according to the WHO guidelines (WHO, 2019) 
 
All blood chemistry analyses were completed by the NHLS following standardized methodology and 
standard operating procedures. Details behind specific instruments used and the principles behind the 
techniques are described below. 
Total cholesterol, HDL, LDL, and triglycerides 
All cholesterol measurements (total cholesterol, HDL, LDL and triglycerides) were completed by the 
NHLS using an enzymatic, colorimetric method and expressed in millimoles per litre (mmol/L). A 
Roche/Hitachi cobas® c system was used. The analysis for total cholesterol and triglycerides is based 
on cleavage of the cholesterol esters by the action of cholesterol esterase which produces cholesterol 
and fatty acids (Roche, Total Cholesterol, accessed September 2020). Thereafter the cholesterol oxidase 
catalyses the oxidation of cholesterol to cholest‑4‑en‑3‑one and hydrogen peroxide. When in presence 
of peroxidase, the hydrogen peroxide mediates the effects of oxidative coupling of phenol and 
4‑aminophenazone which subsequently forms a red quinone‑imine dye. The colour intensity of the dye 
formed is directly proportional to the cholesterol concentration (Roche, Total Cholesterol, accessed 
September 2020).  
The analysis for HDL and LDL levels is based on the homogeneous enzymatic colorimetric test 
principle. In the presence of magnesium ions, dextran sulphate selectively forms water‑soluble 
complexes with LDL which are resistant to polyethylene glycol-modified enzymes. HDL analysis is 
based on the formation of polyethylene glycol coupled amino groups by cholesterol esterase and 
cholesterol oxidase reaction (Roche, HLD, LDL, accessed September 2020). Similar to the cholesterol 
and triglyceride analysis, the colour intensities yielded during these reactions are directly proportional 
to the respective concentrations. This can be quantified photometrically using the instrument mentioned 
above (Roche/Hitachi cobas® c system). 
High-sensitivity C-Reactive Protein (hsCRP) 
The instrument used by the NHLS to quantify hsCRP was a Beckman Coulter IMMAGE® with 
Immunochemistry Systems and Calibrator 5 Plus assay. The analysis is based on near infrared particle 
immunoassay rate methodology. Presence of anti-CRP antibody-coated particles mediate the binding 
of CRP in the serum samples. This results in a formation of insoluble aggregate in the samples. The rate 
of the aggregation formation was measured which is directly proportional to hsCRP concentration. 





Fasting glucose levels and HbA1c 
The instrument used by the NHLS to measure glucose and HbA1c levels was a cobas® 311/501 
analyser; Roche/Hitachi cobas® c systems with Hemolysate application. An enzymatic reference 
method was used based on the UV test principle which relies on hexokinase catalysed phosphorylation 
reaction of glucose in the presence of adenosine triphosphate which ultimately produces 
glucose‑6‑phosphate. Following this, glucose‑6‑phosphate is oxidised in the presence of nicotinamide 
adenine dinucleotide phosphate (NADP) by glucose-6-phosphate dehydrogenase which produces 
gluconate-6-phosphate and nicotinamide adenine dinucleotide phosphate hydrogen (NADPH). The rate 
of NADPH formation can be measured photometrically as it is directly proportional to the glucose 
concentration (Roche, GlUC3, accessed September 2020). Glucose levels are expressed in mmol/l. 
The HbA1c measurement is based on using haemolysed whole blood in a turbidimetric inhibition 
immunoassay. The method relies on the usage of a haemolysing reagent, namely 
tetradecyltrimethylammonium bromide. Glycohemoglobin (HbA1c) in the sample reacts with anti-
HbA1c antibody to produce soluble antigen-antibody complexes. Since the specific HbA1c antibody 
site is present only once on the HbA1c molecule, formation of insoluble complexes does not take place. 
The presence of polyhaptens react with excess anti-HbA1c antibodies to form an insoluble antibody 
polyhapten complex which can be determined turbidimetrically. HbA1c is expressed as mmol/mol 
HbA1c or % HbA1c (calculated as a % of HbA1c/Hb ratio) (Roche, Tina-quant Haemoglobin A1c 
Gen.3 - Hemolysate and Whole Blood Application, accessed September 2020). 
Haemoglobin levels (Hb) 
Measurements of Hb levels by NHLS was determined using whole blood application on a cobas® 
311/501 analyser; Roche/Hitachi cobas® c systems. The analysis is based on chemiluminescence 
methodology where haemolysed blood cells have a specific absorbance spectrum. This can be analysed 
bichromatically during the pre-incubation phase of HbA1c immunoassay (Haemoglobin methods, 
NHLS: SOP), accessed September 2020). Hb levels are expressed in mmol/L. 
Albuminuria, serum and urine creatinine, urine albumin-to-creatinine ratio and eGFR 
A cobas® 501/502 analyser, Roche/Hitachi cobas® c system was used by the NHLS to determine 
albuminuria, expressed as mg/L. The technique is based on an enzymatic reaction method 
(immunoturbidimetric assay), where antigen in the sample reacts with anti‑albumin antibodies and 
produces antigen/antibody complexes known as agglutinates. This can be measured turbidimetrically 
Roche, Albumin plus ver.2, accessed September 2020. 
To determine serum and urine creatinine levels, a cobas® 311/501 analyser (Roche/Hitachi cobas® c 
system was used by the NHLS. The principle is based on the enzymatic method which relies on the 
formation of glycine, formaldehyde, and hydrogen peroxide from creatinine in the presence of 





with 4‑aminophenazone to form a quinone imine chromogen. The colour intensity of the quinone imine 
chromogen formed is directly proportional to the creatinine concentration in the reaction mixture 
(Roche, Creatinine plus ver.2, accessed September 2020). Creatinine levels were measured in μmol/L. 
Albumin-to-creatinine ratio was calculated and expressed as mg/mmol. Estimated glomerular filtration 
rates (eGFR) eGRF was calculated according the CKD-EPI formula (mL/minute/1.73 m3) as previously 
described (Levey et al., 2009).  
γ-Glutamyl transferase (GGT) 
A cobas® 311/501 analyser Roche/Hitachi cobas® c system, was used by the NHLS to measure GGT 
levels. The principle behind the analysis is based on an enzymatic colorimetric assay, which relies on 
γ‑glutamyl transferase to transfer the γ‑glutamyl group of L‑γ‑glutamyl‑3‑carboxy‑4‑nitroanilide to 
produce glycylglycine. The amount of 5‑amino‑2‑nitrobenzoate produced during this reaction is 
proportional to the level GGT (Roche, GGT2, accessed September 2020). Thus, GGT levels can be 
determined photometrically measuring the increase in this absorbance and is expressed in units per litre 
(U/L). 
CD4 count and viral load 
CD4 count was determined by NHLS using a flow cytometer (FC 500 MPL) with MXP software 
(Backman Coulter). The methodology is based on labelling cells with a surface marker which is then 
counted by the instrument. CD4 count was expressed as cells per microliter (cells / uL). For viral load 
analysis, a COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2 was used by the NHLS. The 
measurement is based on the HIV-1 nucleic acid amplification (PCR) test which relies on reverse 
transcription of the target messenger RNA (mRNA) to produce complementary DNA (cDNA). A 
cleaved dual-labelled oligonucleotide detection probe which is specific to its target is used to detect 
viral cDNA which is then quantified and expressed in mRNA/ml (Roche, HIV-1 Test, version 2.0, 
accessed September 2020).  
 
3.9.3 Biomarker analysis 
Serum biomarkers of vascular and endothelial dysfunction and inflammation were analysed using 
Luminex technology in collaboration with the Division of Molecular Biology and Human Genetics, 
University of Stellenbosch. The following biomarkers were determined:  TNF-α, VEGF and adhesion 
molecules (VCAM-1 and ICAM-1, PAI-1 and e-selectin, and p-selectin). All of these parameters were 
selected based on literature analysis where they have been suggested as biomarkers that can be measured 
to assess the role of inflammation, endothelial activation / dysfunction and immune activation in the 
development of CVD in both the HIV-free and HIV-infected populations (Stoner et al., 2013; Kearns 





A Luminex Bio-Plex 200 system- Bio-Rad® BioPlex® 200 analyser was used, as described previously 
by Strijdom et al., 2017, for the analysis by a trained and highly experienced scientist. The Luminex 
200 system is a versatile analyser and is based on the principles of flow cytometry. The system permits 
multiplex (multiple measurements simultaneously) of up to 100 different analytes in each of the 96-
well filter microplates. Furthermore, the system can analyse relatively small sample volumes. 
Moreover, the Luminex cytokine/ chemokine/ protein assays are similar to sandwich ELISA assays, 
which enables multiplex measurements. 
The biomarker analysis protocol was based on R&D Systems® Luminex® Immunoassay Principles 
(R&D System, 2014). (Refer to figure 3.4) Magnetic microparticles (colour coded magnetic beads) 
embedded with fluorophores were precoated with analyte specific antibodies. These fluorophores were 
set at protein specific ratios. Serum samples were pipetted into the plate wells where the specific 
antibodies bound to the proteins/ analytes of interest. Following this, excess unbound antibodies are 
washed off and a biotinylated antibody cocktail specific to the analytes of interest was added to each 
well. Excess unbound biotinylated antibody was washed off and a streptavidin-phycoerythrin conjugate 
(Streptavidin-PE) was added to each well. Streptavidin-PE then binds to the biotinylate antibody and 
excess unbound Streptavidin- PE is also washed off. Thereafter, the proteins of interest are resuspended 
in buffer and read using the Bio-Rad® BioPlex® analyser. (Refer to figure 3.4) The analyser can 
evaluate the sample based on dual-laser flow-based detection technique. One laser is used to excite the 
dyes inside each protein to identify the microparticle regions. The second laser is used to excite the 
Streptavidin -PE to measure the amount of analyte bound to the proteins. All fluorescence emissions 
from each protein as it passes through the flow cell is then analysed to differentiate emission levels 






Figure 3.4: Biomarker analysis protocol. A) The sample is added to a mixture of color-coded beads which are pre-coated with analyte-specific capture 
antibodies. The antibodies bind to the analytes of interest; B) Biotinylated detection antibodies specific to the analytes of interest are added and sandwich the 
analyte between the capture and detection antibodies. Phycoerythrin (PE)-conjugated streptavidin is added which binds to the biotinylated detection antibodies; 
C) One laser classifies the bead and identifies the analyte being detected. The second laser determines the magnitude of the PE-derived signal, which is in direct 





3.10 IMT measurements 
Carotid IMT measurements for this study were based on previously described guidelines and protocols. 
Little to no preparation is required by the participant for this assessment. For standardization purposes, 
the assessments were completed in the mornings and participants were requested to remove any 
jewellery or clothing that interfered in the neck area. To limit operator variability, only a few specific 
(highly trained and experienced) researchers (which included the author of this dissertation) were 
allocated to measure IMT. Furthermore, for quality control purposes, IMT was measured more than 
once on randomly selected participants to evaluate reproducibility.  
IMT was measured using an Esaote MyLab Five portable ultrasound device (Genoa, Italy) with an 
Esaote Doppler probe (LA523, 12 MHz) and QIMT software which automatically and accurately 
measures all the parameters needed for the carotid IMT measurements (Refer to figure 3.5 A). For the 
IMT protocol, participants were requested to be in supine position with their head resting comfortably 
and their neck slightly hyperextended and tilted 45° to the opposite side of the carotid artery that was 
being assessed (Refer to figure 3.5 B). The operator (author of this dissertation) used the index and 
middle fingers to locate the pulsating carotid artery to guide the position of the probe on the participant’s 
neck. The position of the probe is further adjusted until the image is clear and stable on the ultrasound. 
The lateral angle of the image was assessed as far as possible. In the participants where a lateral view 
was not optimal (clear), an anterior or posterior angle was used. Once the image was clear and stable, 
the region of interest was manually placed 5 mm proximal to the dilatation of the carotid bulb. 
Thereafter, QIMT software automatically detected and analysed the vascular boundaries in radio 
frequency (RF)-mode (Refer to figure 3.5 C). The software further calculated the diameter and the 
thickness of the intima media layer as well as the median and standard deviation IMT values, using high 
spatial resolution. At this stage, the IMT measurements are also calculated and expressed in 
micrometres (µm) with the standard deviation changing. As soon as the standard deviation is below 25 
µm (the value also turns green), the IMT image is frozen and saved (Refer to figure 3.6). This automatic 
and accurate measurements are largely independent of the investigator and the device settings. For this 
study both the left and right common carotid arteries were assessed, and values from both sides were 
averaged and used in the data analysis. Furthermore, for the purposes of the current study, sub-clinical 
atherosclerosis was defined as an average IMT of > 900 µm based on guidelines by European Society 
of Cardiology and European Society of Hypertension (Mancia et al., 2013). A plaque was defined as 







Figure 3.5: Instruments and technique used for the IMT measurement. A) Esaote MyLabTM Five 
portable ultrasound device (Genoa, Italy); B) Participant and Esaote Doppler probe (LA523, 12 MHz) 
position for the lateral angle of the image; C) QIMT software automatically detecting the vascular 
boundaries of the intima media layer in radio frequency (RF)-mode. Photographs were taken by the 
author of this dissertation. Consent was obtained by the individuals in the photograph. 
  
Figure 3.6: Longitudinal scan of 1 cm segment of the common carotid artery IMT measurement using 
the QIMTTM software. The IMT value and standard deviation (SD) is expressed in µm and circled in 
yellow. The Carotid bulb is also circled in yellow. Image was captured during an IMT assessment and 





3.11 FMD measurements 
The FMD procedure for this study was based on previously described guidelines and protocols (Corretti 
et al., 2002; Charakida et al., 2010; Thijssen et al., 2011). Based on these recommendations, participants 
were requested to fast for at least 8-10 hours prior to the assessment. Apart from dietary intake, FMD 
measurement can also be influenced by recent exercise, caffeine, intake, alcohol and tobacco use as 
well as some medications. For females, hormonal changes due to the menstrual cycle may also affect 
FMD (Corretti et al., 2002; Charakida et al., 2010). Keeping this in mind, the participants were 
requested to also refrain from smoking, exercise, caffeine and medication for 4 to 6 hours prior to the 
assessments. Additionally, information regarding the menstrual cycle was also recorded from female 
participants.  
Ambient temperature and acute sympathetic nervous system activation can also influence FMD 
(Thijssen et al., 2011). Hence, for standardization, the FMD procedure was performed in the mornings, 
in a quiet, temperature-controlled room at a constant 22°C. Furthermore, time (more than 10 minutes) 
was accommodated for participants to acclimatise and get comfortable in the environment before 
assessments began. To mitigate the influence of operator variability on the FMD measurements, only a 
selected few highly trained and experienced researchers (which included the author of this dissertation) 
were allocated to measure FMD. Additionally, each operator was assigned specific tasks in the 
assessment which remained constant throughout the study. Furthermore, for quality control purposes, 
FMD results were randomly selected and assessed by blinded experts. 
For the FMD protocol, participants were in the supine position with their right arm comfortably 
positioned (extended) at an 80° angle from their body (Refer to figure 3.7A). A blood pressure cuff 
was wrapped below the antecubital fossa (Refer to figure 3.7B). The FMD was measured using an 
Esaote MyLab Five portable ultrasound device (Genoa, Italy) with an Esaote Doppler probe (LA523, 
12 MHz) connected to an Apple MacBook Pro laptop (2010 edition) with software supported by edge 
detection technology (Quipu Cardiovascular Suite™; Pisa, Italy) (Refer to figure 3.8 A & B.). 
CLINICA ultrasound gel was applied to the probe which was securely fixed on a precision probe holder 
from SMT Medical (Wuerzburg, Germany) which allows for micro-metric adjustments (Refer to figure 
3.8C). The probe (attached to the holder) was placed approximately 3 to 4 cm proximal to the elbow 
and the brachial artery was localised by adjusting (manoeuvring) the probe’s angle and position until a 
clear and stable image was visualized (Refer to figure 3.8C). To visualize and locate the brachial artery 
on the ultrasound, doppler mode was used, which displayed the real-time image in colours (arteries 
appeared in red and veins in blue) (Refer to figure 3.8D). This further verified that the image located 
was indeed of the brachial artery and not of a vein. Pulse repetition frequency which is determined by 
the velocity of blood flow rate detected in the blood vessel, was set at 6.7 Hz. The frequency of the 
ultrasound was set to 6.6 Hz and the depth was increased to 3 cm before switching to pulse wave mode. 






Figure 3.7: Participant position for the FMD assessment. A) Participant in supine position with the 
right arm extended at an 80° angle from their body; B) A blood pressure cuff wrapped around the right 
arm, below the antecubital fossa, of the participant. Photograph A was taken by an EndoAfrica team 
member, photograph B was taken by the author of this dissertation. Consent was obtained by the 
individuals in the photograph. 
 
Figure 3.8: Photographs of the instruments used for FMD measurements. A) Esaote MyLabTM Five 
portable ultrasound device (Genoa, Italy); B) Apple MacBook Pro laptop (2010 edition) with software 
with edge detection technology (Quipu Cardiovascular Suite™; Pisa, Italy); C) Probe holder from SMT 
Medical (Wuerzburg, Germany) with an Esaote Doppler probe (LA523, 12 MHz) attached. D) Doppler 
mode on the ultrasound, displaying image in colour. Photographs were taken by the author of this 
dissertation.  
 
Following this, Cardiovascular SuiteTM UE 2.8.1. (build 120) computerised software was used for edge 
detection and calculations. The software settings were selected for vascular measurements and the 





of ischaemia and 120 seconds for the period of reactive hyperaemia. The region of interest on the vessel 
image was selected manually by a highly trained operator and once the edges of the vessel were clearly 
detected, the FMD measurements and recording began (Refer to figure 3.9A). After the baseline 
recording phase, occlusion of the brachial artery was achieved via inflation of the blood pressure cuff 
to a supra- systolic pressure of 200 mmHg (or 50 mmHg above the prior systolic pressure measurement) 
for 300 seconds (Refer to figure 3.9B). Thereafter, the cuff was deflated, which triggered the reactive 
hyperaemia and the maximum brachial artery diameter, and this post occlusion period was recorded for 
120s (Refer to figure 3.9C). The FMD studio and Cardiovascular Suite QUIPU software calculated 
FMD as a percentage change in the brachial artery diameter (maximum diameter minus baseline 
diameter %) in response to the increased shear stress induced by reactive hyperaemia as blood flows 
back into the artery. The basic FMD formula used by the software was 
(
Maximum diameter − Mean Baseline Diameter
Mean Baseline diameter
 X 100). 
 
Figure 3.9: FMD measurement recording by Cardiovascular SuiteTM UE 2.8.1. (build 120) 
computerised software. The line graph indicates the brachial artery diameter A) Mean Baseline artery 
diameter is measured for a duration of 60 seconds. The recording is relatively stable indicating no or 
minimal changes in the artery diameter. B) Inflation of the blood pressure cuff (occlusion) for a total 
duration of 300 seconds which leads to ischaemia C. Deflation of blood pressure cuff leading to 
hyperaemia and subsequent shear stress-induced arterial dilation with maximum diameter recording 
followed by recovery diameter recording (total duration 120 seconds). FMD is then calculated as a 





circled in yellow on the image for this assessment. Images were captured during an assessment and 
figure designed by the author of his dissertation. 
 
3.12 Statistical Analysis 
All statistical analyses were performed with IBM® SPSS® software (version 26; USA). At the start of 
the PhD study, a biostatistician from the Biostatistics Unit (Faculty of Medicine and Health Sciences, 
Stellenbosch University) was consulted to determine whether the proposed sample sizes for the main 
PhD study (proposed HIV-free sample size: n=150 and proposed HIV-infected sample size: n=150) 
would be sufficiently powered. In this regard, a literature search was undertaken. A previous study by 
Ross et al. (2009), demonstrated that a sample size of n= 73 HIV-infected and n= 21 HIV-free 
participants was sufficient in elucidating associations of IMT with serum biomarkers as well as finding 
significant differences in IMT between the two groups in their study. Another study by Donald et al. 
(2008) demonstrated that a case sample size of between n= 100-400 was sufficiently powerful to secure 
endothelial function measurement reproducibility and statistical significance (1-2% effect size; 80% 
statistical power and 5% significance). Additionally, in the preliminary studies of the EndoAfrica parent 
study, significant differences were found in ICAM-1 and VCAM-2 levels between the two groups at a 
sample size of n= 84 (HIV-infected group) and n= 54 HIV-free group. Therefore, after consultation 
with the biostatistician and evaluation of relevant literature, it was concluded that the proposed sample 
sizes were adequate and sufficiently powerful to demonstrate clinical reproducibility and statistical 
significance in the main cross-sectional study. 
The data distribution (normal distribution or non-normal distribution) was identified for each 
continuous variable using Shapiro- Wilk tests, data histograms, and Q-Q plots. For continuous data 
description: Normally distributed results were expressed as mean ± standard deviation (SD) and non-
normally distributed results was expressed as median with interquartile range. Categorical variable 
results were expressed as the number of participants and % of the group sample size (n, %). 
For the main study, comparison between the HIV-infected and HIV-free groups, independent sample t-
tests were conducted for normally distributed data, and for non-normally distributed data, non-
parametric Mann Whitney tests were conducted. For the independent sample t-tests, equal variances 
were assumed unless Levene’s test indicated otherwise, for which correction for unequal variances was 
used.  For the longitudinal sub-study, baseline and 12-month follow-up were considered as two 
dependent samples, and hence a paired analysis was completed. For normally distributed data, a paired 
samples t-test was used, and Wilcoxon signed ranked test (non-parametric analysis) was completed for 
the non-normally distributed data. For comparison between categorical data between the two groups for 





study, cross tabulation between results at two time points was conducted using the paired McNemar 
test or McNemar-Bowker test. 
For the main cross-sectional study, Pearson’s correlation test was used to evaluate the relationship 
between continuous variables. For categorical variables and their relationship with the outcome 
variables (IMT & FMD %), one-way ANOVA was performed with post hoc test for four categories and 
t-test was performed for those variables with two categories. Variables that were significantly correlated 
with the study’s endpoints were shortlisted for regression analysis.  Generalized linear regression model 
was utilized for all regression analysis due to its flexible nature of including both continuous and 
categorical variables in the model. Regression analysis was completed for the total cohort as well as for 
each study group. Mean IMT and FMD % were used separately as dependent variables for the regression 
analyses. Confounding variables such as gender and age were forced to remain in all models. For 
regression analysis in the total cohort, HIV status was forced to remain in the model and in the HIV-
infected group, HIV duration, ART status, viral load and CD4 count were forced to remain in the model. 
Specific independent variables adjusted for in each regression model will be further discussed in the 
results chapter.  The significance threshold for all statistical analysis was set at p < 0.05. The PhD 
candidate performed all statistical analyses, which were verified and validated by a professional 
biostatistician from the Biostatistics Unit, Faculty of Medicine and Health Sciences of Stellenbosch 
University. 
 
3.13 Clinical study protocol 
In summary, all assessments related to this study were performed in a stepwise manner. Refer to figure 












Chapter 4: Results 
4.1 Introduction 
This chapter describes the results obtained from this PhD study in a logical, interpretable format, 
according to the aims and objectives discussed in Chapter 2. The PhD study obtained results from the 
cross-sectional main study, which is described under section A, and a longitudinal sub-study which is 









Section A: Results from the cross-sectional main study 
4.2 Descriptive profile of the study population 
4.2.1 Demographic profile, medical background, lifestyle, and socioeconomic 
characteristics  
A total of 347 volunteers participated in the cross-sectional main study. The mean age was 40.99 years, 
and 23.6% of the total cohort was more than or equal to 50 years of age. The total cohort was mostly 
represented by females (n= 251, 72.3%) and individuals who self-identified as being of mixed ancestry 
(n= 288, 83.0%). The HIV-free group consisted of n= 143 participants and the HIV-infected group 
comprised of n= 204 participants. There were no significant differences in age and ethnicity between 
the HIV-free and HIV-infected groups (refer to table 4.1). Although no significant differences were 
found in gender between the two study groups, additional gender subgroup analyses for all study 
parameters were conducted (refer to appendix B). 
Table 4.1: Demographic profile of the total, HIV-free and HIV-infected study groups. 








Sample size, n (%) 347 (100%) 143 (41.2%) 204 (58.8%) - 
Age (years) (Mean ± 
SD) 
40.99 ± 10.41 41.36 ± 11.83 40.73 ± 9.31 0.56 
Age Categories    0.28 
Age < 50, n (%) 265 (76.4%) 105 (73.4%) 160 (78.4)  
Age ≥ 50, n (%) 82 (23.6%) 38 (26.6%) 44 (21.6%)  
Gender    0.07 
Female, n (%) 251 (72.3%) 111 (77.6%) 140 (68.6%)  
Male, n (%) 96 (27.7%) 32 (22.4%) 64 (31.4 %)  
Ethnicity    0.24 
Mixed ancestry, n (%) 288 (83.0%) 137 (95.8%) 151 (74.0%)  
African, n (%) 52 (15.0%) 5 (3.5%) 47 (23.0%)  
Data presented as mean ± SD or n (% of group). n, number of participants; SD, standard deviation. 
Previous history of TB was the most prevalent form of comorbidity in the total cohort and the HIV-
infected group. Additionally, HIV-infected group presented with a significantly higher previous history 
of TB prevalence in comparison to HIV-free group (p < 0.001). Previous history of hypertension was 
significantly lower in the HIV-infected group in comparison to HIV-free (p= 0.03). Furthermore, 
previous hypertension was the most prevalent form of comorbidity in the HIV-free group. With regards 
to lifestyle characteristics, more than half of the total cohort, and HIV-free and HIV-infected study 
groups (58.8%, 62.9%, 55,9%, respectively) reported to be current smokers, and to have consumed 





Table 4.2: Medical background and lifestyle characteristics of the total, HIV-free and HIV-infected 
study groups. 






    
Previous TB, n (%) 109 (31.4%) 22 (15.4%) a 87 (42.6%) a <0.001 
Previous stroke, n (%) 13 (3.7%) 4 (2.8%) 9 (4.4%) 0.43 
Diabetes mellitus, n 
(%) 
11 (3.2%) 5 (3.5%) 6 (2.9%) 0.78 
Previous hypertension, 
n (%) 
61 (17.6%) 33 (23.1%) b 28 (13.7%) b 0.03 
Previous 
dyslipidaemia, n (%) 
15 (4.3%) 10 (7.0%) 5 (2.5%) 0.11 
Previous heart disease, 
n (%) 
3 (0.9%) 1 (0.7%) 2 (1%) 0.85 
Smoking     
Current smoker n (%) 204 (58.8%) 90 (62.9%) 114 (55.9%) 0.37 
History of smoking    0.06 
History of smoking n 
(%) 
31 (8.9%) 10 (7.0%) 21 (10.3%)  
No history of smoking 
n (%) 
111 (32.0%) 43 (30.1 %) 68 (33.3%)  
Alcohol consumption     
Alcohol consumption 
in the past 12 months, 
n (%) 
192 (55.3%) 80 (55.9%) 112 (54.9%) 0.85 
Frequency of alcohol 
consumption 
   0.22 
< 8 days per month, n 
(%) 
129 (83.2%) 53 (37.1%) 91 (44.6%)  
Data presented as n (% of group). n, number of participants; SD, standard deviation; TB, tuberculosis. 
Means with same superscript letter: differ significantly (p <0.05). 
There were no significant differences in socioeconomic characteristics such as employment status and 
monthly income between the HIV-free and HIV-infected groups (Refer to table 4.3) 
Table 4.3: Socioeconomic characteristics of the total, HIV-free and HIV-infected study groups. 








Employment status    0.71 
Unemployed, n (%) 179 (51.6%) 79 (55.2%) 100 (49.0%)  
Employed full-time, n 
(%) 
102 (29.4%) 39 (27.3%) 63 (30.9%)  
Employed part-time, n 
(%) 





Monthly income    0.06 
> R1,000, n (%) 100 (28.0%) 45 (31.5%) 55 (27.0%)  
 R1,000 - R4,999, n 
(%) 
191 (55.0%) 74 (51.7%) 117 (57 %)  
R5,000 - R9,999, n 
(%) 
30 (8.6%) 10 (7.0%) 20 (9.8%)  
R10,000 - R20,000, n 
(%) 
13 (3.7%) 6 (4.2%) 7 (3.4%)  
Data presented as n (% of group). n, number of participants. 
 
4.2.2 HIV-related and ART characteristics 
The majority of the HIV-infected participants were receiving ART, with 81.9% on NRTI / NNRTI-
containing first line ART. Viral load was significantly lower (p < 0.001) and CD4 count was 
significantly higher (p= 0.011) in the HIV-infected on ART group in comparison to the HIV-infected/no 
ART group. Additionally, there was a significantly higher prevalence of participants with high viral 
load measurements (> 1000 mRNA/ml) in the HIV-infected/ no ART group compared to the HIV-
infected on ART group (p < 0.001) (Refer to table 4.4).  
Table 4.4: HIV related and ART characteristics of the total HIV-infected, HIV-infected/ no ART and 
HIV-infected + ART study groups. 









Sample size, n (%) 204 (100%) 16 (7.8%) 188 (92.2%) - 
HIV duration, (> 5 
years), n (%) 
87 (46.8%) 6 (42.9%) 81 (47.1%) 0.82 






50.00 (10- 161.50) a < 0.001 
Viral load category b 
High (> 1000 
mRNA/ml), n (%) 
44 (21.6%) 13 (81.3%) c 31 (16.5%) c < 0.001 
CD4 count 
(cells/mm3) 
509.03 ± 239.220 353.21 ± 206.30 d 520.99 ± 238.52 d 0.01 
CD4 category b 
Low (< 250 
cells/mm3), n (%) 
28 (13.7%) 4 (25.0%) 24 (12.8%) 0.17 
ART Duration 
(Weeks) 
- - 175.00 (96.00- 
361.00) 
- 
First line ART, n (%) - - 167 (81.9%) - 
Data presented as mean ± SD or n (% of group) or median with 25th and 75th percentiles for 
interquartile range (for non-normally distributed data). n, number of participants; SD, standard 
deviation. Means with same superscript letter: differ significantly (p <0.05). b Viral load and CD4 





4.2.3 Anthropometric characteristics  
The mean BMI in the total cohort and the HIV-infected group fell within the normal range according 
to WHO guidelines. However, the mean BMI in the HIV-free group was in the overweight range 
according to the same guidelines by WHO (Refer to table 4.5).  Furthermore, the HIV-infected group 
had a significantly lower BMI (p < 0.001) and waist circumference (p= 0.001) in comparison to HIV-
free group. Additionally, there were significant differences between the HIV-infected and HIV-free 
group with regards to BMI categories (p= 0.001) and high waist circumference categories (p= 0.003). 
No differences were seen in waist to hip ratio between any of the groups (Refer to table 4.5). For 
gender differences in anthropometric measurements, refer to appendix B. 
Table 4.5: Anthropometric characteristics of the total, HIV-free and HIV-infected study groups. 














BMI categories b      0.001 
Underweight (BMI < 
18.5 kg/m2), n (%) 
59 (17.0%) 15 (10.5%)  44 (21.6%)  
Normal weight (BMI 
18.5 to < 25 kg/m2), n 
(%) 
141 (40.6%) 53 (37.1%) 88 (43.1%)  
Overweight (BMI 25 
to < 30 kg/m2), n (%) 
66 (19.0%) 27 (18.9%) 39 (19.1%)  
Obese (BMI > 30 
kg/m2), n (%) 
81 (23.3%) 48 (33.6%) 33 (16.2%)  
Waist circumference 










High (≥ 80/ ≥ 94 
females/ males), n (%) 
193 (55.6%)  93 (65.0%)  100 (49.0%)  0.003 
Waist to hip ratio  0.89 (0.83- 0.95) 0.89 (0.84- 0.95) 0.89 (0.83 - 0.96) 0.96 
Waist to hip ratio 
categories d 
   0.24 
Low (≥ 0.80/ ≥ 0.95 
females/ males), n (%) 
105 (30.3%) 40 (28.0%) 65 (31.9%)  
Moderate (0.81–
0.85/0.96–1.0 females/ 
males), n (%) 
71 (20.5%) 25 (17.5%) 46 (22.5%)  
High (> 0.86/ > 1.0 
females/ males), n (%) 
171 (49.3%) 78 (54.5%) 93 (45.6%)  
Data presented as n (% of group) or median with 25th and 75th percentiles for interquartile range (for 
non-normally distributed data). n, number of participants; BMI, body mass index. Means with same 
superscript letter: differ significantly (p < 0.05). b BMI category based on WHO.  d Waist circumference 






In HIV sub-group analyses, the HIV-infected group on ART demonstrated a significantly higher BMI 
(p= 0.02) and waist circumference (p= 0.01) in comparison to HIV-free group (Refer to table 4.6).  
Table 4.6: Anthropometric characteristics of the HIV/ no ART and HIV on ART study groups. 
Variable HIV-infected/ no 
ART 
 




BMI (kg/m2)  19.00 (17.62- 21.30) a 22.60 (18.91- 27.66) a 0.02 
BMI categories b   0.32 
Underweight (BMI < 18.5 kg/m2), n 
(%) 
6 (37.5%) 38 (20.2%)  
Normal weight (BMI 18.5 to < 25 
kg/m2), n (%) 
7 (43.8%) 81 (43.1%)  
Overweight (BMI 25 to < 30 kg/m2), n 
(%) 
2 (12.5%) 37 (19.7%)  
Obese (BMI > 30 kg/m2), n (%) 1 (6.3%) 32 (17.0%)  
Waist circumference (cm)  71.00 (69.00- 81.00) c 84.00 (75.00- 93.00) c 0.01 
Waist circumference category d 
High (≥ 80/ ≥ 94 females/ males), n 
(%) 
5 (31.3%) 95 (50.5%) 0.14 
Waist to hip ratio  0.86 (0.80- 0.93) 0.89 (0.83- 0.96) 0.17 
Waist to hip ratio categories d   0.91 
Low (≥ 0.80/ ≥ 0.95 females/ males), n 
(%) 
5 (31.3%) 60 (31.9%)  
Moderate (0.81–0.85/0.96–1.0 
females/ males), n (%) 
3 (18.8%) 43 (22.9%)  
High (> 0.86/ > 1.0 females/ males), n 
(%) 
8 (50.0%) 85 (45.2%)  
Data presented as n (% of group) or median with 25th and 75th percentiles for interquartile range (for 
non-normally distributed data). n, number of participants; SD, standard deviation; BMI, body mass 
index. b BMI category based on WHO. Means with same superscript letter: differ significantly (p < 
0.05) d Waist circumference and waist to hip ratio category based on guidelines by Alberti et al., 2009. 
 
4.2.4 Blood pressure and heart rate measurements  
The median SBP and DBP in the total cohort fell within the normal clinical ranges according to Seedat 
and Rayner, 2013. The median SBP (p= 0.02) and median DBP (p= 0.03) values were significantly 
higher in the HIV free group compared to the HIV infected group. Additionally, there was a significant 
difference in DBP categories between HIV-infected and HIV-free group (p= 0.02). Furthermore, there 
was a higher prevalence of participants with hypertension in the HIV free group compared to HIV 
infected (p= 0.002). The median heart rate was also significantly different between HIV-infected and 





Table 4.7: Blood pressure and heart rate measurements of the total, HIV-free and HIV-infected study 
groups. 



















pressure categories b 
   0.10 
Low (< 120 mmHg), n 
(%) 
162 (46.7%) 57 (39.9%) 105 (51.5%)  
Normal (120- 129 
mmHg), n (%) 
69 (19.9%) 28 (19.6%) 41 (20.1%)  
Elevated (130- 139 
mmHg), n (%) 
46 (13.3%) 24 (16.8%) 22 (10.8%)  
High (≥ 140 mmHg), n 
(%) 
70 (20.2%) 34 (23.8%) 36 (17.6%)  
Diastolic Blood 









pressure categories b 
   0.02 
Low (< 80 mmHg), n 
(%) 
123 (35.4%) 44 (30.8%) 79 (38.7%)  
Normal (80- 84 
mmHg), n (%) 
51 (14.7%) 20 (14.0%) 31 (15.2%)  
Elevated (85- 89 
mmHg), n (%) 
54 (15.6%) 17 (11.9%) 37 (18.1%)  
High (≥ 90 mmHg), n 
(%) 
119 (34.3%) 62 (43.4%) 57 (27.9%)  
Hypertension b (SBP 
> 140 mmHg or DBP 
>90 mmHg), n (%) 
125 (36.0%) 65 (45.5%) d 60 (29.4%) d 0.002 









Data presented as n (% of group) or median with 25th and 75th percentiles for interquartile range (for 
non-normally distributed data). n, number of participants; SD, standard deviation; SBP, systolic blood 
pressure; DBP, diastolic blood pressure. Means with same superscript letter: differ significantly (p < 
0.05) b Systolic, diastolic blood pressure category, as well as hypertension cut off based on guidelines 
by  Seedat and Rayner, 2013 
 
In HIV subgroup analyses, there were no significant differences in blood pressure and heart rate 








Table 4.8: Blood pressure and heart rate measurements of the HIV/ no ART and HIV on ART study 
groups. 
Variable HIV-infected/ no 
ART 




Systolic Blood Pressure (mmHg)  117.00 (109.00- 
132.00) 
119 (109.00- 133.50) 0.88 
Systolic blood pressure categories a   0.55 
Low (< 120 mmHg), n (%) 10 (62.5%) 95 (50.5%)  
Normal (120- 129 mmHg), n (%) 1 (6.3%) 40 (21.3%)  
Elevated (130- 139 mmHg), n (%) 2 (12.5%) 20 (10.6%)  
High (≥ 140 mmHg), n (%) 3 (18.8%) 33 (17.6%)  
Diastolic Blood pressure (mmHg)  86.00 (75.00- 93.00) 82.00 (75.25- 91.00) 0.60 
Diastolic blood pressure categories a   0.44 
Low (< 80 mmHg), n (%) 4 (25.0%) 75 (39.9%)  
Normal (80- 84 mmHg), n (%) 3 (18.8%) 28.14.9%)  
Elevated (85- 89 mmHg), n (%) 5 (31.3%) 32 (17.0%)  
High (≥ 90 mmHg), n (%) 4 (25.0%) 53 (28.2%)  
Hypertension a (SBP > 140 mmHg or 
DBP > 90 mmHg), n (%) 
4 (25.0%) 56 (29.8%) 0.69 
Heart Rate (bpm)  75.00 (70.00- 81.00) 70.00 (64.00- 80.00) 0.10 
Data presented as n (% of group) or median with 25th and 75th percentiles for interquartile range (for 
non-normally distributed data). n, number of participants; SD, standard deviation; SBP, systolic blood 
pressure; DBP, diastolic blood pressure. Means with same superscript letter: differ significantly (p < 
0.05). a Systolic, diastolic blood pressure category, as well as hypertension cut off based on guidelines 
by  Seedat and Rayner, 2013. 
 
4.2.5 Fasting lipid, glucose and HBA1c measurements  
There were no significant differences in the lipid profile between the HIV-infected and HIV-free groups 
(refer to table 4.9). Median fasting glucose was found to be significantly higher in the HIV-infected 
group in comparison to HIV-free group (p= 0.02). Furthermore, HbA1c% was found to be significantly 








Table 4.9: Fasting lipid, glucose and HBA1c measurements of the total, HIV-free and HIV-infected 
study groups. 








Lipid profile     
Total cholesterol 
(mmol/L) 
4.31 (3.82- 4.96) 4.30 (3.80- 4.90) 4.40 (3.86- 5.07) 0.51 
Total cholesterol 
categories a 
Elevated (≥ 5 
mmol/L), n (%) 





1.35 (1.10- 1.71) 1.32 (1.10- 1.63) 1.43 (1.08- 1.83) 0.21 
HDL categories a 
Decreased (≤ 1.2/1.0 
mmol/L females 
/males), n (%) 





2.43 ± 0.81 2.50 ± 0.86 2.38 ± 0.77 0.18 
LDL categories a 
Elevated (≥ 3 
mmol/L), n (%) 
77 (22.2%) 35 (24.5%) 42 (20.6%) 0.39 
Triglycerides 
(mmol/L)  
0.98 (0.75- 1.39) 0.96 (0.73- 1.35) 1.00 (0.78- 1.39) 0.39 
Triglycerides 
categories a Elevated 
(≥ 1.7 mmol/L), n (%) 
56 (16.1%) 19 (13.3%) 37 (18.1%) 0.23 
Glucose & HbA1c     
Fasting glucose 
(mmol/L)  
4.70 (4.30- 5.20) 4.60 (4.30- 5.00) b 4.80 (4.40- 5.28) b 0.02 
Fasting glucose 
categories a Elevated 
(≥ 5.6 mmol/L), n (%) 
43 (12.4%) 16 (11.2%) 27 (13.2%) 0.57 
Glycated 
Haemoglobin 
(HbA1c) (%)  
5.30 (5.00- 5.50) 5.40 (5.00- 5.60) c 5.20 (5.00- 5.40) c 0.01 
HbA1c categories a 
Elevated (≥ 5.9%), n 
(%) 
27 (7.8%) 13 (9.1%) 14 (6.9%) 0.45 
Data presented as mean ± SD or n (% of group) or median with 25th and 75th percentiles for interquartile 
range (for non-normally distributed data). n, number of participants; SD, standard deviation.  Means 
with same superscript letter: differ significantly (p < 0.05). a Lipid profile and glucose and HbA1c % 





In HIV subgroup analyses, the HIV-infected on ART group demonstrated a significantly higher total 
cholesterol (p= 0.001), LDL cholesterol (p= 0.04) and HDL cholesterol (p= 0.013) in comparison to 
HIV-infected/ no ART group. Additionally, the prevalence of participants with low HDL levels was 
higher in the HIV-infected/ no ART group compared to the treated group (p= 0.002). (Refer to table 
4.10).  
Table 4.10: Fasting lipid, glucose and HBA1c measurements of the HIV/ no ART and HIV with ART 
study groups. 
Variable HIV-infected/ no 
ART 




Lipid profile    
Total cholesterol (mmol/L) 3.66 (2.75- 4.00) a 4.46 (3.89- 5.13) a 0.001 
Total cholesterol categories b 
Elevated (≥ 5 mmol/L), n (%) 
1 (6.3%) 47 (25.0%) 0.09 
High-Density Lipoprotein 
Cholesterol (HDL) (mmol/L)  
0.97 (0.85- 1.44) c 1.45 (1.12- 1.83) c 0.01 
HDL categories b  
Decreased (≤ 1.2/1.0 mmol/L females 
/males), n (%) 
10 (62.5%) d 49 (26.1%) d 0.002 
Low-Density Lipoprotein 
Cholesterol (LDL) (mmol/L)  
1.96 ± 0.80 e 2.41 ± 0.76 e 0.04 
LDL categories b Elevated (≥3 
mmol/L), n (%) 
2 (12.5%) 40 (21.3%) 0.41 
Triglycerides (mmol/L)  1.04 (0.64- 1.55) 1.00 (0,78- 1.39) 0.47 
Triglycerides categories b  
Elevated (≥1.7 mmol/L), n (%) 
2 (12.5%) 35 (18.6%) 0.54 
Glucose & HbA1c    
Fasting glucose (mmol/L)  4.30 (4.10- 5.10) 4.8 (4.40- 5.30) 0.07 
Fasting glucose categories b Elevated 
(≥ 5.6 mmol/L), n (%) 
1 (6.3%) 26 (13.8%) 0.39 
Glycated Haemoglobin (HbA1c) (%)  5.00 (4.90- 5.40) 5.20 (5.00- 5.55) 0.26 
HbA1c categories b Elevated (≥ 
5.9%), n (%) 
3 (18.8%)  11 (5.9%)  0.05 
Data presented as n (% of group) or median with 25th and 75th percentiles for interquartile range (for 
non-normally distributed data). n, number of participants; SD, standard deviation. Means or medians 
with same superscript letter: differ significantly (p < 0.05). b Lipid profile and glucose and HbA1c % 
categories is based on guidelines by Seedat and Rayner, 2013 and Alberti et al., 2009. 
 
4.2.6 Haemoglobin and GGT measurements  
There was a significant difference in the prevalence of HIV infected participants with decreased Hb 
levels (anaemia) compared to HIV free participants (p= 0.05). Additionally, median GGT was 





Furthermore, the prevalence of participants with high GGT levels was higher in the HIV infected group 
compared to HIV free (p< 0.001) (Refer to table 4.11). 
Table 4.11: Haemoglobin and GGT measurements of the total, HIV-free and HIV-infected study 
groups. 















categories a Decreased 
(< 12.0/ 13.0 g/dL 
females/males), n (%) 
71 (20.5%) 22 (15.4%) b 49 (24.0%) b 0.05 
Liver function     







GGT categories d 
Elevated (≥ 40/ ≥ 60 
U/L women/men), n 
(%) 
131 (37.8%) 32 (22.4%) e 99 (48.5%) e < 0.001 
Data presented as n (% of group) or median with 25th and 75th percentiles for interquartile range (for 
non-normally distributed data). n, number of participants; SD, standard deviation. Means or medians 
with same superscript letter: differ significantly (p < 0.05). a Haemoglobin categories are based on WHO 
guidelines. d GGT categories are based on guidelines by NHLS, SA. 
 
In HIV subgroup analyses, median Hb as well as GGT was significantly higher in the HIV-infected on 
ART group in comparison to the HIV-infected/ no ART group (p < 0.001; p= 0.01, respectively). 
Additionally, the prevalence of low Hb (anaemia) was higher in the untreated group compared to HIV-
infected on ART (p= 0.002) (Refer to table 4.12). 
Table 4.12: Haemoglobin and GGT measurements of the HIV/ no ART and HIV with ART study 
groups. 
Variable HIV-infected/ no 
ART 
HIV-infected + ART 
 
P value 
Haemoglobin (g/dL)  11.20 (10.60- 12.70) a 13.35 (12.40- 14.40) a p<0.001 
Haemoglobin categories b Decreased 
(< 12.0/ 13.0 g/dL females/males), n 
(%) 
9 (56.3%) c 40 (21.3%) c 0.002 
Liver function    
GGT (U/L)  28.00 (22.00- 40.00) d 45.00 (29.00- 86.75) d 0.01 
GGT categories e Elevated (≥ 40/ ≥ 
60 U/L women/men), n (%) 





Data presented as n (% of group) or median with 25th and 75th percentiles for interquartile range (for 
non-normally distributed data). n, number of participants; SD, standard deviation. Means or medians 
with same superscript letter: differ significantly (p < 0.05). b Haemoglobin cut-off values for anaemia 
are based on WHO guidelines. e GGT cut-off values are according to the NHLS, South Africa. 
 
4.2.7 Kidney function measurements  
With regards to kidney function measurements, the albumin-to-creatinine ratio (ACR) was significantly 
higher in the HIV-infected group in comparison to HIV-free group (p= 0.04). No significant differences 
were observed in serum creatinine, urine albumin and eGFR measurements between the two study 
groups (refer to table 4.13). 
Table 4.13: Kidney function measurements of the total, HIV-free and HIV-infected study groups. 
























0.76 (0.40- 2.00) 0.70 (0.40- 1.50) a 0.80 (0.41- 2.48) a 0.04 
ACR categories b 
Increased (> 3 
mg/mmol), n (%) 
64 (18.4%) 22 (15.4%) 42 (20.6%) 0.22 
eGRF 
(mL/minute/1.73 m3) 
categories b Decreased 
(< 60 mL/minute/1.73 
m3), n (%) 
4 (1.2%) 2 (1.4%) 2 (1.0%) 0.72 
Data presented as n (% of group) or median with 25th and 75th percentiles for interquartile range (for 
non-normally distributed data). n, number of participants; SD, standard deviation. Means or medians 
with same superscript letter: differ significantly (p < 0.05). b ACR and eGFR categories used as 
previously reported (Du Plessis, 2013). 
 
In HIV subgroup analyses, the median serum creatinine was significantly higher in the HIV-infected on 
ART group in comparison to HIV-infected/no ART group (p= 0.003). There were no other significant 
differences in kidney function variables between the HIV-infected ART and HIV-infected/ no ART 







Table 4.14: Kidney function measurements of the HIV/ no ART and HIV with ART study groups. 
Variable HIV-infected/ no 
ART 




Serum creatinine (μmol/L)  50.50 (45.00- 61.25) a 62.00 (53.25- 71.00) a 0.003 
Urine albumin (mg/L) 22.05 (4.45- 67.15) 8.90 (4.20- 30.80) 0.33 
Albumin-to-creatinine ratio 
(mg/mmol)  
2.05 (0.63- 6.85) 0.80 (0.40- 2.20) 0.08 
ACR categories b Increased (> 3 
mg/mmol), n (%) 
5 (31.3%) 37 (19.7%) 0.27 
eGRF (mL/minute/1.73 m3) 
categories a Decreased (< 60 
mL/minute/1.73 m3), n (%) 
0 (0%) 2 (1.1%) 0.68 
Data presented as n (% of group) or median with 25th and 75th percentiles for interquartile range (for 
non-normally distributed data). n, number of participants; SD, standard deviation. Means or medians 
with same superscript letter: differ significantly (p < 0.05). b ACR and eGFR categories used as 
previously reported (Du Plessis, 2013). 
 
4.2.8 Systemic inflammation and biomarker measurements  
In the HIV-infected group the median VCAM-1 was observed to be significantly higher (p= 0.01) in 
comparison to HIV-free group. PAI-1 was found to be significantly lower in the HIV-infected group in 
comparison to HIV-free (p= 0.01). No other significant differences were observed in the biomarkers of 
inflammation and endothelial dysfunction as shown in table 4.15. 
Table 4.15: Systemic inflammation and biomarker measurements of the total, HIV-free and HIV-
infected study groups. 









hsCRP (mg/L) 4.70 (1.70- 10.60) 4.60 (1.80- 9.00) 4.90 (1.63- 11.98) 0.35 
hsCRP categories a 
Elevated (> 3mg/L in 
HIV-free; > 3.3mg/L 
in HIV-infected), n 
(%) 
207 (59.7%) 83 (58.0%) 124 (60.8%) 0.61 






















































Data presented as n (% of group) or median with 25th and 75th percentiles for interquartile range (for 
non-normally distributed data). n, number of participants. Means or medians with same superscript 
letter: differ significantly (p < 0.05). a HsCRP categories based on guidelines by Ridker et al., 2000 and 
De et al., 2013; Vishwanath, Quaiser and Khan, 2016 for HIV-free population and HIV-infected 
population, respectively. 
 
In the HIV subgroup analyses, VCAM-1 was observed to be significantly lower in the HIV-infected on 
ART group in comparison to HIV-infected/ no ART group (p= 0.004). No other significant differences 
were observed in the biomarkers of inflammation and endothelial dysfunction as shown in table 4.16. 
Table 4.16: Systemic inflammation and biomarker measurements of the HIV/ no ART and HIV with 
ART study groups. 
Variable HIV-infected/ no 
ART 




hsCRP (mg/L) 3.30 (0.58- 15.45) 5.00 (1.70- 11.85) 0.50 
hsCRP categories a Elevated (> 
3mg/L), n (%) 
1 (6.3%) 116 (61.7%) 0.36 
Tnf-α (pg/ml) 24.35 (19.23- 26.90) 21.53 (18.15- 25.77) 0.43 
VEGF (pg/ml) 89.87 (62.83- 248.66) 73.57 (47.95- 147.48) 0.44 










E-selectin (ng/ml) 40.30 (27.63- 51.04) 32.36 (24.06- 43.44) 0.23 
P-selectin (ng/ml) 37.71 (31.64- 49.19) 32.48 (23.72- 42.28) 0.15 
PAI-1 (ng/ml) 94.37 (75.96- 140.71) 79.26 (57.57- 108.02) 0.09 
Data presented as n (% of group) or median with 25th and 75th percentiles for interquartile range (for 
non-normally distributed data). n, number of participants. Means or medians with same superscript 






4.2.9 Carotid IMT and subclinical atherosclerosis measurements  
There were no significant differences in the mean IMT or the prevalence of subclinical atherosclerosis 
and plaque between the HIV-infected and HIV-free groups (refer to table 4.17). 
Table 4.17: Carotid IMT and subclinical atherosclerosis measurements of the total, HIV-free and HIV-
infected study groups. 








Mean IMT (µm)  627.74 ± 135.37 631.21 ± 136.61 625.33 ± 134.79 0.69 
IMT categories    0.91 
Subclinical 
atherosclerosis a (> 900 
µm), n (%) 
14 (4.0%) 5 (3.5%) 9 (4.4%)  
Plaque b (> 1000 µm), 
n (%) 
7 (2.0%) 3 (2.1%) 4 (2.0%)  
Data presented as mean ± SD or n (% of group). n, number of participants; SD, standard deviation. a 
Subclinical atherosclerosis cut off was based on guidelines by European Society of Cardiology and 
European Society of Hypertension. b Plaque was defined as an average IMT of more than 1000 µm, as 
suggested by Roozen et al., 2020. 
 
In the HIV subgroup analyses, the HIV-infected on ART group demonstrated a significantly higher 
mean IMT (p= 0.004) in comparison to HIV-infected/ no ART group. Additionally, subclinical 
atherosclerosis and plaque were only present in participants from the HIV-infected on ART group 
(Refer to table 4.18). 
Table 4.18: Carotid IMT and subclinical atherosclerosis measurements of the HIV/ no ART and HIV 
with ART study groups. 
Variable HIV-infected/ no 
ART 
 




Mean IMT (µm)  530.33 ± 92.79 a 633.24 ± 135.17 a 0.004 
IMT categories   0.55 
Subclinical atherosclerosis b (> 900 
µm), n (%) 
0 (0%) 9 (4.8%)  
Plaque c (> 1000 µm), n (%) 0 (0%) 4 (2.1%)  
Data presented as mean ± SD or n (% of group). n, number of participants; SD, standard deviation. 
Means or medians with same superscript letter: differ significantly (p < 0.05).  b Subclinical 
atherosclerosis cut off was based on guidelines by European Society of Cardiology and European 
Society of Hypertension. c Plaque was defined as an average IMT of more than 1000 µm, as suggested 





4.2.10 Endothelial function measurements (flow-mediated dilatation) 
There were no significant differences in the mean baseline brachial artery diameter and FMD% between 
HIV-infected and HIV-free groups (Refer to table 4.19). 
Table 4.19: Endothelial function measurements of the total, HIV-free and HIV-infected study groups. 









3.39 ± 0.62 3.37 ± 0.60 3.40 ± 0.62 0.59 
Flow-mediated 
dilatation (%)  
6.78 ± 5.43 6.74 ± 5.18 6.81 ± 5.61 0.90 
Data presented as mean ± SD. SD, standard deviation. 
 
In the HIV subgroup analyses, HIV-infected on ART group demonstrated a significantly higher baseline 
brachial artery (p= 0.036) and FMD% (p= 0.01) in comparison to HIV-infected/no ART (Refer to table 
4.20). 
Table 4.20: Endothelial function measurements of the HIV/ no ART and HIV with ART study groups. 
Variable HIV-infected/ no 
ART 
 




Baseline brachial artery diameter 
(mm)  
3.19 ± 0.35 a 3.42 ± 0.64 a 0.04 
Flow-mediated dilatation (%)  3.47 ± 5.60 b 7.09 ± 5.54 b 0.01 
Data presented as mean ± SD. SD, standard deviation. Means or medians with same superscript letter: 





4.3 Associations of various demographic and cardiovascular risk variables 
with IMT in the total, HIV-free, and HIV-infected cohort. 
To evaluate associations with IMT, the Pearson’s correlation test was conducted to determine the 
relationship between continuous variables and IMT (Refer to figure 4.2, 4.3, 4.4 for scatter plot graphs 
demonstrating significant correlations of selected continuous variables with IMT; refer to table 4.21 
for a summary of correlations with IMT). For categorical variables and their relationship with IMT, 
one-way ANOVA was performed with Bonferroni post hoc test for four categories and t-test was 
performed for those variables with two categories (Refer to table 4.21 for summary of significant 
categorical relationships with IMT).  
Biomarkers of inflammation and endothelial dysfunction did not significantly correlate with IMT (refer 











Figure 4.3: Scatter plot graphs of selected significant correlations of variables with IMT in the HIV-free group. 
 






Table 4.21: Summary of significant correlations of variables with IMT. 
Variables Total cohort HIV-free HIV-infected 
Continuous variables 
BMI (kg/m2) R=0.183; p= 0.001 R= 0.294; p< 0.001 R= 0.091, p= 0.20 
Waist circumference 
(cm) 
R= 0.178; p= 0.001 R= 0.248; p= 0.003 R= 0.116; p= 0.10 
SBP (mmHg) R= 0.264; p< 0.001 R= 0.291; p < 0.001 R= 0.243; p< 0.001 
DBP (mmHg) R= 0.159; p= 0.003 R= 0.143; p= 0.09 R= 0.172; p= 0.014 
Total cholesterol 
(mmol/L) 
R= 0.165; p= 0.002 R= 0.210; p= 0.01 R= 0.136; p= 0.05 
Lipid LDL cholesterol 
(mmol/L) 
R=0.183; p= 0.001 R= 0.272; p= 0.001 R= 0.152; p= 0.030 
Baseline brachial 
artery diameter (mm) 
R= 0.189; p< 0.001  R= 0.159; p= 0.06 R= 0.212; p= 0.002 
Age (years) R= 0.423; p< 0.001 R= 0.411; p< 0.001 R= 0.439; p <0.001 
Categorical variables 
SBP categories p < 0.001 p= 0.01 p= 0.01 
DBP categories P= 0.03 p= 0.23 p= 0.16 
Age categories p < 0.001 P= 0.003 p <0.001 
BMI categories P = 0.01 p= 0.003 p= 0.01 
Waist circumference 
category  
p < 0.001 p= 0.001 p= 0.09 
Hypertension  p= 0.01 p= 0 .17 p= 0.02 
ART status - - p= 0.004 
LDL categories p= 0.01 p= 0.01 p= 0.19 
Fasting glucose 
categories 
p= 0.05 p= 0.02 p= 0.05 
HbA1c categories p= 0.01 p= 0.03 p= 0.01 
R, Pearson correlation; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low density 









Table 4.22: Correlations of biomarkers of inflammation and endothelial dysfunction with IMT. 
Variables Total cohort HIV-free HIV-infected 
hsCRP (mg/L) R= 0.058; p= 0.29 R= 0.100; 0.24 R= 0.056; p= 0.43 
hsCRP categories a 
Elevated (> 3mg/L in 
HIV-free; > 3.3mg/L in 
HIV-infected), n (%) 
p= 0.06 P= 0.13 p= 0.22 
Tnf-α (pg/ml) R= 0.029; p= 0.73 R= -0.111; p= 0.45 R= 0.079; p= 0.46 
VEGF (pg/ml) R= -0.073; p= 0.40 R= 0.113; p= 0.45 R= -0.123; p= 0.25 
VCAM-1 (ng/ml) R=0.074; p= 0.39 R= 0.032; p= 0.83 R= 0.099; p= 0.35 
ICAM-1 (ng/ml) R= -0.016; p= 0.85 R= 0.087; p= 0.56 R= -0.018; p= 0.87 
E-selectin (ng/ml) R= 0.128; p= 0.13 R= 0.031; p= 0.83 R= 0.175; p= 0.10 
P-selectin (ng/ml) R= 0.067; p= 0.43 R= 0.158; p= 0.28 R= 0.021; p= 0.84 
PAI-1 (ng/ml) R= 0.016; p= 0.85 R= 0.091; p= 0.54 R= -0.021; p= 0.84 
R, Pearson correlation; a HsCRP categories based on guidelines by Ridker et al., 2000 and De et al., 
2013, Vishwanath, Quaiser and Khan, 2016 for HIV-free population and HIV-infected population, 
respectively. 
Variables that significantly correlated with IMT were shortlisted for generalized linear regression 
analysis to determine independent associations.  
For the total population, HIV status was forced to remain in the model, and age categories, gender 
categories, systolic blood pressure categories, BMI categories and LDL cholesterol were adjusted for 
in the model. Age ≥ 50 years, high systolic blood pressure as well as obese BMI category and LDL 
cholesterol demonstrated a positive significant association with IMT (refer to table 4.23a).  
For the HIV-free group, age categories, gender categories, systolic blood pressure categories, BMI 
categories and LDL cholesterol were adjusted for in the model. High systolic blood pressure as well as 
obese BMI category and LDL cholesterol demonstrated a significant positive association with IMT 
(refer to table 4.23a). 
For the total HIV-infected group, HIV duration categories, ART status and CD4 count as well as viral 
load were forced to remain in the model. Age categories, gender, systolic blood pressure categories and 
LDL cholesterol were adjusted for in the model. Age ≥ 50 years demonstrated a significant positive 
association with IMT (refer to table 4.23a). 
For HIV-infected group on ART, HIV duration categories, ART duration, CD4 count as well as viral 
load were forced to remain in the model. Age ≥ 50 years demonstrated a significant positive association 





Table 4.23a: Independent associations of various cardiovascular and HIV related factors with IMT. 
Average IMT 
Likelihood ratio Chi square 
Total cohort 
66.185; p <0.001 
HIV-free group 
33.297; p <0.001 
HIV-infected group 
41.932; p <0.001 
β (95% CI) p β (95% CI) p β (95% CI) p 
HIV status (yes) 10.85 (452.08; 566.14) 0.44 - - - - 
HIV duration: > 5 years - - - - 20.93 (-95.77; 137.63) 0.73 
ART status (yes) -  - - 70.01 (-5.98; 145.99) 0.07 
Age (years): ≥ 50 years 73.42 (40.91; 105.93) <0.001 26.12 (27.07; -26.96) 0.34 99.32 (55.52; 143.12) <0.001 
Gender: female -14.79 (-45.41; 15.83) 0.34 18.55 ( -32.11; 69.21) 0.47 -14.27 (-51.79; 23.25) 0.46 
Systolic blood pressure category:        
High (≥ 140 mmHg) 66.75 (30.39; 103.10) <0.001 78.09 (19.97; 136.22) 0.01 40.58 (-8.75; 89.91) 0.46 
Elevated (130- 139 mmHg) 6.53 (-34.80; 47.86) 0.76 -1.38 (-61.28; 58.52) 0.96 33.73 (-24.56; 92.02) 0.46 
Normal (120- 129 mmHg) 16.22 (-19.45; 51.88) 0.37 3.71 (-53.22; 60.63) 0.90 11.46 (-35.28; 58.20) 0.46 
BMI categories        
Obese (BMI > 30 kg/m2), n (%) 56.28 (11.37; 101.19) 0.01 79.72 (4.35; 155.09) 0.03 - - 
Overweight (BMI 25 to < 30 kg/m2) 34.51 (-11.57; 80.60) 0.14 50.71 (-31.75; 133.16) 0.23 - - 
Normal weight (BMI 18.5 to < 25 
kg/m2) 
20.85 (-17.48; 59.18) 0.29 33.56 (-37.98; 105.11) 0.36 - - 
Low-Density Lipoprotein Cholesterol 
(LDL) (mmol/L) 
25.09 (8.10; 42.09) 0.004 32.10 (6.90; 57.30) 0.01 12.02 (-11.15;35.19) 0.31 
CD4 count (cells/mm3) - - - - 0.04 (-0.04; 0.13) 0.30 
Viral Load (copies mRNA/ml): high     -2.42 (-52.43; 47.60) 0.93 
IMT, intima media thickness; β, partial regression coefficient; CI, confidence interval; BMI, body mass index; ART, antiretroviral treatment; HIV, human 





Table 4.23b: Independent associations of various cardiovascular and HIV related factors with IMT in the HIV-infected on ART study population. 
Average IMT 
Likelihood ratio Chi square 
HIV-infected +ART cohort 
35.507; p <0.001 
β (95% CI) p 
HIV duration: > 5 years -24.52 (-150.21; 101.17) 0.70 
ART duration (weeks) 0.13 (-0.01; 0.26) 0.07 
Age (years): ≥ 50 years 92.05 (47.64; 136.46) <0.001 
Gender: female -8.40 (-47.05; 30.25) 0.67 
Systolic blood pressure category:    
High (≥ 140 mmHg) 34.58 (-17.32; 86.47) 0.19 
Elevated (130- 139 mmHg) 26.78 (-34.32; 87.88) 0.39 
Normal (120- 129 mmHg) 13.91 (-33.05; 60.87) 0.56 
Low-Density Lipoprotein Cholesterol (LDL) (mmol/L) 20.61 (-3.54; 44.77) 0.09 
CD4 count (cells/mm3) 0.05 (-0.03; 0.14) 0.23 
Viral Load (copies mRNA/ml): high -1.78 (-53.60; 50.05) 0.95 
IMT, intima media thickness; β, partial regression coefficient; CI, confidence interval; BMI, body mass index; ART, antiretroviral treatment; HIV, human 





4.4 Associations of various demographic and cardiovascular risk variables 
with FMD% in the total, HIV-free, and HIV-infected cohort. 
To evaluate possible associations with FMD%, the Pearson’s correlation test was conducted to 
determine the relationship between continuous variables and FMD% (Refer to figure 4.5, 4.6, 4.7 for 
scatter plot graphs demonstrating significant correlations of selected continuous variables with FMD%; 
refer to table 4.24 for a summary of correlations with FMD%). For categorical variables and their 
relationship with FMD%, one-way ANOVA was performed with Bonferroni post hoc test for four 
categories and t-test was performed for those variables with two categories (Refer to table 4.24 for 
summary of significant categorical relationships with FMD%). 
Biomarkers of inflammation and endothelial dysfunction did not significantly correlate with FMD% 













Figure 4.6: Scatter plot graphs of selected significant correlations of variables with FMD% in the HIV-free study group. 
 





Table 4.24: Summary of significant correlations of variables with FMD%. 
Variables Total cohort HIV-free HIV-infected 
Continuous variables 
BMI (kg/m2) R= -0.092; p= 0.09 R= -0.210; p= 0.01 R= -0.004; p= 0.96 
Waist circumference 
(cm) 
R=-0.114; p= 0.03 R= -0.203; p= 0.02 R= -0.045; p= 0.52 
SBP (mmHg) R=-0.169; P=0.002 R= -0.195; P=0.02 R=0.152; p= 0.03 
Mean DBP (mmHg) R=-0.152; p= 0.01 R= -0.199; p= 0.02 R= -0.118; p= 0.09 
HBA1c % R=-0.110, p= 0.04 R= -0.147; p= 0.08 R= -0.082; p= 0.25 
CD4 (count) R=0.175; p= 0.01 - R=0.175; p= 0.01 
Urine albumin (mg/L) R= -0.110; p= 0.04 R= -0.018; p= 0.83 R=0.175; p= 0.01 
Baseline brachial 
artery diameter (mm) 
R= -0.367; p<0.001 R=-0.334; p<0.001 R=-0.388; p< 0.001 
Maximum diameter 
(mm) 
R= -0.113; p= 0.04 R=-0.068; p= 0.42 R=-0.141; p= 0.04 
Recovery diameter 
(mm) 
R= -0.106; p= 0.05 R= -0.092; p= 0.28 R=-0.113; p=0.11 
Average carotid 
diameter (mm) 
R= -0.224; p <0.001 R= -0.333; p <0.001 R=-0.142; p= 0.04 
Age (years) R= -0.129; p=0.02 R=- 0.161; p= 0.06 R=0.106; p= 0.13 
Haemoglobin (g/dL) R= -0.088; p= 0.10 R=-0.212; p= 0.01 R= -0.025; p= 0.73 
Serum creatinine 
(μmol/L) 
R= -0.101; p=0.06 R=-0.283; p= 0.001 R= -0.017; p= 0.81 
Categorical variables 
Gender p= 0.02 p= 0.06 p= 0.16 
SBP categories p= 0.02 P= 0.06 p= 0.06 
DBP categories p= 0.03 p= 0.02 p=0.95 
Age categories p= 0.003 p= 0.01 p= 0.11 
BMI categories p= 0.56 p= 0.04 p=0.92 
GGT categories p= 0.30 P= 0.02 p= 0.01 
High Viral load - - p=0.002 
ART status - - p=0.01 
R, Pearson correlation; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low density 
lipoproteins, BMI, body mass index; ART, antiretroviral treatment. 





Variables Total cohort HIV-free HIV-infected 
hsCRP (mg/L) R= -0.016; p= 0.77 R= 0.070; P= 0.41 R= -0.058; p= 0.42 
hsCRP categories a 
Elevated (> 3mg/L in 
HIV-free; > 3.3mg/L in 
HIV-infected), n (%) 
p= 0.69 p= 0.63 P=0.39 
Tnf-α (pg/ml) R= -0.031; p= 0.72 R= -0.151; p= 0.30 R= 0.011; p= 0.92 
VEGF (pg/ml) R= 0.053; p= 0.54 R= 0.108; p= 0.46 R= 0.044; p= 0.68 
VCAM-1 (ng/ml) R= -0.091; p= 0.29 R= 0.127; p= 0.38 R= -0.167; p=0 .11 
ICAM-1 (ng/ml) R= -0.051; p= 0.55 R= 0.010; p= 0.94 R= -0.096; p= 0.37 
E-selectin (ng/ml) R= -0.069; p= 0.42 R= -0180; p= 021 R= -0.018; p= 0.87 
P-selectin (ng/ml) R= 0.009; p= 0.92 R= 0.042; p= 0.77 R= -0.016; p= 0.88 
PAI-1 (ng/ml) R= -0.072; p= 0.40 R= 0.073; p= 0.62 R= -0.157; p= 0.14 
R, Pearson correlation; a HsCRP categories based on guidelines by Ridker et al., 2000, and De et al., 
2013, Vishwanath, Quaiser and Khan, 2016 for HIV-free population and HIV-infected population, 
respectively. 
 
Variables that significantly correlated with FMD% were shortlisted for generalized linear regression 
analysis to determine independent associations. All regression models were repeated to observe 
associations when baseline brachial artery diameter is additionally adjusted for.  
For the total population, HIV status was forced to remain in the model, and age categories, gender, 
systolic blood pressure categories, waist circumference, and urine albumin were adjusted for in the 
model. Age ≥ 50 years, high and normal systolic blood pressure as well as waist circumference and 
urine albumin demonstrated significant inverse associations with FMD%. Gender (female) 
demonstrated a significant positive association with FMD% (refer to table 4.26a). When brachial 
artery was adjusted for in the model, no significant associations were found (refer to table 4.27a). 
In the HIV-free group, age categories, gender, systolic blood pressure categories, BMI categories and 
serum creatinine level were adjusted for in the model. Serum creatinine demonstrated a significant 
inverse association with FMD% (refer to table 4.26a). The significant association remained after 
adjusting for baseline brachial artery diameter (refer to table 4.27a). 
In the total HIV-infected group, HIV duration categories, ART status and CD4 count as well as viral 
load were forced to remain in the model. Age categories, gender, systolic blood pressure categories and 
BMI categories were adjusted for in the model. Presence of ART showed significant positive 





association with FMD (refer to table 4.26a). When brachial artery diameter was adjusted for in the 
model, presence of ART continued to demonstrate a significant positive association with FMD% while 
viral load demonstrated a significant inverse association with FMD% (refer to table 4.27a). 
In the HIV-infected on ART group, HIV duration categories, ART duration, CD4 count as well as viral 
load were forced to remain in the model. Age categories, gender, systolic blood pressure categories and 
BMI categories were adjusted for in the model. Normal systolic blood pressure demonstrated a 
significant inverse association with FMD% (refer to table 4.26b). When brachial artery diameter was 
adjusted for in the model, viral load demonstrated a significant inverse association with FMD% (refer 






Table 4.26a: Independent associations of various cardiovascular and HIV related factors with FMD%. 
FMD% 
Likelihood ratio Chi square 
Total Cohort 
31.284; p <0.001 
HIV-free group 
28.335; p= 0.001 
HIV-infected group 
29.562, p= 0.009 
β (95% CI) p β (95% CI) p β (95% CI) p 
HIV status (yes) -0.14 (-1.21; 1.01) 0.81 - - - - 
HIV duration: > 5 years - - - - -1.31 (-7.24; 4.62) 0.66 
ART status - - - - 3.93 (0.43; 7.43) 0.03 
Age (years): ≥ 50 years -1.23 (-2.60; 0.14) 0.08 -1.02 (-3.01; 1.02) 0.33 -1.1 (-3.12; 0.92) 0.29 
Gender: female 1.63 (0.37; 2.89) 0.01 1.41 (-0.95; 3.77) 0.24 1.03 (-0.75; 2.80) 0.26 
Systolic blood pressure categories:        
High (≥ 140 mmHg) -1.73 (-3.27; -0.20) 0.03 -2.02 (-4.25; 0.21) 0.08 -1.61 (-3.92; 0.69) 0.17 
Elevated (130- 139 mmHg) -.057 (-2.30; 1.16) 0.52 -0.60 (-2.91; 1.71) 0.61 0.32 (-2.42; 3.07) 0.82 
Normal (120- 129 mmHg) -1.75 (-3.26; -0.25) 0.02 -1.55 (-3.75; 0.65) 0.17 -3.27 (-5.43; -1.12) 0.003 
Waist circumference (cm) -0.04 (-0.08; -0.004) 0.03 - - - - 
Urine albumin (mg/L) -0.01 (-0.013; 0.001) 0.04 - - - - 
Viral Load (copies mRNA/ml): high     -2.04 (-4.32; 0.24) 0.08 
CD4 count (cells/mm3) - - - - 0.001 (-0.002; 0.01) 0.47 
BMI categories        
Obese (BMI > 30 kg/m2), n (%) - - -2.20 (-5.15; 0.752) 0.14 -1.03 (-3.80; 1.73)  0.46 
Overweight (BMI 25 to < 30 kg/m2) - - -2.52 (-5.68; 0.65) 0.12 -0.04 (-2.59; 2.52)  0.98 
Normal weight (BMI 18.5 to < 25 
kg/m2) 
- - -0.31 (-3.07; 2.45) 0.83 -0.44 (-2.53; 1.65)  0.68  





FMD, flow mediated dilatation; β, partial regression coefficient; CI, confidence interval; BMI, body mass index; ART, antiretroviral treatment; HIV, human 




















Table 4.26b Independent associations of various cardiovascular and HIV related factors with FMD% in the HIV-infected on ART study population. 
FMD% 
Likelihood ratio Chi square 
HIV-infected + ART cohort 
23.012; p= 0.060 
β (95% CI) p 
HIV duration: > 5 years -2.48 (-8.98; 4.02)  0.46 
ART duration (weeks) 0.002 a (-0.01; 0.01)  0.61 
Age (years): ≥ 50 years -1.21 (-3.27; 0.86)  0.25 
Gender: female 0.93 (-0.92; 2.77)  0.33 
Systolic blood pressure categories:    
High (≥ 140 mmHg) -2.03 (-4.49; 0.43)  0.11 
Elevated (130- 139 mmHg) 1.15 (-1.79; 4.08)  0.44 
Normal (120- 129 mmHg) -3.22 (-5.41; -1.04)  0.004  
Viral Load (copies mRNA/ml): high -2.12 (-4.51; 0.26)  0.08 
CD4 count (cells/mm3) 0.001b (-0.003c; 0.01)  0.55 
BMI categories    
Obese (BMI > 30 kg/m2), n (%) -0.83 (-3.74; 2.09)  0.58 
Overweight (BMI 25 to < 30 kg/m2) 0.18 (-2.5; 2.86)  0.90 
Normal weight (BMI 18.5 to < 25 kg/m2) 0.02 (-2.25; 2.30)  0.98  
FMD, flow mediated dilatation; β, partial regression coefficient; CI, confidence interval; BMI, body mass index; ART, antiretroviral treatment; HIV, human 





Table 4.27a: Independent (after adjusting for brachial artery diameter) associations of various cardiovascular and HIV related factors with FMD%. 
FMD% 
Likelihood ratio Chi square 
Total Cohort 
61.705; p <0.001 
HIV-free group 
32.956; p <0.001 
HIV-infected group 
56.310; p <0.001 
β (95% CI) p β (95% CI) p β (95% CI) p 
HIV status (yes) 0.03 (-1.07; 1.13) 0.96 - -   
HIV duration: > 5 years - - - - -0.71 (-6.20; 4.79)  0.80  
ART status - - - - 3.44 (0.19; 6.69)  0.04 
Age (years): ≥ 50 years -0.75 (-2.06; 0.57) 0.26 -0.50 (-2.53; 1.53) 0.63 -0.76 (-2.64; 1.12)  0.43 
Gender: female -0.437 (-1.84; 0.97) 0.54 0.449 (-2.03; 2.93) 0.72 -1.70 (-3.62; 0.22)  0.08 
Systolic blood pressure categories       
High (≥ 140 mmHg) -1.25 (-2.73; 0.23) 0.09 -2.07 (-4.26; 0.13) 0.07 -0.95 (-3.10; 1.20)  0.39 
Elevated (130- 139 mmHg) -0.58 (-2.23; 1.08) 0.49 -1.04 (-3.35; 1.27) 0.38 0.56 (-1.99; 3.10)  0.67  
Normal (120- 129 mmHg) -1.07 (-2.53; 0.39) 0.15 -1.54 (-3.70; 0.63) 0.16 -1.79 (-3.86; 0.28)  0.09 
Waist circumference (cm) -0.01 (-0.05; 0.03) 0.67 - - - - 
Urine albumin (mg/L) -0.01 (-0.01; 0.00) 0.06 - - - - 
Baseline brachial artery diameter 
(mm) 
-3.03 (-4.08; -1.98) <0.001 -1.73 (-3.28; -0.17) 0.03 -4.08 (-5.57; -2.60) <0.001 
Viral Load (copies mRNA/ml): high - - - - -2.21 (-4.32; -0.10)  0.04 
CD4 count (cells/mm3) - - - - 0.001 (-0.002; 0.01)  0.48  
BMI categories        
Obese (BMI > 30 kg/m2), n (%) - - -1.19 (-4.23; 1.85) 0.44 0.01 (-2.58; 2.59)  0.10 
Overweight (BMI 25 to < 30 kg/m2) - - -1.96 (-5.11; 1.20) 0.22 1.68 (-0.77; 4.13)  0.18  
Normal weight (BMI 18.5 to < 25 
kg/m2) 





Serum creatinine (μmol/L) - - -0.07 (-0.138; 0.00) 0.04 - - 
FMD, flow mediated dilatation; β, partial regression coefficient; CI, confidence interval; BMI, body mass index; ART, antiretroviral treatment; HIV, human 



















Table 4.27b: Independent (after adjusting for brachial artery diameter) associations of various cardiovascular and HIV related factors with FMD% in the HIV-
infected on ART study population. 
FMD% 
Likelihood ratio Chi square 
HIV-infected + ART cohort 
53.084; p <0.001 
β (95% CI) p 
HIV duration: > 5 years -1.73 (-7.65; 4.20)  0.57 
ART duration (weeks) 0.002 (-0.004; 0.01)  0.60 
Age (years): ≥ 50 years -0.85 (-2.74; 1.03)  0.38 
Gender: female -2.00 (-3.95; -0.05)  0.05 
Systolic blood pressure categories   
High (≥ 140 mmHg) -1.38 (-3.63; 0.87)  0.23 
Elevated (130- 139 mmHg) 1.46 (-1.21; 4.13)  0.28 
Normal (120- 129 mmHg) -1.64 (-3.71; 0.42)  0.12  
Baseline brachial artery diameter (mm) -4.37 (-5.86; -2.88) <0.001 
Viral Load (copies mRNA/ml): high -2.35 (-4.53; -0.17)  0.03 
CD4 count (cells/mm3) 0.001 (-0.003; 0.004)  0.67 
BMI categories    
Obese (BMI > 30 kg/m2), n (%) 0.27 (-2.42; 2.95)  0.85  
Overweight (BMI 25 to < 30 kg/m2) 2.03 (-0.50; 4.55)  0.12 
Normal weight (BMI 18.5 to < 25 kg/m2) 0.94 (-1.16; 3.03)  0.38 
FMD, flow mediated dilatation; β, partial regression coefficient; CI, confidence interval; BMI, body mass index; ART, antiretroviral treatment; HIV, human 





Section B: Results from longitudinal sub-study 
4.5 Descriptive profile of the baseline population 
4.5.1 Demographic profile, medical background, lifestyle and 
socioeconomic characteristics of the baseline population 
For the longitudinal sub-study, 57 volunteering participants completed baseline and 12-month follow 
up visits. The mean age was 44.91 years, and 36.8% of the cohort was more than or equal to 50 years 
of age. The cohort was mostly represented by females (n= 50, 87.7%) and individuals who self-
identified as being of mixed-race ancestry (n= 56, 98.2%). Refer to table 4.28 for the baseline 
demographic profile of the cohort.  
Table 4.28: Demographic profile of the study cohort at baseline. 
Variable Baseline characteristics 
Age (years) (Mean ± SD) 44.91 ± 12.11 
Age categories  
Age < 50, n (%) 36 (63.2%) 
Age ≥ 50, n (%) 21 (36.8%) 
Gender 
Female, n (%) 50 (87.7%) 
Male, n (%) 7 (12.3%) 
Ethnicity  
Mixed ancestry, n (%) 56 (98.2%) 
African, n (%) 1 (1.8%) 
Data presented as mean ± SD or n (% of group). n, number of participants; SD, standard deviation. 
In the cohort, the most prevalent form of previous comorbidity was hypertension. History of all the 
other comorbidities was low (Refer to table 4.29). The current smoking status in the cohort was high 
(n= 40, 70.2%) while only 24.6 % of the participants reported to have never smoked before. Less than 
half (n= 24, 42.1%) of participants reported to have consumed alcohol in the last year prior to the 
baseline visit with almost all reporting a consumption frequency of less than 8 days per month (n= 23, 











Table 4.29: Medical background and lifestyle characteristics of the study cohort at baseline. 
Variable Baseline characteristics 
History of comorbidities   
Previous TB n (%) 7 (12.3%) 
Previous Stroke n (%) 2 (3.5%) 
Type 2 Diabetes n (%) 4 (7%) 
Previous hypertension 18 (31.6%) 
Previous dyslipidaemia  11 (19.3%) 
Previous heart disease 0 (0%) 
Smoking  
Current smoker n (%) 40 (70.2%) 
History of smoking n (%) 3 (5.3%) 
No history of smoking n (%) 14 (24.6%) 
Alcohol consumption  
Alcohol consumption in the past 12 months, n (%) 24 (42.1%) 
< 8 days per month, n (%) 23 (95.8%) 
Data presented as mean ± SD or n (% of group). n, number of participants; SD, standard deviation; TB, 
tuberculosis.  
Approximately half of the study population was unemployed (n= 30, 52.6%) and those that were 
employed, most of them reported to be working part-time (n= 20, 35.1%). The majority of the 
participants (n= 34, 59.6%) reported to have a total household income between R1,000 - R4,999, with 
a substantial number of participants (n=19, 33.3%), reported to have a total household income of less 
than R1,000 (Refer to table 4.30). 
Table 4.30: Socioeconomic characteristics of the study cohort at baseline. 
Variable Baseline characteristics 
Employment status  
Unemployed, n (%) 30 (52.6%) 
Employed full-time, n (%) 7 (12.3%) 
Employed part-time, n (%) 20 (35.1%) 
Monthly income  
< R1,000, n (%) 19 (33.3%) 
 R1,000 - R4,999, n (%) 34 (59.6%) 
R5,000 - R9,999, n (%) 2 (3.5%) 
R10,000 - R20,000, n (%) 1 (1.8%) 






4.5.2 Anthropometric characteristics of the baseline population 
The mean BMI in the cohort was ~ 28.33 kg/m2, which is in the overweight category according to the 
WHO guidelines. Additionally, the largest percentage of the cohort (n= 21, 36.8%) was in the obese 
category. Furthermore, the mean waist circumference was 89.93 cm and waist to hip ratio was 0.88, 
both of which falling under the high categories according to Alberti et al., 2009 (Refer to table 4.31 
for the composition of waist hip ratio and waist circumference categories).  
Table 4.31: Anthropometric characteristics of the study cohort at baseline. 
Variable Baseline characteristics 
BMI (kg/m2)  28.33 ± 8.21 
BMI categories a    
Underweight (BMI < 18.5 kg/m2), n (%) 6 (10.5%) 
Normal weight (BMI 18.5 to < 25 kg/m2), n (%) 17 (29.8%) 
Overweight (BMI 25 to < 30 kg/m2), n (%) 13 (22.8%) 
Obese (BMI > 30 kg/m2), n (%) 21 (36.8%) 
Waist circumference (cm)  89.93 ± 16.84 
Waist circumference category b  
High (≥ 80/ ≥ 94 females/ males), n (%) 37 (64.9%) 
Waist to hip ratio  0.88 ± 0.09 
Waist to hip ratio categories b  
Low (≥ 0.80/ ≥ 0.95 females/ males), n (%) 13 (22.8%) 
Moderate (0.81–0.85/0.96–1.0 females/ males), n (%) 14 (24.6%) 
High (> 0.86/ > 1.0 females/ males), n (%) 30 (52.6%) 
Data presented as mean ± SD or n (% of group). n, number of participants; SD, standard deviation; 
BMI, body mass index. a BMI category based on WHO.  b Waist circumference and waist to hip ratio 
category based on guidelines by Alberti et al., 2009. 
 
4.5.3 Blood pressure and heart rate measurements of the baseline 
population 
The mean SBP and DBP (~ 125.98 mmHg; ~ 84.64 mmHg, respectively) in the cohort fell within the 
normal range according to Seedat and Rayner, 2013. About half of the cohort (n= 29, 50.9%) presented 
with low SBP, while less than half of the cohort (n= 20, 35.1%) presented with low DBP (Refer to 
table 4.5 for the SBP and DBP categorical composition in the total cohort). Furthermore, less than half 
of the cohort (n=20, 35.1%) presented with hypertension according to guidelines by Seedat and Rayner, 





Table 4.32: Blood pressure and heart rate measurements of the study cohort at baseline. 
Variable Baseline characteristics 
Systolic Blood Pressure (mmHg)  125.98 ± 19.78 
Systolic blood pressure categories a  
Low (< 120 mmHg), n (%) 29 (50.9%) 
Normal (120- 129 mmHg), n (%) 9 (15.8%) 
Elevated (130- 139 mmHg), n (%) 4 (7.0%) 
High (≥ 140 mmHg), n (%) 15 (26.3%) 
Diastolic Blood pressure (mmHg) 84.64 ± 11.73 
Diastolic blood pressure categories a  
Low (< 80 mmHg), n (%) 20 (35.1%) 
Normal (80- 84 mmHg), n (%) 12 (21.1%) 
Elevated (85- 89 mmHg), n (%) 9 (15.8%) 
High (≥ 90 mmHg), n (%) 16 (28.1%) 
Hypertension a (SBP > 140 mmHg or DBP >90 mmHg), n 
(%) 
20 (35.1%) 
Heart Rate (bpm)  70.96 ± 11.73 
Data presented as mean ± SD or n (% of group). n, number of participants; SD, standard deviation; 
SBP, systolic blood pressure; DBP, diastolic blood pressure. a Systolic, diastolic blood pressure 
category, as well as hypertension cut off based on guidelines by Seedat and Rayner, 2013 
 
4.5.4 Fasting lipid, glucose and HBA1c measurements of the baseline 
population 
The mean total cholesterol, HDL level, LDL level as well as triglycerides, were all within the normal 
range according to guidelines by Seedat and Rayner, 2013 and Alberti et al., 2009. Refer to table 4.33 
for the mean values and categorical composition of the lipid profile. 
Additionally, the median fasting glucose level as well as the HbA1c % (~ 4.9 mmol/L; ~ 5.4 %, 
respectively) were within the normal range according to guidelines by Seedat and Rayner, 2013 and 
Alberti et al., 2009. Furthermore, less than quarter of the study cohort presented with elevation in these 









Table 4.33: Fasting lipid, glucose and HBA1c measurements of the study cohort at baseline. 
Variable Baseline characteristics 
Lipid profile 
Total cholesterol  4.32 ± 0.70 
Total cholesterol categories a 
Elevated (≥ 5 mmol/L), n (%) 
8 (14.0%) 
High-Density Lipoprotein Cholesterol (HDL) (mmol/L)  1.37 ± 0.30 
HDL categories a 
Decreased (≤ 1.2/1.0 mmol/L females /males), n (%) 
14 (24.6%) 
Low-Density Lipoprotein Cholesterol (LDL) (mmol/L)  2.45 ± 0.67 
LDL categories a  
Elevated (≥ 3 mmol/L), n (%) 
13 (22.8%) 
Triglycerides (mmol/L) 0.92 (0.67 - 1.43) 
Triglycerides categories a  
Elevated (≥1.7 mmol/L), n (%) 
6 (10.5%) 
Fasting glucose and HbA1c 
Fasting glucose (mmol/L)  4.90 (4.35 - 5.60) 
Fasting glucose categories a  
Elevated (≥ 5.6 mmol/L), n (%) 
13 (22.8%) 
Glycated Haemoglobin (HbA1c) (%)  5.40 (4.95 - 5.70) 
HbA1c categories a  
Elevated (≥ 5.9%), n (%) 
13 (22.8%) 
Data presented as mean ± SD or n (% of group) or median with 25th and 75th percentiles for 
interquartile range (for non-normally distributed data). n, number of participants; SD, standard 
deviation. a Lipid profile and glucose and HbA1c % categories is based on guidelines by Seedat and 
Rayner, 2013 and Alberti et al., 2009. 
 
4.5.5 Haemoglobin and GGT measurements of the baseline population 
The mean Hb level and the median GGT level in the cohort was within the normal range, according to 
guidelines by WHO and NHLS, South Africa, respectively. Refer to table 4.34 for the categorical 
composition of these parameters in the cohort. 
Table 4.34: Haemoglobin and GGT measurements of the study cohort at baseline. 
Variable Baseline characteristics 
Haemoglobin (g/dL)  13.17 ± 1.22 
Haemoglobin categories a  
Decreased (< 12.0/ 13.0 g/dL females/males), n (%) 
12 (21.1%) 
Liver function 





GGT categories b  
Elevated (≥ 40/ ≥ 60 U/L women/men), n (%) 
14 (24.6 %) 
Data presented as mean ± SD or n (% of group) or median with 25th and 75th percentiles for 
interquartile range (for non-normally distributed data). n, number of participants; SD, standard 
deviation. a Haemoglobin categories are based on WHO guidelines. b GGT categories are based on 
guidelines by NHLS, SA. 
 
4.5.6 Kidney function measurements of the baseline population 
The median ACR ratio in the cohort was 0.60, which is below the normal range according to Du Plessis, 
2013. Furthermore, very few participants (n= 4, 7.0%; n= 2, 3.5%) presented with increased ACR ratio 
or decreased eGFR, respectively (refer to table 4.35). 
Table 4.35: Kidney function measurements of the study cohort at baseline. 
Variable Baseline characteristics 
Kidney function 
Serum creatinine (μmol/L)  63.95 ± 14.78 
Urine albumin (mg/L) 6.80 (3.05 - 15.80) 
Albumin-to-creatinine ratio (mg/mmol)  0.60 (0.31 - 1.30) 
ACR categories a  
Increased (> 3 mg/mmol), n (%) 
4 (7.0%) 
eGRF (mL/minute/1.73 m3) categories a  
Decreased (< 60 mL/minute/1.73 m3), n (%) 
2 (3.5%) 
Data presented as mean ± SD or n (% of group) or median with 25th and 75th percentiles for 
interquartile range (for non-normally distributed data). n, number of participants; SD, standard 
deviation. a ACR and eGFR categories used as previously reported (Du Plessis, 2013). 
 
4.5.7 Systemic inflammation and biomarker measurements of the baseline 
population 
The mean hsCRP of the cohort was 5.20 mg/L, which falls within the elevated range according to 
guidelines by Ridker et al., 2000. Additionally, more than half of the study cohort (n= 36, 63.2%) 
represented with elevated hsCRP. TNF-α, VEGF as well as adhesion molecules such as VCAM-1, 
ICAM-1, E-selectin, P-selectin and PAI-1 were all presented as median and are described in table 4.36. 
Table 4.36: Systemic inflammation and biomarker measurements of the study cohort at baseline. 
Variable Baseline characteristics 
hsCRP (mg/L) 5.20 (1.20 - 10.70) 
hsCRP categories a  






Tnf-α (pg/ml) 22.95 (20.07- 27.13) 
VEGF (pg/ml) 98.75 (79.91- 146.12) 
VCAM-1 (ng/ml) 727.45 (578.20 - 1041.60) 
ICAM-1 (ng/ml) 415.94 (255.84 - 651.28) 
E-selectin (ng/ml) 34.35 (28.27 - 46.48) 
P-selectin (ng/ml) 36.87 (30.01- 45.97) 
PAI-1 (ng/ml) 91.52 (77.32- 114.13) 
Data presented as n (% of group) or median with 25th and 75th percentiles for interquartile range (for 
non-normally distributed data). n, number of participants. a HsCRP categories based on guidelines by 
Ridker et al., 2000. 
 
4.5.8 Endothelial function measurements of the baseline population 
The mean baseline brachial artery diameter and FMD% is described in table 4.37. 
Table 4.37: Endothelial function measurements of the study cohort at baseline. 
Variable Baseline characteristics 
Baseline brachial artery diameter (mm)  3.41 ± 0.61 
Flow-mediated dilatation (%)  5.72 ± 4.62 
Data presented as mean ± SD. SD, standard deviation. 
 
4.5.9 Subclinical atherosclerosis measurements of the baseline population 
The mean IMT of the cohort was 651.10 µm, which is within the normal range according to guidelines 
supplied by the European Society of Cardiology and European Society of Hypertension (Mancia et al., 
2013). Subclinical atherosclerosis was present in n=2, 3.5% of the cohort and no participants presented 
with plaque (refer to table 4.38). 
Table 4.38: Subclinical atherosclerosis measurements of the study cohort at baseline. 
Variable Baseline characteristics 
Mean IMT (µm)  651.10 ± 124.70 
Subclinical atherosclerosis (> 900 µm), n (%) 2 (3.5%) 
Plaque (> 1000 µm), n (%) 0 (0%) 






4.6 Differences in variables between baseline and 12-month follow up 
As the study comprised of both males and females, additional gender subgroup analyses were conducted 
to note differences between the two time points (refer to appendix C). 
 
4.6.1 Differences in anthropometric measurements between baseline and 
12-month follow up 
The cohort’s mean BMI did not significantly change over the 12-month time. Refer to appendix C, 
table C3, for cross tabulation of BMI categories using McNemar-Bowker Test. The majority (n= 48) 
of the individuals did not change categories over time. n=7 moved to a higher BMI category, while n= 
2, moved to a lower BMI category. There were no significant changes in the BMI categories between 
the two time points.  
Although there were no significant changes in the waist circumference categories between the two time 
points, the mean waist circumference was significantly higher at 12-month follow up in comparison to 
baseline (p = 0.03). No significant differences in the mean waist to hip ratio were found between the 
two time points (table 4.39).  With regards to waist to hip ratio categories, the majority (n= 41) of the 
participants did not change categories over time. N= 5 tended to move to a higher category, while n=11 
moved to a lower category (refer to appendix C, table C4 for cross tabulation for waist to hip ratio). 
There were no significant changes in the waist to hip ratio categories between the two time points.  
 
Table 4.39: Differences in anthropometric measurements between baseline and 12-month follow up. 
Variable Baseline  
(time point 1) 
12-month 
follow up 
(time point 2) 
N  Difference 
(Time point 1- 
Time point 2)a 
P value 
BMI (kg/m2)  28.33 ± 8.21 28.51 ± 7.97 54 -0.18 0.47 
BMI categories b - - 57 - 0.34 
Waist circumference 
(cm)  
89.93 ± 16.84 91.70 ± 17.43 56 -1.77 0.03 
Waist circumference 
c categories 
- - 57 - 0.29 
High, n (%) 37 (64.9%) 41 (71.9%) - - 4 (11%) - 
Waist to hip ratio 0.88 ± 0.09 0.87 ± 0.09 56 0.01 0.35 
Waist to hip ratio c  
categories 
- - 57 - 0.23 
Data presented as mean ± SD or n (% of group). n, number of participants; SD, standard deviation. a 
Negative difference indicates an increase in the variable at 12-month follow up. b BMI category 
based on WHO. c Waist circumference and waist to hip ratio category based on guidelines by Alberti et 





between categories at the two time points, cross tabulation using the McNemar-Bowker test was 
conducted.  
 
4.6.2 Differences in heart rate and blood pressure measurements between 
baseline and 12-month follow up 
Mean systolic blood pressure was significantly higher at 12-month follow up in comparison to baseline 
(p < 0.001). Similarly, the mean diastolic blood pressure was also significantly higher at 12-month 
follow up in comparison to baseline (p < 0.001). Furthermore, at baseline, the mean values fell within 
the normal clinical range for both systolic and diastolic blood pressure according to guidelines by Seedat 
and Rayner, 2013, while at 12-month follow up, the mean values were in the elevated blood pressure 
range based on the same guidelines.  
There were no significant changes between systolic blood pressure categories and diastolic blood 
pressure categories between the two time points. Refer to appendix C, table C5 & C6, for cross 
tabulation of systolic blood pressure and diastolic blood pressure categories using McNemar-Bowker 
Test. Both for the systolic and diastolic blood pressure, n= 27, did not change categories over time, 
while n= 9 changed to a lower category and n=21 moved to a higher category between time point 1 and 
2.  
 
There was a significant difference (p= 0.03) in the hypertension category between baseline and 12-
month follow up. 50% more individuals presented with hypertension at 12-month follow up in 
comparison to baseline time point (table 4.40). No significant difference was observed in the heart rate 
measurements between the two time points. 
 
Table 4.40: Differences in blood pressure and heart rate measurements between baseline and 12-month 
follow up. 
Variable Baseline  
(time point 1) 
12-month 
follow up 
(time point 2) 
N  Difference 
(Time point 1- 
Time point 2) a 
P value 
Systolic Blood 





56 -6.28 <0.001 
Systolic blood 
pressure categories b 
- - 57 - 0.06 
Diastolic Blood 
pressure (mmHg)  
84.64 ± 11.73 89.21 ± 13.59 56 -4.57 <0.001 
Diastolic blood 
pressure categories b 
- - 57 - 0.07 
Hypertension, n (%) 
b 





Heart Rate (bpm)  70.96 ± 11.73 67.87 ± 11.82 57 3.10 0.29 
Data presented as mean ± SD or n (% of group). n, number of participants; SD, standard deviation.  
a Negative difference indicates an increase in the variable at 12-month follow up. b Systolic, 
diastolic blood pressure category, as well as hypertension cut off based on guidelines by  Seedat and 
Rayner, 2013 category based on WHO. For normally distributed data, a paired samples t-test was 
conducted and for comparison between categories at the two time points, cross tabulation using the 
McNemar- Bowker test was conducted.  
 
 
4.6.3 Differences in fasting lipid, glucose and HBA1c measurements 
between baseline and 12-month follow up 
There were no significant differences in the lipid profile parameters between baseline and 12-month 
follow up time point. However, the median fasting glucose was significantly higher at 12-month follow 
up in comparison to baseline (p= 0.03). There were no significant differences in fasting glucose 
categories and HbA1c measurements (both continuous and categorical) between the two time points 
(Table 4.41).  
 
Table 4.41: Differences in fasting lipid, glucose and HbA1c measurements between baseline and 12-
month follow up. 
Variable Baseline  
(time point 1) 
12-month 
follow up 
(time point 2) 
N  Difference 
(Time point 1- 





4.32 ± 0.70 4.29 ± 0.88 56 0.03 0.68 
Total cholesterol 
categoriesb 
- - 56 - 1.00 





1.37 ± 0.30 1.35 ± 0.36 56 0.02 0.42 
HDL categoriesb 
Decreased, n (%) 





2.45 ± 0.67 2.43 ± 0.81 56 0.09 0.75 
LDL categoriesb - - 56 - 0.45 











57 0.15 0.67 
Triglycerides 
categoriesb 
- - 57 - 1.00 
Elevated, n (%) 6 (10.5%) 5 (8.8.%) - 1 (16.7%) - 
Glucose and HbA1c 
Fasting glucose 
(mmol/L)  
4.90 (4.35 - 
5.60) 
4.60 (4.30 - 
5.10) 
57 -0.10 0.03 
Fasting glucose 
categoriesb 
- - 57 - 0.44 
Elevated, n (%) 13 (22.8%) 6 (10.5%) - 7 (53.8%) - 
Glycated 
Haemoglobin 
(HbA1c) (%)  




57 0.10 0.07 
HbA1c categoriesb - - 57 - 0.12 
Elevated, n (%) 13 (22.8%) 8 (14.0%) - 5 (38.5%) - 
Data presented as mean ± SD or n (% of group) or median with 25th and 75th percentiles for 
interquartile range (for non-normally distributed data). n, number of participants; SD, standard 
deviation. a Negative difference indicates an increase in the variable at 12-month follow up. b Lipid 
profile and glucose homeostasis categories is based on guidelines by Seedat and Rayner, 2013 and 
Alberti et al., 2009. For normally distributed data, a paired samples t-test was conducted, for non-
normally distributed data, Wilcoxon signed ranked test was conducted, and for comparison between 
categories at the two time points, cross tabulation using the McNemar-Bowker test was conducted. 
 
 
4.6.4 Differences in Hb and GGT measurements between baseline and 12-
month follow up 
There were no significant differences in Hb and GGT measurements between the two time points of 
the study (refer to table 4.42). 
Table: 4.42: Differences in Hb and GGT measurements between baseline and 12-month follow up. 
Variable Baseline  
(time point 1) 
12-month 
follow up 
(time point 2) 
N  Difference 
(Time point 1- 
Time point 2) a 
P value 
Haemoglobin (g/dL)  13.17 ± 1.22 13.19 ± 1.51 56 -0.03 0.81 
Haemoglobin 
categories b 
- - 57 - 0.73 
Decreased, n (%) 12 (21.1%) 14 (24.6%) - -2 (16.7%) - 
  Liver function    
GGT (U/L)  27.00 (17.50 - 
40.00) 
27.00 (18.50 - 
38.50) 
57 0.00 0.62 





Elevated, n (%) 14 (24.6 %) 12 (21.1%) - 2 (14.3%) - 
Data presented as mean ± SD or n (% of group) or median with 25th and 75th percentiles for 
interquartile range (for non-normally distributed data). n, number of participants; SD, standard 
deviation. a Negative difference indicates an increase in the variable at 12-month follow up. b 
haemoglobin categories based on WHO guidelines and GGT categories are based on guidelines by 
NHLS, SA. For normally distributed data, a paired samples t-test was conducted, for non-normally 
distributed data, Wilcoxon signed ranked test was conducted, and for comparison between categories 
at the two time points, cross tabulation using the McNemar- Bowker test was conducted. 
 
 
4.6.5 Differences in kidney function measurements between baseline and 
12-month follow up 
There were no significant differences in the kidney function measurements between baseline and 12-
month follow up (refer to table 4.43). 
 
Table 4.43: Differences in kidney function measurements between baseline and 12-month follow up. 
Variable Baseline  
(time point 1) 
12-month 
follow up 
(time point 2) 
N  Difference 
(Time point 1- 




63.95 ± 14.78 63.02 ± 15.85 55 0.930 0.38 
Urine albumin 
(mg/L) 












57 0.02 0.45 
ACR categoriesb - - 57 - 0.23 
Increased, n (%) 4 (7%) 9 (15.8%) - -5 (125%) - 
eGRF categories b - - 57 - 1.00 
Decreased, n (%) 2 (3.5%) 1 (1.8%) - 1 (50%) - 
Data presented as mean ± SD or n (% of group) or median with 25th and 75th percentiles for 
interquartile range (for non-normally distributed data). n, number of participants; SD, standard 
deviation. a Negative difference indicates an increase in the variable at 12-month follow up. b ACR 
and eGFR categories used as previously reported (Du Plessis, 2013). For normally distributed data, a 
paired samples t-test was conducted, for non-normally distributed data, Wilcoxon signed ranked test 
was conducted, and for comparison between categories at the two time points, cross tabulation using 






4.6.6 Differences in systemic inflammation and biomarker measurements 
between baseline and 12-month follow up 
There were no significant differences in systemic inflammation and biomarker measurements between 
the two time points of the study (table 4.44). 
Table 4.44: Differences in systemic inflammation and biomarker measurements between baseline and 
12-month follow up. 
Variable Baseline  
(time point 1) 
12-month 
follow up 
(time point 2) 
N  Difference 
(Time point 1- 
Time point 2) a 
P value 




56 -0.50 0.20 
hsCRP categoriesb - - 55 - 0.45 
Elevated, n (%) 36 (63.2%) 33 (57.9%) - 3 (8.3%) - 




39 -0.66 0.54 





38 -6.27 0.11 






39 0.42 0.44 






38 5.18 0.80 




39 1.85 0.70 




39 0.37 0.62 
PAI-1 (ng/ml) 91.52 (77.32- 
114.13) 
97.68 (78.47 - 
121.46) 
39 1.90 0.66 
Data presented as mean ± SD or n (% of group) or median with 25th and 75th percentiles for 
interquartile range (for non-normally distributed data). n, number of participants; SD, standard 
deviation. a Negative difference indicates an increase in the variable at 12-month follow up. b 
HsCRP categories based on guidelines by Ridker et al., 2000. For normally distributed data, a paired 
samples t-test was conducted, for non-normally distributed data, Wilcoxon signed ranked test was 
conducted, and for comparison between categories at the two time points, cross tabulation using the 









4.6.7 Differences in endothelial function measurements between baseline 
and 12-month follow up 
There were no significant differences in FMD% between baseline and 12-month follow up (table 
4.45).  
Table 4.45: Differences in endothelial function measurements between baseline and 12-month follow 
up. 
Variable Baseline  
(time point 1) 
12-month 
follow up 
(time point 2) 
N  Difference 
(Time point 1- 





3.41 ± 0.61 3.41 ± 0.65 54 0.00 0.89 
Flow-mediated 
dilatation (%)  
5.72 ± 4.62 6.49 ± 6.19 55 -0.78 0.36 
Data presented as mean ± SD or n (% of group). n, number of participants; SD, standard deviation. a 
Negative difference indicates an increase in the variable at 12-month follow up.  
 
 
4.6.8 Differences in Subclinical atherosclerosis measurements between 
baseline and 12-month follow up 
There were no significant differences in mean IMT or subclinical atherosclerosis between baseline 
and 12-month follow up (table 4.46). Two participants presented with plaque at 12-month follow up.  
Table 4.46: Differences in subclinical atherosclerosis measurements between baseline and 12-month 
follow up. 
Variable Baseline  
(time point 1) 
12-month 
follow up 
(time point 2) 
N  Difference 
(Time point 1- 
Time point 2) a 
P value 
Mean IMT (µm) 





57 11.54 0.59 
Subclinical 
atherosclerosis, n (%) b  
2 (3.5%) 2 (3.5%) 57 0 - 
Plaque, n (%) c 0 (0%) 2 (3,5%) 57 -2 (3.5%) - 
Data presented as mean ± SD or n (% of group). n, number of participants; SD, standard deviation. a 
Negative difference indicates an increase in the variable at 12-month follow up. b Subclinical 
atherosclerosis cut off was based on guidelines by European Society of Cardiology and European 
Society of Hypertension. c Plaque was defined as an average IMT of more than 1000 µm, as suggested 





Chapter 5: Discussion 
 
5.1 Introduction 
This chapter evaluates the findings generated from the PhD study and critically analyses its implications 
and relevance to the PhD aims and objectives, as well as in the scientific research field applicable. 
Results from both the cross-sectional main study and the longitudinal sub-study will be argued in a 
combined and logical manner in this chapter. 
 
5.2 Demographic, medical background and lifestyle related findings 
The cross-sectional main study as well as the longitudinal sub-study were largely represented by 
participants who self-identified as being of mixed ancestry, which is plausible considering the 
geographical location of the studies. According to the Department of Statistics of South Africa, South 
Africans of mixed ancestry predominantly reside in the Western Cape Province (Statistics South Africa, 
2012) and thus the cohort is reasonably representative of the demographic make-up of the region.  
Additionally, both studies were represented mostly by females. According to literature, there are 
cultural as well as economical barriers related to gender in healthcare (Camlin et al., 2016; Mbokazi et 
al., 2020). For example, culturally, males often view ‘care-seeking’ as an activity for females and 
children, and clinics are said to be ‘female spaces’ by males (Camlin et al., 2016). Economically, men 
are often more likely to be employed in the South African context and may find it difficult to go to the 
clinic and miss a day’s work (Mbokazi et al., 2020). Furthermore, literature suggests that generally 
males have been ‘missing’ from HIV testing and care (both prevention and treatment) (Cornell, Cox 
and Wilkinson, 2015; Mbokazi et al., 2020). This could potentially be the reason why it was difficult 
to recruit more males for the current study. The study participants were recruited from local clinics by 
registered nurses. These clinics are often used more by females than males to access healthcare. Thus, 
generally, females were easier to recruit and available to volunteer for the assessments. Although no 
significant differences were noted in gender between the cross-sectional study groups of HIV-infected 
and HIV-free (refer to chapter 4, table 4.1), additional statistical subgroup gender analyses were 
conducted (refer to appendix  B) to understand gender differences in the results found and this will be 
included in the discussion of the relevant findings in this chapter. Additionally, in all the independent 
association analyses, gender was always adjusted for. Overall, it is noteworthy that in all the cross-
sectional study groups, there were no significant differences in the demographic data such as age, gender 
and ethnicity (refer to chapter 4, table 4.1). This further ensured that the study groups were reasonably 





With regards to medical background, the most prevalent form of previous comorbidity in the cross-
sectional total cohort was TB (refer to chapter 4, table 4.2). Furthermore, the HIV-infected group had 
a significantly higher prevalence of previous history of TB in comparison to HIV-free group. The risk 
of developing TB in HIV is well known. Research confirms that HIV-infected individuals infected with 
TB are 20- 40 times at a higher risk at developing active TB than those that are HIV-free (Sandhu, 2011; 
Méda et al., 2013). Additionally, TB is known to be the most common HIV-associated opportunistic 
disease globally, where it can poorly impact the HIV-infected individual by accelerating HIV disease 
progression and reducing ART efficacy (Lawn, 2005; Dagnra et al., 2010). Hence, this finding in the 
cross-sectional main study is very much in line with existing research. It is further noteworthy that the 
burden of TB is particularly high in South Africa, where the country is one of the six countries 
contributing to 60% of the global TB burden (Naidoo et al., 2017). 
In the HIV-free group of the cross-sectional main study, as well as the longitudinal total study cohort 
(comprising of only HIV-free participants), a history of hypertension was the most prevalent form of 
reported comorbidities (refer to chapter 4, table 4.2). Research suggests that the incidence of 
hypertension is on the rise in SSA and this could be as a result of urbanization and westernization in 
this region (Seedat, Ali and Ferdinand, 2018). Furthermore, in South Africa, hypertension prevalence 
rates of up to 60% have been reported in studies (Gaziano et al., 2017). Interestingly, in the cross-
sectional main study, the prevalence of hypertension was the second most common form of comorbidity 
in the HIV-infected group (refer to chapter 4, table 4.2). Previous studies have shown that 
hypertension is increasingly observed in HIV-infected individuals (Medina-Torne et al., 2012),  
however, in the current study, the HIV-infected group demonstrated a significantly lower prevalence in 
comparison to HIV-free group (14% vs. 23%) (refer to chapter 4, table 4.2). Global data suggest 
that 35% of all HIV-infected individuals on ART have hypertension in comparison to an estimated 30% 
of HIV-free individuals (Fahme, Bloomfield and Peck, 2018). Furthermore, HIV-infected individuals 
on ART are found to be at a higher risk of hypertension in comparison to those that are  HIV-free 
(Fiseha et al., 2019). However, the PI class of ART has been largely implicated in the development of 
hypertension (Fahme, Bloomfield and Peck, 2018), and it is noteworthy, that the majority of the HIV-
infected participants in the current study were reported to be receiving NRTI / NNRTI-containing ART. 
Additionally, it is interesting to note that studies also suggest that the presence of hypertension is often 
under-diagnosed in people living with HIV (Fiseha et al., 2019), which should be considered with 
regards to the findings of the present study.  
In the cross-sectional main study and the longitudinal sub-study, the prevalence of smoking was high 
(59% and 70%, respectively). The prevalence rates observed in the present cohort are high compared 
to the prevalence of approximately 20% reported in general South African population (World Health 
Organization, 2018). Although smoking prevalence has declined country-wide over the years, 





al., 2013; Lau et al., 2018). Particularly, the prevalence of both smoking and alcohol consumption is 
found to be relatively higher in the lower socioeconomic status groups (Lau et al., 2018). Both the cross-
sectional and longitudinal studies presented with participants from a lower socioeconomic status, for 
example, more than half of the study population reported to be unemployed and had a household income 
below R4,999 per month (refer to chapter 4, table 4.3). Both the employment status as well as 
household income are measures of socioeconomic status of an individual.  
Interestingly, there were no significant differences in smoking between HIV-infected and HIV-free 
groups of the cross-sectional main study (refer to chapter 4, table 4.2). Literature suggests that HIV-
infected individuals are more likely to smoke in comparison to the HIV-free individuals (Jackson-
Morris, Fujiwara and Pevzner, 2015; Okello et al., 2020). Furthermore, a study from South Africa, 
reports an alarmingly high prevalence of smoking in people living with HIV (Elf et al., 2018).  However, 
contradicting the said study, another South African study reports a relatively low prevalence of smoking 
in HIV-infected population (Waweru et al., 2013). However, it is important to note that the current 
study did not clinically validate tobacco consumption; for instance, no urine cotinine measurements 
were conducted. All lifestyle related questions were self-reported, and the possibility of under-reporting 
of lifestyle parameters need to be considered. Overall, there were no significant differences between 
smoking, alcohol consumption or socioeconomic characteristics between the HIV-infected and HIV-
free cross-sectional study groups (refer to chapter 4, table 4.2 & 4.3).  
 
5.3 HIV- related and ART descriptive findings from the cross-sectional main 
study 
Although the latest guidelines from the WHO and the South African National Department of Health 
recommend the initiation of ART immediately after HIV diagnosis (WHO, 2016; South African 
National Department of Health, 2019), not all the HIV-infected participants in the present study reported 
to be receiving ART at the time of data collection (2017-2018). This is concerning but can be justified 
by the fact that the HIV ART-naïve participants were still transitioning from the previous HIV treatment 
guidelines (that used CD4 count cut-off values to determine commencement of ART) to the revised 
treatment guidelines at the time of data collection. South Africa is known to have the largest ART roll-
out program globally, however as of 2020, only 70% of HIV-infected individuals are receiving ART. 
With regards to the 90-90-90 target set by UNAIDS, which aims to provide ART for 90% of those 
diagnosed with HIV, unfortunately, the country is yet to achieve this goal (UNAIDS, 2020). The current 
PhD study included the group of HIV-infected participants not receiving ART. Although a relatively 
small group of participants was not receiving ART, statistically, in the majority of the comparisons, 
there were not only significant statistical differences but also clinical differences in several important 





statistical effect sizes for many of the parameters were large enough (above the cut off values as 
suggested by Lakens, 2013), which further validated the results found. Refer to appendix D, table D1 
for the Cohen’s D effect size categories used to validate the results when comparing the HIV-infected 
receiving ART group with HIV-infected without ART group.  
As expected, in the cross-sectional main study, the HIV-infected group receiving ART had a 
significantly lower viral load and a higher CD4 count in comparison to the HIV-infected group without 
ART (refer to chapter 4. Table 4.4). It is well known that ART acts on various stages of the HIV life 
cycle and inhibits key steps in viral replication which ultimately reduces viral load (as measured 
clinically) (Arts and Hazuda, 2012). Furthermore, it is known that HIV gp120 attacks and binds to the 
CD4 receptor in the HIV replication cycle (Arts and Hazuda, 2012). In a way, measurement of CD4 
count can represent the extent of immune deficiency and declines in CD4 count are a measure of disease 
progression (Martinson et al., 2014). Literature confirms that ART can reduce viral load (even achieve 
viral suppression) and increase CD4 count in majority of the patients (Autran et al., 1997; Wilson and 
Sereti, 2013). Furthermore, research from South Africa suggests that CD4 count in the HIV-infected 
individual without ART will decline over time (Martinson et al., 2014). 
Additionally, as expected, there was a significantly higher prevalence of participants with high viral 
load measurements (> 1000 mRNA/ml) in the HIV-infected group without ART (81%) in comparison 
to the group receiving ART (17%) (refer to chapter 4, table 4.4). It is well known that without ART, 
viral load will increase over time as a result of the HIV replication cycle. Furthermore, the WHO 
classifies viral load above 1000 mRNA/ml as virologic failure, which generally implies ART failure 
(WHO, 2019). In the present cohort, 17% of the HIV-infected receiving ART group demonstrated 
high viral load/ virologic failure. This could mean that there is presence of either drug resistance, or 
toxicity or poor adherence to ART among some participants in our study population. Research suggests 
that virologic failure on first-line regimens (i.e. NRTI/ NNRTI-containing first line ART) largely occurs 
due to pre-existing (transmitted) drug resistance or due to poor adherence (Usach, Melis and Peris, 
2013). Literature has consistently suggested socio-economic variables such as unemployment, poverty, 
food insecurity, and transport costs as culprits of poor adherence in HIV (Tuller et al., 2010; Weiser et 
al., 2010). Furthermore, in the South African context, financial constraints, substance abuse, alternative 
therapy use, as well as stigma of HIV have known to obstruct adherence (Azia and Mukumbang, 2016). 
 
5.4 Cardiovascular risk profile findings  
Anthropometric characteristics 
In the HIV-free group of the cross-sectional main study, as well as the longitudinal total study cohort 





overweight range according to WHO criteria (refer to chapter 4, table 4.5 for cross-sectional data; 
table 4.31 for longitudinal data). This is in line with the current weight and obesity trends in South 
Africa. Due to epidemiological transition, there is an increase in prevalence of obesity nationwide. In 
fact, South Africa is known to have the highest prevalence of obesity in SSA (Ramlal and Govender, 
2016). Interestingly, when gender analysis was conducted (refer to appendix B, table B3), the males 
in the HIV-free cohort of the cross-sectional study presented with a normal mean BMI, while in the 
females, the mean BMI fell within the overweight BMI range. Furthermore, females demonstrated a 
significantly higher mean BMI in comparison to men in the HIV-free group of the cross-sectional study. 
This finding too, is in line with literature. Existing research indicates that 68% of females and 31% of 
males are overweight or obese based on BMI categories in South Africa (South Africa demographic 
and health survey, 2016). The higher prevalence of overweight or obesity in females in comparison to 
males in the South African context is further consistent with results from other low and middle-income 
countries (Kruger, 2018).  
In the longitudinal sub-study, the mean waist circumference of the HIV-free participants was 
significantly higher at 12-month follow up in comparison to baseline (refer to chapter 4, table 4.39). 
This is in line with the current obesity and weight trends across the world. Particularly in South Africa, 
literature suggests that obesity prevalence is likely to increase in the country due to the continued 
epidemiological transition (Cois and Day, 2015). Interestingly, in the current study’s gender subgroup 
analysis (refer to appendix C, table C2), female participants demonstrated a borderline significant (p= 
0.053) increase in waist circumference at 12-month follow up. Males showed no significant differences 
between the two time points (refer to appendix C, table C1). This is further in line with existing 
literature where, globally, females are increasingly gaining weight more rapidly than males (Cois and 
Day, 2015). Several factors can contribute to this, including socioeconomic, behavioural drivers as well 
as the effects of menopause, which can impact metabolism and body fat which can promote weight gain 
(Westerman, Engberding and Wenger, 2015). It is noteworthy that majority of the longitudinal sub-
study cohort comprised of females. Thus, although the overall cohort included both male and females, 
it is likely that our overall anthropometric findings are largely driven by the female group (as 
demonstrated by gender subgroup analysis).  
In the cross-sectional study, the HIV-infected group had significantly lower mean BMI and waist 
circumference values in comparison to the HIV-free group (refer to chapter 4, table 4.5). This is in 
line with some previous research findings from SSA and South Africa, where HIV has been shown to 
be associated with a lower BMI and a lower prevalence of obesity and overweight (Malaza, Mossong 
et al., 2012, Bärnighausen, Welz et al., 2008, Manne-Goehler et al., 2017). However, a large body of 
literature points to the emergence of increased obesity and visceral adiposity in HIV-infected 
populations. Previously, HIV infection was known to be riddled with under-nutrition, weight loss, loss 





is important to note that the current study’s HIV-infected group presented with a mean BMI (22.3 
kg/m2) that fell within the normal weight range. However, despite this, 22% of the HIV-infected 
participants presented with a BMI in the underweight category, suggesting that one in five of the 
participants may have shown signs of HIV-related wasting effects.  
On the other hand, approximately 35% of the HIV-infected participants were in the overweight or obese 
category. Furthermore, 49% of the HIV-infected participants presented with visceral obesity as 
measured by waist circumference. This is an interesting finding, since increased body fat composition 
measures are often associated with certain ART drug classes. In particular, PI-based ART drug 
formulations have been shown to have adverse effects such as weight gain, visceral adiposity and 
eventually lipodystrophy (Price et al., 2018; Okello et al., 2020). However, in the current cohort the 
majority of the treated participants were receiving NRTI/ NNRTI containing ART, which is not readily 
known to be associated with abnormal adiposity or obesity related effects (Godfrey et al., 2019). It has 
to be noted that some research findings do point to weight gain with NRTI/ NNRTI containing ART, 
especially the second generation NNRTI such Rilpivirine (Sax et al., 2020). However, none of the 
current study participants did not report to be receiving any second generation NNRTI. Thus, it can be 
speculated that the overweight and obesity findings in our HIV-infected participants may have been 
mainly due to lifestyle factors (resembling the general population), and were unlikely the result of ART. 
Additionally, when conducting statistical analysis in the female and male sub-populations separately 
(refer to appendix B, table B2), only females demonstrated evidence of underweight (significantly 
lower BMI and waist circumference) in the HIV-infected group compared to the HIV-free group. This 
finding is in line with another study from South Africa, which noted that lower BMI and prevalence of 
overweight and obesity is more pronounced in HIV-infected females in comparison to HIV-free females 
(Malaza et al., 2012).  Additionally, in the current study, there were no differences in BMI and waist 
circumference between the two groups in the male population (refer to appendix B, table B1), which 
further suggests that the body composition related anthropometric findings in the HIV-infected cohort 
may have been largely driven by the female participants.  
In the HIV sub-group analyses, the HIV-infected group receiving ART demonstrated a significantly 
higher mean BMI and waist circumference in comparison to HIV-infected without ART group (refer 
to chapter 4, table 4.6). Once again, it is important to note that, clinically, both parameters fell within 
the normal ranges according to WHO criteria for BMI and according to waist circumference cut-off 
values suggested by Alberti et al., 2009. Furthermore, interestingly, 37% of the HIV-infected without 
ART group presented with a BMI in the underweight category in comparison to 20% in the HIV-
infected receiving ART group. This could be due to the HIV associated wasting syndrome, which is a 
well-known effect of the virus and was common in the pre-HAART era.  In fact, initially, wasting was 
the AIDS defining diagnosis (Weiss et al., 1993). Wasting in HIV is characterized by a loss of fat mass 





(Smit et al., 2002; Erlandson et al., 2015). It is well-established that ART can reverse HIV-related 
weight loss and wasting as well as improve overall health (Coodley, Loveless and Merrill, 1994; Malaza 
et al., 2012). Thus, it can be speculated that the 20% of the HIV-infected receiving ART group, which 
presented with a BMI in the underweight category are likely the proportion which also presented with 
virologic failure as discussed in earlier sections. This further points to the presence of poor adherence 
or drug resistance in some of the ART receiving group. In the literature, several studies suggest that 
initiation of ART is associated with weight gain. Some of that weight gain following ART initiation 
may be attributed to a “return to health” phenomenon; however, excessive weight gain can also occur 
depending on the type of ART and other patient factors (McComsey et al., 2016; Lake, 2017).  
 
Blood pressure and heart rate measurements 
In the longitudinal sub-study, blood pressure (both SBP and DBP) was significantly higher at 12-month 
follow up in comparison to baseline (refer to chapter 4, table 4.40). Additionally, at baseline, mean 
blood pressure values (both SBP and DBP) fell within the normal clinical range, while at 12-month 
follow up, the values were in the elevated blood pressure range. Furthermore, 50% more individuals 
than in baseline presented with hypertension at 12-month follow up (refer to chapter 4, table 4.40). 
These findings are mostly in agreement with the current blood pressure and hypertension trends present 
in low and middle-income countries such as South Africa. Countries in this region are experiencing a 
constant increase in mean blood pressure over time (Cois and Ehrlich, 2018). This can be attributed to 
rapid economic development, urbanization and adoption of westernized lifestyles which often 
accompanies low levels of exercise, increased consumption of salt-rich, processed, and energy-dense 
food (Ibrahim and Damasceno, 2012; Cois and Ehrlich, 2018). Contradicting this, some literature also 
suggests that South Africa, may in fact be in full demographic and epidemiological transition (Kahn, 
2011), and there may actually be a decrease in blood pressure trends (Cois and Ehrlich, 2018). However, 
more recent longitudinal studies suggest otherwise, such as the study by Davids et, al., 2019, which 
concluded that there is a significant increase in blood pressure over 7 years in the mixed-race ancestry 
population of South Africa (Davids et al., 2019). It is notable, that in the current cohort, there was also 
an increase in visceral obesity as shown by waist circumference measurements (refer to chapter 4. 
Table 4.39). There is general agreement in the literature that an interaction exists between blood 
pressure and obesity, with a particularly strong relationship between increased waist circumference and 
blood pressure (Siani et al., 2002). Interestingly, as was shown with the waist circumference findings 
in this cohort, the blood pressure findings were also more relevant to the females. In gender subgroup 
analysis (refer to appendix C, table C2), females demonstrated a significantly higher blood pressure 
(both SBP and DBP) at 12-month follow up, which was not observed in the males. Previously, studies 
have demonstrated that males are more prone to increased blood pressure, however menopausal and 





2001; Everett et al., 2015). Female reproductive hormones are implicated in this phenomenon (Everett 
et al., 2015). In the current cohort, however, it can be speculated that in addition to menopause (mean 
age of the female participants was approximately 45 years), increase in waist circumference may have 
influenced blood pressure or vice versa.  
In the cross-sectional study, mean blood pressure values (both SBP and DBP) were found to be 
significantly lower in the HIV-infected group in comparison to HIV-free group (refer to chapter 4, 
table 4.7). Additionally, there was significant difference in DBP categories between HIV-infected and 
HIV-free group. More HIV-infected individuals were found to have low DBP. This contradicts the 
literature as studies suggest that HIV-infected individuals have a higher prevalence of diastolic 
dysfunction which can influence the DBP.  Although it is noteworthy that ART plays a role in this 
mechanism (Hsue, et al., 2010).  Furthermore, the overall prevalence of hypertension was significantly 
lower in the HIV-infected group (29%) versus the HIV-free group (46%). Existing literature suggests 
that HIV-infected individuals on ART, specifically, have higher rates of hypertension in comparison to 
HIV-free (Diouf et al., 2012; Sachithananthan, Loha and Gose, 2013; Fiseha et al., 2019). However, in 
the current study’s HIV sub-group analyses, no significant differences were found between the HIV-
infected receiving ART group in comparison to HIV-infected without ART group (refer to chapter 4, 
table 4.8). With regards to the type of treatment, PIs have particularly been implicated in the 
pathogenesis of hypertension due to their mechanistic effect on RAAS activation, endothelial 
dysfunction, arterial stiffness and dyslipidaemia (Fahme, Bloomfield and Peck, 2018; Rodolphe 
Thiébaut, Wafaa M El-Sadr, Nina Friis-Møller Rickenbach, Martin et al., 2005). Rather, fewer studies 
suggest that use of NNRTI-containing HAART is associated with elevation of both SBP and DBP in 
HIV-infected individuals (Chow et al., 2003). Thus, the findings of the present study could be attributed 
to the type of treatment as the majority of our participants received NRTI/ NNRTI ART. Interestingly, 
studies also suggest that an increase in blood pressure in HIV-infected populations is often related to 
other cardiovascular risk factors such as elevated BMI (Baekken et al., 2008; Medina-Torne et al., 
2012). Since our HIV-infected group did not present with any other elevated cardiovascular risk factors 
compared to their HIV-free counterparts, the blood pressure related findings appear to be plausible. On 
the other hand, the HIV-free group has consistently presented with higher cardiovascular risk related 
findings (discussed in earlier sections and will also be discussed further). For instance, the prevalence 
of hypertension was significantly higher in the HIV-free group in comparison to HIV-infected group. 
Finally, in the cross-sectional study, the HIV-infected group demonstrated a significantly higher heart 
rate in comparison to HIV-free group (refer to chapter 4, table 4.7). Interestingly, HIV is known to 
affect the cardiac autonomic function (Benseñor et al., 2011). Studies have evaluated heart rate 
variability in HIV patients with most suggesting a decreased variability (Godijk et al., 2020). The 





Fasting lipid, glucose and HBA1c measurements 
In the longitudinal study, there were no differences in the lipid profile measurements between the two 
time points (refer to chapter 4, table 4.41). Additionally, the mean values of all the lipid parameters 
fell within the normal range. Interestingly, this same cohort demonstrated no changes in BMI at 12- 
month follow up, which in the literature has been found to associate with lipids (Shamai et al., 2011). 
Thus, the current finding is plausible and can be expected. However, there was a significant increase in 
fasting glucose levels at 12-month follow up in comparison to baseline (refer to chapter 4, table 4.41). 
Literature has long suggested that on average fasting blood glucose levels increase over time and with 
age (O’Sullivan, 1974). Although, clinically, it is important to note that the current study’s fasting 
glucose level were in the normal range at both time points, the effect of change in blood glucose levels 
in the literature has been associated with increased cardiovascular risk in healthy individuals (Jin et al., 
2017). For example, a study suggests that increasing fasting glucose in a non-diabetic population is 
associated with risks of CVD such as MI and stroke (Lee et al., 2018). Additionally, in the literature 
there is a particularly stronger link between visceral fat (measured by waist circumference) and insulin 
resistance (known to cause increased blood glucose levels) (Wahrenberg et al., 2005). To this end, the 
current cohort also demonstrated a significant increase in waist circumference at 12-month follow-up. 
Thus, it can be speculated that increase in waist circumference may have influenced the increasing 
fasting glucose or vice versa.  
In the cross-sectional study, there were no significant differences in any of the lipid parameters between 
the HIV-infected and HIV-free groups (refer to chapter 4, table 4.9). However, when the HIV group 
was further analysed in terms of ART treatment status, the HIV-infected group receiving ART 
demonstrated significantly higher total cholesterol, LDL cholesterol as well as HDL cholesterol levels, 
in comparison to HIV-infected without ART group (refer to chapter 4, table 4.10). In the literature, it 
is well known that ART can increase total cholesterol, LDL-cholesterol, and triglycerides (Hemkens 
and Bucher, 2014). It is further known that the type of ART and drug classes may impact the extent of 
lipid changes. Drugs from the NRTI class are particularly known to increase total and LDL cholesterol 
(Sax et al., 2009; Hemkens and Bucher, 2014). In the literature, ART is also known to lower HDL-
cholesterol (Hemkens and Bucher, 2014). In contrast, the current study showed a higher mean HDL 
level in the HIV-infected group receiving ART compared to the untreated group. Furthermore, the 
prevalence of participants with clinically low HDL levels was higher in the untreated group. Studies 
have observed a decrease in total, HDL and LDL cholesterol in untreated HIV individuals (Riddler et 
al., 2003; Hemkens and Bucher, 2014; Feeney, 2011; Baza et al., 2007; Njoroge et al., 2017). The HI 
virus itself is implicated in inducing these effects through persistent inflammation and immune 
activation as well as through its increased thrombotic activity (Hemkens and Bucher, 2014; Beltrán et 
al., 2015). Particularly, the function of cholesterol ester transfer protein (CETP) which is known to 





be elevated in HIV-infection (Feeney, 2011). The activity of these CETP inversely correlates with HDL 
levels (Rose et al., 2008). This is a potential mechanism that could explain the lower mean HDL levels 
and higher prevalence of participants with clinically low HDL levels in the HIV-infected without ART 
group of the current study (Feeney, 2011). 
In the cross-sectional study, fasting glucose was found be elevated in the HIV-infected group in 
comparison to HIV-free group, whilst HbA1c% was found to be significantly lower in HIV-infected 
group in comparison to HIV-free (refer to chapter 4, table 4.9). Although these differences are 
statistically significant, their clinical or physiological relevance is not clear. It is also notable that both 
mean fasting glucose and HbA1c levels fell within the normal clinical range in both the study groups. 
However, in general, impaired glucose regulation is common in HIV (Spollett, 2006). Particularly 
certain classes of antiretroviral drugs have been associated with impaired glucose regulation and insulin 
resistance. Additional HIV subgroup analysis did not show any significant effects in the glucose 
parameters between untreated and treated HIV-infected groups (refer to chapter 4, table 4.10). 
 
Haemoglobin and GGT measurements 
In the longitudinal sub-study, the mean Hb and GGT levels in the total cohort fell within the normal 
clinical ranges (refer to chapter 4, table 4.34). Furthermore, there were no differences between 
baseline and 12-month follow-up. In the literature, elevated GGT levels have been demonstrated in 
individuals with high alcohol consumption, since the current cohort did not report on increased alcohol 
consumption at 12-month follow up, our finding is plausible in this cohort.  
In the cross-sectional study, there was a higher prevalence of participants presenting with clinically low 
Hb levels (anaemia) in the HIV-infected group in comparison to HIV-free group (refer to chapter 4, 
table 4.11). These findings are very much in line with existing literature. It is well established that the 
prevalence of anaemia is high in people living with HIV, particularly those with an increased disease 
progression (Curkendall et al., 2007). Studies suggest that approximately 95% of HIV-infected 
individuals have anaemia prior to ART initiation, while up to 46% of HIV-infected individuals 
receiving ART develop anaemia at some point in the disease (Ssali et al., 2006; Tamir, Alemu and 
Tsegaye, 2018). Anaemia appears to be particularly common in HIV-infected individuals from low and 
middle-income regions such as SSA, as these individuals are more likely to be malnourished, have 
increased immunosuppression, and comorbidities such as TB, than those in high income regions 
(Takuva et al., 2013). The pathophysiology of anaemia in HIV includes impaired erythropoiesis (due 
to increased inflammatory cytokines, and deceased production of hematopoietic growth factors), 
malabsorption and impaired recycling of iron, nutritional deficiencies, malignant bone marrow 
infiltration, bone marrow infection and haemolysis (Jacobson et al., 1990; Volberding et al., 2004). 





reducing HIV replication (Curkendall et al., 2007; Moor et al., 2002). Thus, as expected, in the current 
study’s HIV subgroup analysis, the prevalence of low Hb (anaemia) was higher in the untreated group 
compared to HIV-infected receiving ART group (refer to chapter 4, table 4.12).  
In the cross-sectional study, the HIV-infected group presented with a higher prevalence of high GGT 
levels in comparison to HIV-free group (refer to chapter 4, table 4.11). Furthermore, in additional 
HIV subgroup analyses, mean GGT levels were significantly higher in the HIV-infected receiving ART 
group in comparison to the HIV-infected without ART group (refer to chapter 4, table 4.12). This 
observation is in line with other studies which have also reported high GGT levels in HIV-infected on 
ART populations in comparison to HIV-infected/ no ART populations (De Socio et al., 2007; Peluso et 
al., 2020).  Clinically, elevated GGT levels are mainly used as a marker of abnormal liver or biliary 
tract function and alcohol consumption, and in the literature both HIV and ART are well known for 
their adverse effects on the liver (Soriano, Barreiro and Sherman, 2013; Mayanja et al., 2017). The 
literature suggests several mechanisms of HIV-related liver injury, which includes cytotoxicity, 
oxidative stress, systemic inflammation, immune mediated injury and mitochondrial injury (Kaspar and 
Sterling, 2017). Furthermore, increased GGT has been associated with CVD risk in the literature (Jiang, 
Jiang and Tao, 2013), where studies suggest that elevated GGT may be a marker of increased oxidative 
stress (Ndrepepa and Kastrati, 2016). In addition, circulating GGT levels have been association with 
markers of inflammation such as ICAM-1 and VCAM-1 (Bradley et al., 2014), interestingly the HIV-
infected group in this cohort also demonstrated increased VCAM-1 in comparison to HIV-free 
(discussed later under section 5.5). Thus, it can be speculated that the heightened inflammatory state of 
HIV may have influenced the GGT levels. Additionally, in gender analyses, in the male population 
(refer to appendix B, table B1) as well as the female population (refer to appendix B, table B2), HIV-
infected groups demonstrated a higher GGT level in comparison to HIV-free groups. However, when 
comparing males versus females (refer to appendix B, table B3 & B4), males demonstrated a 
significantly higher GGT in comparison to females in both the HIV-infected and HIV-free populations. 
Considering that GGT is also a marker for alcohol consumption, literature is in agreement that males 
exceed females in alcohol consumption, especially high-volume consumption (Wilsnack et al., 2009), 
and thus often present with higher GGT levels than females as also reported by Ha et al., 2014. Thus, 
it can be speculated that in addition to HIV, there may be alcohol consumption related increase in GGT, 
especially in the males of the current study.  
 
Kidney function measurements 
In the longitudinal sub-study, there were no significant differences in the measured markers of kidney 





as this cohort demonstrated a relatively healthy kidney function at baseline as well, with less than 10% 
presenting with increased ACR ratio or decreased eGFR (refer to chapter 4, table 4.35).  
In the cross-sectional study, ACR was significantly higher in the HIV-infected group in comparison to 
HIV-free group (refer to chapter 4, 4.13), which supports previous findings in the literature. HIV can 
induce direct as well as indirect adverse effects on the kidneys and result in HIV-associated kidney 
disease (Yilma et al., 2019). Microalbuminuria is a well-known recognized early marker of renal 
dysfunction, which is expressed by urine albumin to creatinine ratio (Glassock, 2010). Increased ACR 
in HIV has been demonstrated in previous studies (Szczech et al., 2007; Pirro et al., 2016), and has 
been suggested as a marker of CVD risk in HIV (Tongma et al., 2013).  On the other hand, creatinine 
is widely known in the literature to be increased in individuals receiving ART (Lucas et al., 2014; 
Cristelli et al., 2017). Mechanistically, some ART drugs may increase serum creatinine through their 
effect of the excretion of creatinine by the proximal renal tubule, causing an apparent change in 
glomerular function, without altering the eGFR. Other drugs are known to inhibit the excretion of serum 
creatinine by proximal renal tubular cells by the blockade of specific transporters (Australasian Society 
for HIV Medicine, 2019). To this end, in the current study’s HIV subgroup analyses, serum creatinine 
levels were significantly higher in HIV-infected receiving ART group in comparison to HIV-infected 
without ART group (refer to chapter 4. 4.14). Interestingly, previous studies suggest that increased 
serum creatinine levels may be predictive of future CVD (Matts et al., 1993). Both increased 
inflammation and oxidative stress have been implicated in the relationship between renal impairment 
and CVD (Ryom et al., 2016). It is highly interesting that there seems to be presence of ‘non-traditional’ 
markers of CVD in the HIV-infected group of this cohort, as supported by both increased ACR and 
creatinine levels as well as presence of elevated GGT (as discussed earlier).  
 
5.5. Biomarker findings 
In the longitudinal sub-study, no significant differences were found in biomarker levels between the 
baseline and 12-month time points (refer to chapter 4, table 4.44). In the literature, the biomarkers of 
inflammation and endothelial dysfunction measured in the present study have all been associated with 
atherosclerosis and cardiovascular diseases (Stoner et al., 2013; Gimbrone and García-Cardeña, 2016). 
Since the current longitudinal study did not demonstrate differences in the clinical measurements of 
endothelial function (FMD) or subclinical atherosclerosis (IMT), our temporal biomarker related 
findings were not unexpected. 
In the cross-sectional main study, VCAM-1 was observed to be significantly higher in the HIV-infected 
group in comparison to HIV-free group (refer to chapter 4, table 4.15). This is in line with the findings 
from previous studies. Several studies suggest elevation of biomarkers such as VCAM-1 in HIV-





(Melendez et al., 2008; Ross et al., 2009; Fourie and Fourie, 2011; Miller and Coppola, 2011; Graham, 
Mwilu and Conrad Liles, 2013; Fourie et al., 2015). Mechanistically, HIV can activate several 
inflammatory pathways causing the release of cytokines and endothelial adhesion molecule expression 
which facilitate adhesion and transmigration of leukocytes (Fisher, Miller and Lipshultz, 2006). HIV is 
known to produce direct endothelial cell damage, increasing endothelial permeability, favoring 
apoptosis and increasing the expression of adhesion molecules such as VCAM-1 and ICAM-1 (Ren, 
Yao and Chen, 2002; Beltrán et al., 2015). Interestingly, in gender analysis, only females demonstrated 
increased VCAM-1 in the HIV-infected group versus HIV-free group (refer to appendix B, table B2). 
No differences in VCAM-1 were found in the male population, between the HIV-infected and HIV-free 
groups (refer to appendix B, table B1). A study from Kenya, also demonstrated a significantly higher 
VCAM-1 in HIV-infected women in comparison to HIV-free women (Graham et al., 2013). However, 
the literature is not clear about gender differences regarding biomarkers in the HIV-context. 
Interestingly, in vivo studies have emerged suggesting the role of sex hormones (oestrogen and 
progesterone) in females which may lead to a higher expression of inflammatory or cytotoxic pathways 
(Scully, 2018). However, more research is required to shed clearer light regarding the role of gender in 
HIV-related inflammation.  
In the additional HIV subgroup analyses, VCAM-1 was observed to be significantly lower in the HIV-
infected on ART group in comparison to HIV-infected/ no ART group (refer to chapter 4, table 4.16). 
Existing research demonstrates that levels of VCAM-1 are elevated in HIV, while presence of ART 
reduces the expression of this marker of endothelial activation (Calmy et al., 2009; McComsey et al., 
2012; Hemkens and Bucher, 2014). Although the present study could not demonstrate differences in 
any of the other biomarkers between the ART vs no/ART group, it has been reported that ART is 
associated with lower levels of biomarkers of inflammation, particularly, reduced levels of VCAM-1, 
ICAM-1 and CRP were reported in a study of 115 HIV-infected individuals after 2 months and 14 
months of ART (Duprez et al., 2012). Furthermore, another study showed that VCAM-1 and ICAM-1 
levels were significantly decreased after 24 weeks and 96 weeks of ART (McComsey et al., 2012). 
Refer to table 5.1, for an overview of the effects of HIV and ART on selected biomarkers. 
Table 5.1: Overview of reported effects of HIV infection and antiretroviral therapy on selected 
biomarkers based on contents from (Hadigan et al., 2001; Kamin and Grinspoon, 2005; Nyagol et al., 
2008; Ross et al., 2009; Keating et al., 2011; Hunt et al., 2012; McComsey et al., 2012; Vaidya et al., 








Biomarkers Effect of HIV-infection Effect of ART 
ICAM-1, VCAM-1  in blood plasma and serum 
levels 
 after initiation of ART 
 after stopping ART 
PAI-1  in blood plasma and serum 
levels 
 In HIV-associated 
lipodystrophy 
 in ART-associated 
lipodystrophy and obesity 
 
hsCRP  in blood levels   ART 
e-selectin, p selectin  in serum levels  in serum levels 
TNF-α  serum levels  in serum levels 
VEGF  in serum levels  in serum levels 
 , increase;  decrease;  mixed results 
In the cross-sectional main study, PAI-1 was found to be the significantly lower in the HIV-infected 
group in comparison to HIV-free group (refer to chapter 4, table 4.15), which is in contrast to the 
findings of previous studies. PAI-1 is mainly produced in the liver, adipose tissue and vascular 
endothelium (Yasar Yildiz et al., 2014), and strongly and irreversibly inhibits plasminogen activators 
which are responsible for the conversion of plasminogen to plasmin which accelerates fibrosis (Mira et 
al., 2020). Many studies have reported that PAI-1 levels are generally elevated in HIV, despite ART 
and viral suppression (C Hadigan et al., 2001; Kamin and Grinspoon, 2005; Janssen et al., 2017). It is 
difficult to explain why PAI-1 levels were lower in the HIV-infected group of the current cohort. 
Existing literature suggests that PAI-1 is found to be elevated in HIV-infected individuals who have 
HIV-associated lipodystrophy syndrome and obesity in comparison to HIV-free individuals 
(Wirunsawanya et al., 2017). The current study’s HIV-infected group did not present with significantly 
higher rates of obesity (high BMI) or other detectable body composition abnormalities (increased waist 
circumference), which could have provided some speculative explanation for the PAI-1 findings. 
There were no other differences observed in the biomarkers between HIV-infected and HIV-free groups 
of the cross-sectional study (refer to chapter 4, table 4.15 & 4.16). Literature largely suggests that 
biomarkers of inflammation such as hsCRP, and adhesion molecules such as ICAM-1 are elevated in 
HIV-infected populations in comparison to HIV-free populations. Refer to table 5.1 for current 
research on the effect of HIV and ART on these biomarkers.  However, the levels of these biomarkers 
can be affected by the type of ART (Laurence, Elhadad and Ahamed, 2018). Research on this has been 
contradictory so far with some studies suggesting that ART may have a protective effect in HIV-infected 
populations (Kurz et al., 2012; Beltrán et al., 2015). In the current cohort, it appears that ART may be 
imposing a more protective effect in the HIV-infected group, however the current study’s results are 
not conclusive, considering only two out of the eight biomarkers measured demonstrated a difference 





relatively small sample size as not all participants were included in the analysis due to budgetary 
constraints, but rather chosen by randomization. This may have influenced the statistical power and 
results. Additionally, in the literature, these markers of inflammation and endothelial dysfunction have 
been known to increase with age, including in the HIV context (Aberg et, al., 2012), thus it can be 
speculated that the relatively young age of the present study’s cohort (41 years) may have also 
impacted our results. Furthermore, in the literature, the progression of HIV and duration of ART are 
known to influence inflammation. For instance, increased biomarkers are correlated with increased 
progression of HIV (Muswe et al., 2017), while the duration of ART has been shown to reduce 
biomarkers of inflammation, such as TNF-α (Muswe et al., 2017). However, it is important to note that 
although ART is known to reduce inflammation, existing literature also suggests that the inflammation 
persists even at undetectable viremia, suggesting that despite ART, HIV can elevate these biomarkers 
(Hearps et al., 2012; Paiardini and Müller‐Trutwin, 2013). Thus, it can be speculated, that it is rather 
the HIV duration or progression that is influencing the biomarker results in our cohort. Especially since, 
in the current study only 47% (less than half) had HIV for more than 5 years. Overall, it appears that, 
in the current cohort, endothelial activation and dysfunction may not yet be sufficiently established to 
be biochemically and clinically detectable, despite the presence of traditional risk factors such as obesity 
and hypertension and non-traditional risk factors such as increased GGT and creatinine. 
 
5.6 Subclinical atherosclerosis findings 
In the longitudinal sub-study, there were no significant differences in mean IMT measurements or 
subclinical atherosclerosis between baseline and 12-month follow-up (refer to chapter 4, table 4.46). 
However, interestingly, two participants presented with plaque at 12-month follow-up. The lack of 
temporal changes may suggest that the 12-month follow up period was too short to observe differences 
in the cohort. However, this cohort demonstrated increase in obesity related parameters at 12-month 
follow-up, which are known to be associated with subclinical atherosclerosis and plaque. Additionally, 
there were no differences in the lipid profile of this cohort at 12-month time point. Lipid levels have 
been associated with the progression of IMT in the general population and since in the current cohort, 
no changes in lipid levels were demonstrated, the lack of difference in IMT progression is plausible. 
Furthermore, IMT is known to be associated with age in literature (Madhuri, Chandra and Jabbar, 2010), 
thus it can be speculated that the relatively young age (45 years) of this cohort may have also 
influenced the results. Overall, it is noteworthy that not many previous studies have evaluated IMT in 
this demographically distinct population from the Western Cape; hence, our findings should be regarded 
as novel in this regard.  
In the cross-sectional study, the mean IMT measurements fell within the normal range in the HIV-





significant differences in the mean IMT or the prevalence of subclinical atherosclerosis and plaque 
between the HIV-infected and HIV-free groups. Our findings agree with studies from the USA, Ghana, 
Botswana as well as a South African study which also demonstrated no differences in this measurement 
between the HIV-infected and HIV-free groups (Currier et al., 2005; Johnsen et al., 2006; C M T Fourie 
et al., 2015; Mosepele et al., 2018; Sarfo et al., 2019). On the other hand, our findings contradict several 
other studies which have demonstrated a higher IMT in HIV-infected individuals in comparison to HIV-
free individuals (Chironi, et al., 2003; Lorenz et al., 2008; Ross et al., 2009; Grunfeld et al., 2009; Van 
Vonderen et al., 2009). As suggested by Fourie et al., 2015 and Hsue et al., 2012, contradictions in the 
literature can be explained by the choice of the anatomical location of the IMT measurement, for 
instance, the current study measured IMT in the common carotid artery, while differences have been 
noted by some studies in the carotid bifurcation region (Hsue et al., 2012). Interestingly, in the carotid 
bifurcation region, shear stress is low which may enhance the effect of chronic inflammation which 
potentially can induce increase expression of vascular adhesion molecules such as VCAM-1 
(Chatzizisis et al., 2007; Fourie et al., 2015), which the current study also demonstrated. In the 
additional gender analyses, it was interesting to note that in the male participants, the mean IMT was 
higher in the HIV-infected group compared to the HIV-free group (649 μm vs 595 μm; p=0.05), 
which was not observed in female participants (refer to appendix B, table B1 for male population 
and table B2 for female population). This finding could suggest that HIV-infected male participants 
are more susceptible to pro-atherosclerotic changes than their female counterparts.  
It is important to note that the prevalence of participants presenting with subclinical atherosclerosis and 
plaque in the cross-sectional cohort was low. This could be explained by the cut-off value used in the 
current study. In comparison to two other studies from Africa (Ssinabulya et al., 2014; Sarfo et al., 
2019) and one from South Africa (Schoffelen et al., 2015), the current study’s cut-off value for 
subclinical atherosclerosis (> 900 µm), may be perceived to be too high. The cut-off value used by these 
mentioned studies for subclinical atherosclerosis was > 780 µm based on the observation that on average 
a healthy adult reaches an IMT of 780 µm by the age of 76 (de Groot et al., 2004). The current study 
also performed supplementary statistical analyses using the cut-off value of 780 µm (refer to appendix 
E). With this new cut-off category, it is interesting that although the prevalence of subclinical 
atherosclerosis increased slightly in the total cohort from 4% to 10% (refer to appendix E, table E1), 
there were still no differences in subclinical atherosclerosis between HIV-infected and HIV-free groups 
(refer to appendix E, table E1). Thus, it can be speculated that, in the present cohort, the choice of 
IMT cut-off value did not significantly influence the findings, and that there may in fact be a low 
presence of subclinical atherosclerosis in this cohort. It can be suggested that our findings are influenced 
by the relatively young age of the cohort (45 years) or the technique used to measure IMT. However, 





in clinical research, and future studies are recommended to standardize this definition for specific 
populations.  
Interestingly, in the HIV subgroup analyses, the HIV-infected on ART group demonstrated a 
significantly higher mean IMT in comparison to HIV-infected/ no ART group (refer to chapter 4, 
table 4.18). Clinically, however, it is noteworthy that both groups presented with mean IMT values that 
fell within the normal range. Although both HIV and ART are known to influence IMT, several studies 
have demonstrated increased IMT  in HIV-infected on ART versus HIV-infected/ no ART (Priscilla Y. 
Hsue et al., 2009; Hanna et al., 2016; Msoka et al., 2019). Thus, in this respect, the findings from our 
cohort are in agreement with previous studies. However, literature is not conclusive on whether these 
modifications in the IMT are due to the direct effects of ART or caused indirectly, by their metabolic 
side-effects (Schoffelen et al., 2015). Interestingly, one study showed an increase in IMT after initiation 
of ART, especially with tenofovir based therapy (which forms part of the first line therapy in South 
Africa) (Delaney, Scherzer et al. 2010). However, the results are contradictory with regards to the type 
of ART. For example, another study found faster progression of IMT among HIV-infected individuals 
on PI-containing ART compared to those on NNRTI-based regimens (Baker et al., 2009). The same 
study showed that HIV infected individuals on PIs have a significantly higher IMT (Baker et al., 2009). 
Overall, in the current study, ART certainly appears to influence IMT. It is further notable that presence 
of subclinical atherosclerosis and plaque was only present in the HIV-infected ART group, additionally 
suggesting adverse, potentially pro-atherogenic effects of ART in our cohort.  
 
5.7 Endothelial function findings 
In the longitudinal study, there were no significant differences in endothelial function as measured by 
FMD%, between baseline and 12-month follow-up (refer to chapter 4, table 4.45). This finding is 
plausible in the current cohort, with HIV-free participants who were generally healthy and did not 
demonstrate changes in many cardiovascular risk parameters. However, the current cohort did 
demonstrate an increase in blood pressure at 12-month follow up. In the literature, it has been shown 
that blood pressure inversely associates with FMD% and endothelial function (Benjamin et al., 2004; 
Yufu et al., 2009). Decreased FMD% is often observed with elevated blood pressure and hypertension 
in individuals (Juonala et al., 2006). It has been suggested that high blood pressure may interfere with 
the integrity of endothelial cells causing endothelial activation and dysfunction (Cohn et al., 2004; 
Juonala et al., 2006). Similarly, obesity and waist circumference have been known to inversely correlate 
with FMD% (Williams et al., 2005; Arkin et al., 2008). One can speculate that although there were 
differences in blood pressure and waist circumference in this population, clinically there was a very 
small change over time (clinically, only blood pressure changed from normal to elevated category), 





unexpected. In the literature, endothelial dysfunction has been associated with aging in the general 
population (Seals, Jablonski and Donato, 2011), thus it can be speculated that the relatively young age 
(45 years) of the current cohort may have influenced our finding. Furthermore, it can be suggested 
that the 12-month follow up period may have been too short to observe any detectable temporal changes 
in endothelial function; thus, a longer follow-up period is recommended for future studies.  
In the cross-sectional study, there were no significant differences in FMD% between HIV-infected and 
HIV-free groups (refer to chapter 4, table 4.19). The absence of changes in the clinical measurement 
of endothelial function by FMD was generally underpinned by the endothelial biomarker findings which 
showed that the majority of biomarkers (except VCAM-1 and PAI-1) were not different between the 
groups (see Section 5.5). The current study’s findings are in agreement with some studies in literature 
which also demonstrated no differences in endothelial function as measured by FMD% between HIV-
infected and HIV-free groups (Nolan et al., 2003; Blanco, 2006; Mondy et al., 2008). However, 
generally, several studies suggest a lower FMD%  or endothelial dysfunction  in HIV-infected 
individuals (with or without ART) in comparison to HIV-free individuals (Solages et al., 2006; Van 
Wijk et al., 2006; Stein, Currier and Hsue, 2014; Sharma, Gupta and Srivastava, 2018). Both the 
treatment and the virus itself have been implicated as potential mechanisms. ART is known for its 
adverse effects of increasing oxidative stress and endothelial recruitment of mononuclear cells, in 
addition to its lipid related effects (Skowyra et al., 2012). With regards to the virus itself, especially, 
viral proteins gp120, Tat and Nef have been implicated (Anand, Rachel and Parthasarathy, 2018). The 
pathogenesis of HIV and ART related endothelial dysfunction has been described in detail in chapter 2, 
section C of this dissertation.  
Particularly, with regards to ART and FMD, studies have demonstrated mixed results. Variability in 
this regard could be attributed to differences in ART combinations, treatment duration, as well the 
cardio-metabolic profiles of the study population. The current cross-sectional study demonstrated a 
significantly higher FMD% (implying improved endothelial function) in the HIV-infected on ART 
group in comparison to HIV-infected/ no ART group (refer to chapter 4, table 4.20). In this regard, 
our findings contradict many studies. For instance, a study by Andrade et al., 2008 demonstrated that 
FMD was significantly lower in their ART receiving HIV group in comparison to their untreated HIV 
group (Andrade et al., 2008). Additionally, another study from Ethiopia observed that FMD was lower 
in younger adults receiving ART (efavirenz and lopinavir in combination with ritonavir) in comparison 
to untreated younger adults (Gleason et al., 2016). It appears as though certain classes of ART, 
especially those that are PI-based, are implicated in lower FMD in HIV-infected individuals. For 
example, a study of adult HIV-infected individuals by Stein et al. 2001 reported on impaired (lower 
FMD% relative to study’s control group FMD%) endothelial function in HIV-infected individuals using 
PI-containing regimens while the HIV-infected ART naïve individuals presented with normal FMD% 





This study further concluded that PIs are associated with pro-atherogenic lipoprotein changes and with 
endothelial dysfunction (Stein, Currier et al., 2014, Stein, Klein et al., 2001). It is notable that the current 
study’s participants were not receiving ART from the PI class but from the NRTI/ NNRTI class. It 
therefore appears that the vascular endothelial function of participants on ART in the current cohort 
was protected from the harmful effects of HIV. Our finding supports some existing studies in the 
literature. For instance, a study by Torriani et, al., 2008 demonstrated improved endothelial function in 
their cohort after commencement of ART (Torriani et al., 2008). Their study demonstrated 
improvement of FMD after four weeks of treatment and then again after 24 weeks of treatment (Torriani 





5.8 Summary of descriptive findings from the PhD. 
The current study has yielded interesting descriptive findings from both the cross-sectional main study 







Figure 5.1: Summary of descriptive findings from the cross-sectional main study as well as the longitudinal sub-study showing potential pathophysiological 











5.9 Independent associations with IMT 
Biomarker related associations with IMT 
Overall, no correlations were observed between any of the biomarkers of inflammation and endothelial 
dysfunction with IMT in any of the study groups. Our findings are to some extent in line with existing 
literature which have also demonstrated no relationships of biomarkers with the common carotid IMT 
(as measured in the current PhD). In the HIV context, there are a few notable studies, especially relevant 
to the current PhD, which will be discussed.  
A study by Ross et. al., 2009 demonstrated that CRP positively correlated with internal carotid IMT in 
both HIV-infected and HIV-free groups. Furthermore, their study showed that endothelial markers were 
not correlated with common carotid IMT in HIV-infected study participants, while only VCAM-1 
negatively correlated with internal carotid IMT in the HIV-free group. Regression analysis showed that 
VCAM-1 and TNF-α independently associated with internal carotid IMT in the HIV-infected 
population (Allison C. Ross et al., 2009).  Similarly, a more recent study by Subramanya et. al., 
demonstrated CRP and TNF-α to be correlated with bifurcation IMT in total population including HIV-
infected and HIV-free individuals. However, in regression analysis, after adjusting for demographic and 
cardiovascular factors, the association was lost. Similarly, in their HIV-infected group, correlations 
were found between ICAM-1, CRP and bifurcation IMT, but the associations were lost after adjusting 
for traditional risk factors (Subramanya et al., 2019).  
Overall, interestingly, both studies demonstrated that these biomarkers largely associated with internal 
carotid artery IMT (Allison C. Ross et al., 2009) or bifurcation IMT (Subramanya et al., 2019), and it 
is important to note that these studies also measured common carotid artery IMT. This is interesting 
and there seems to be no plausible explanation in literature on why biomarkers do not correlate with 
common carotid artery IMT, as one would expect the development of atherosclerosis to occur in a 
diffuse and systematic process (also suggested by Ross et. al., 2009). Furthermore, there are other 
studies that demonstrated biomarker relationships with IMT other than common carotid artery IMT 
such as Thakore et al., 2007. Thus, the lack of relationship between the biomarkers and IMT in the 
current study may be ascribed to the choice of the anatomical region of the carotid artery for the 
measurement. Additionally, as mentioned in earlier sections, the current study’s biomarker analysis was 
based on a relatively small sample size as not all samples were included in the analysis but rather chosen 
by randomization. This may have influenced the statistical power and results.  
 
 





HIV infection status did not significantly associate with IMT in the current study (refer to chapter 4, 
table 4.23a). This contradicts many studies in the literature, for instance, a large case control study with 
1500 participants showed that HIV is an independent predictor of early carotid atherosclerosis as 
measured by IMT (Lorenz et al., 2008; Margaritis, 2019). Additionally, another study reported that HIV 
was independently associated with IMT even after adjusting for demographics and cardiovascular risk 
factors. In fact, the study reported the strength of the association was similar in magnitude to that of a 
traditional cardiovascular risk factor such as diabetes (Grunfeld et al., 2009). However, it is important 
to note that the said study also measured internal carotid IMT (including the bulb region) and they found 
a stronger association of HIV with this measurement in comparison to the common carotid IMT (as 
measured in the present study). Furthermore, interestingly, studies that found little to no association of 
HIV with IMT, measured only the common carotid artery (Depairon et al., 2001; Currier et al., 2005, 
2007; Johnsen et al., 2006). Thus, the current finding could be explained by the differences in the 
anatomical location at which IMT was measured.  
Additionally, several studies in the literature have demonstrated that ART is an independent predictor 
of IMT (Jericó et al., 2006; Lorenz et al., 2008). In the current study, ART status demonstrated a 
significant correlation with IMT (refer to chapter 4, table 4.21), however when included in the 
regression model for the HIV-infected group where several other factors were adjusted for, independent 
associations were not found (refer to chapter 4, table 4.23a). Literature regarding this has 
demonstrated mixed results, where some studies demonstrate that cardiovascular risk factors rather than 
HIV-related factors associate with IMT (Depairon et al., 2001; Schoffelen et al., 2015). The current 
study findings are in agreement with another study from South Africa, albeit in a cohort from a different 
geographical region, which also found no association between HIV, ART and IMT (Schoffelen et al., 
2015). However, it is important to note that in the said study, participants were largely receiving PI-
based ART. Another study demonstrated similar results (no independent associations of ART and HIV 
with IMT) (Chironi, Escaut, Gariepy, Cogny, J. Monsuez, et al., 2003), however, their participants 
received NRTI/ NNRTI based treatment, similar to the participants of our study. It could therefore be 
speculated that in our cohort, the absence of PI-based ART may explain the lack of association between 
ART and IMT. Furthermore, in the HIV-infected on ART group, ART duration did not significantly 
associate with IMT. Our finding is in line with existing studies (including a study from South Africa) 
which also demonstrated no association (Jericó et al., 2006; Schoffelen et al., 2015).  
 
Cardiovascular related associations with IMT 
In our total cohort, as well as the HIV-free group, systolic hypertension (high systolic blood pressure), 





associations with IMT (refer to chapter 4, table 4.23a). These findings are in line with existing 
literature. In both the HIV and non-HIV context, traditional cardiovascular risk factors such as the 
aforementioned parameters, are known to associate with IMT. Several studies demonstrate obesity (as 
measured by BMI) to be an independent predictor of IMT (Tan and Chuang, 2012; Dalmas et al., 2013; 
Jin et al., 2018). Furthermore, the impact of LDL cholesterol on IMT is well known. Several previous 
studies have demonstrated LDL to be an independent predictor of IMT (Salonen and Salonen, 1991; 
Sun et al., 2005; Yang et al., 2014, 2020). Physiologically, the role of LDL is well established in the 
development of atherosclerosis (as described in chapter 2). With regards to hypertension, the literature 
also confirms its association with IMT (Salonen and Salonen, 1991; Sun et al., 2005; Takase et al., 
2017). Furthermore, studies suggest that systolic blood pressure, and not the diastolic blood pressure 
associates with IMT (Salonen and Salonen, 1991; Zanchetti et al., 2001), and systolic hypertension 
(high systolic blood pressure) is associated with increased IMT (Lim et al., 2009). According to the 
widely accepted ‘response to injury’ model of atherogenesis, various factors such as hemodynamic 
forces and chemical agents, induce endothelial dysfunction, which is followed by aggregation of 
platelets, lipids and smooth muscle cells in the intimal layer. All the mentioned factors increase IMT, 
which ultimately leads to the formation of plaques (Sun et al., 2005). Accordingly, it is known that 
atherosclerotic deposition of LDL cholesterol may require prior injury to the endothelium by factors 
such as hypertension and obesity (which is what the current study also suggests). Overall, hypertension, 
obesity and LDL cholesterol are established independent predictors of IMT, and the current study 
confirms that, even after adjusting for age and gender in both groups, as well as HIV status in the total 
study group. It is interesting that these cardiovascular parameters did not associate with IMT in the 
HIV-infected group, when a study has demonstrated BMI, hypertension and types of cholesterols (such 
as total and triglycerides) to be associated with IMT in the HIV-context (Currier et al., 2005). It can be 
speculated that the type of treatment as well as the viral load may influence these associations. For 
instance, the in the study by Currier et, al., 2005, the HIV-infected participants were on PI treatment, 
while the current study participants were largely receiving NRTI/ NNRTI ART.  
In the total, HIV-infected, and HIV-infected on ART study groups, age ≥ 50 years demonstrated a 
significant positive association with IMT (refer to chapter 4, table 4.23a and 4.23b). In fact, age was 
the only variable that independently associated with IMT in the HIV-infected group. The positive 
association between increasing age and IMT is well established in the literature. It has been shown that 
carotid IMT increases with age among both HIV-infected and HIV-free individuals (‘Hsue PY et al., 
2004; Fitch et al., 2013). Aging is a well-known risk factor of CVD (Nonterah et al., 2019), particularly 
age of 50 years and above is known to be a risk factor of CVD (Lloyd-Jones et al., 2006). Additionally, 
it is established that aging is independently associated with a decline in physiological function (Chia, 
Egan and Ferrucci, 2018). Within the HIV-context, the virus can lead to a premature aging phenotype, 





function (Fitch et al., 2013). Several studies have found age to be an independent predictor of IMT in 
HIV-infected populations (Ross et al., 2009; Fitch et al., 2013; Ssinabulya et al., 2014; Hanna et al., 
2016; Nonterah et al., 2019). The current study confirms this finding in the HIV context. 
Finally, it is highly interesting that age did not associate with IMT in the HIV-free group. Our finding 
suggests that in the general population, modifiable risk factors such as LDL-cholesterol, hypertension 
and obesity are independent predictors of IMT. However, in our cohort, the HIV-infected participants 
appeared to be distinctly susceptible to the vascular wall thickening effects of increasing age.  
 
5.10 Independent associations with FMD%  
IMT associations with FMD% 
The current study found no significant association between IMT and FMD% in any of the study 
populations. This is in line with other studies which also included HIV-infected and HIV-free groups 
(Odueyungbo et al., 2009; Sharma, Gupta and Srivastava, 2018). However, there are studies which also 
demonstrated a significant inverse correlation between FMD% and IMT such as by Ghiadoni et al., 
2015. Interestingly, in the current study, there was a significant inverse correlation between carotid 
artery diameter and FMD% in all the study groups (refer to chapter 4, table 4.24). This is interesting 
and plausible as the brachial artery diameter is also inversely associated with FMD% (refer to chapter 
4, table 4.24, 4.27a & 4.27b). This finding suggests that the relative changes in the diameters of 
medium-sized arteries in the body, other than the brachial artery, may be inversely related to the FMD%.  
Brachial artery association with FMD% 
For independent associations with FMD% in the current study, all regression analyses were repeated 
with baseline brachial artery diameter adjustment. The confounding impact of brachial artery diameter 
with FMD% has often been debated. Baseline arterial diameter has been known to independently 
influence vasodilation, with small arteries dilating relatively more than the large arteries (Barac, Campia 
and Panza, 2007). Hence, studies recommend to adjust for the diameter in all statistical models 
(Longenecker and Hoit, 2012). However, statistically, it is also suggested that by adjusting for brachial 
artery diameter, it may be a covariate adjustment in the model as brachial artery diameter is already 
used to calculate FMD% (Thijssen et al., 2011). Hence in the current study, we explored both methods 
(inclusion and exclusion of brachial artery diameter in the model) to assess associations with FMD%. 
However, it is notable that independent associations even after adjusting for brachial artery, may 
demonstrate higher clinical relevance but further research is recommended to standardize 
methodologies.  





As with the IMT, the biomarkers of inflammation and endothelial dysfunction did not correlate with 
FMD% in any of the study groups (refer to chapter 4, table 4.25). Existing literature has demonstrated 
mixed results on the relationship between biomarkers of inflammation and endothelial function, and 
FMD. For instance, the relationship between CRP and FMD% in individuals appears to be 
controversial; two studies suggested that higher CRP was associated with impaired endothelial function 
in HIV (Ho et al., 2012; Grome et al., 2017), while other studies demonstrated no associations in HIV-
infected on ART populations (Nolan et al., 2003; Deanfield Muriel Caslake et al., 2005; Van Wijk et 
al., 2006; Mondy et al., 2008; Torriani et al., 2008). Overall, our findings agree with a few studies that 
also could not demonstrate correlations between FMD % and biomarkers such TNF-α, VEGF, VCAM-
1, ICAM-1, PAI-1, e-selectin, and p-selectin (Masiá et al., 2010; Dysangco et al., 2017; Grome et al., 
2017). Interestingly, these inflammatory molecules are known in the literature for their role in 
endothelial activation and endothelial dysfunction (discussed in detail in chapter 2), as well as in HIV-
infection, however, not many studies have demonstrated their relationship with endothelial dysfunction 
as measured by FMD%. It has been suggested that these markers, especially VCAM-1 and ICAM-1 are 
expressed on numerous cells apart from the endothelium, such as inflammatory leukocytes and smooth 
muscle cells, and therefore they may be imposing a stronger effect on systemic inflammation in HIV 
rather than in vascular inflammation (Blankenberg, Barbaux and Tiret, 2003; Masiá et al., 2010). 
Similarly, other markers such as PAI-1 are also expressed in adipocytes, platelets, and hepatocytes in 
addition to endothelial cells (Yasar Yildiz et al., 2014). Thus, a similar mechanism can be speculated 
to be at play in this regard (Masiá et al., 2010).  However, on the other hand, it is also possible that the 
variability in findings from different studies may be due the technique used to measure endothelial 
function as well as the current study’s limited sample size for biomarker analysis (as described earlier). 
HIV and ART related associations with FMD% 
In the total population, HIV infection status did not associate with FMD% (refer to chapter 4, table 
4.26a % 4.27a). Existing literature suggests that both HIV and ART are inversely associated with 
FMD%. For instance, a study demonstrated that untreated HIV is associated with endothelial 
dysfunction (Oliviero et al., 2009). Other cross-sectional studies, as well as a meta-analysis, reported 
that both HIV and ART are associated with decreased FMD% (Solages et al., 2006; Priscilla Y Hsue et 
al., 2009; Sun et al., 2015). Interestingly, in the current study’s HIV-infected group, ART demonstrated 
a significant positive association with FMD%, suggesting a more vasculo-protective role in HIV. 
Furthermore, viral load demonstrated a significant inverse association with FMD% (refer to chapter 
4, table 4.47a and 4.27b). It is notable that associations remained even after adjusting for brachial 
artery diameter.  Very few studies demonstrate this cardioprotective effect of ART on FMD% 
(Deanfield Muriel Caslake et al., 2005; Torriani et al., 2008), however, this could be attributed to the 
type of ART as well. For instance, ART from the PI class has shown an inverse association with FMD% 





known to be an independent predictor of FMD% in the HIV-context (Blum et al., 2005; Solages et al., 
2006; Oliviero et al., 2009; Ho et al., 2012; Torriani et al., 2008). This suggests that the virus itself may 
influence endothelial function while the ART may in fact provide some protection to the HIV-infected 
population not only from harmful effects of HIV but also from vascular dysfunction. 
Overall, our study confirms that in the HIV-context, ART is an independent predictor of endothelial 
function, where the virus (using viral load as a surrogate marker) is an independent predictor of 
endothelial dysfunction. 
Cardiovascular related associations with FMD% 
In the total population, female gender demonstrated a significant positive association with FMD% 
(refer to chapter 4, table 4.26a). It can be speculated that the finding is due to hormonal changes in 
female body. Literature suggests that hormonal changes related to the menstrual cycle may affect 
FMD% (Corretti et al., 2002; Charakida et al., 2010). Especially one of the main female hormones, 
estrogen, is known to enhance endothelial vasodilation (Arora et al., 1998). In the literature, it has been 
suggested that estrogen may be able to stimulate endothelial nitric oxide synthesis as well as release 
nitric oxide or prevent nitric oxide degradation due its antioxidant properties (Rainbow et al., 1980; 
Arora et al., 1998). However, in addition to female hormones, our finding is more likely due to the 
diameter of the female brachial artery in comparison to males. In the literature it is established that 
females generally have a smaller baseline brachial artery diameter than males (Pham, Kim et al., 2016, 
Kapuku, Treiber et al., 2004). Since brachial artery diameter has a significant inverse association with 
FMD%, this finding is plausible when brachial artery diameter is not adjusted for in the model. As 
expected, once brachial artery diameter was adjusted for, this finding was lost in the total population 
(refer to chapter 4, table 4.27a).  
Additionally, in the total population, high and normal systolic blood pressure, as well as waist 
circumference and urine albumin demonstrated significant inverse associations with FMD% (refer to 
chapter 4, table 4.26a). All these parameters have been associated with FMD% in the literature 
(Benjamin et al., 2004; Cohn et al., 2004; Williams et al., 2005; Juonala et al., 2006; Arkin et al., 2008; 
Yufu et al., 2009). Furthermore, literature suggests that microalbuminuria as expressed by albumin and 
creatine ratio (ACR) is associated with endothelial dysfunction. Studies have demonstrated inverse 
associations between, albumin, creatinine levels as well as ACR with FMD% (Gardin et al., 2008; 
Younis, Nafady and Mahmoud, 2011; Pirro et al., 2016). The mechanisms linking microalbuminuria to 
increased renal and cardiovascular risk are not fully understood, but it has been proposed that 
microalbuminuria is a reflection of generalized endothelial dysfunction (Ochodnicky et al., 2006). Thus, 
all mechanisms of endothelial dysfunction such as increased ROS, oxidative stress, inflammation and 
endothelial activation are implicated (Ochodnicky et al., 2006). It is interesting that in the current study, 





(refer to chapter 4, table 4.27a). However, in the HIV-free group, creatinine remained as an 
independent, inverse predictor of FMD% even after adjusting for brachial artery diameter, suggesting 
that creatinine is an independent predictor of impaired endothelial function (as measured by FMD%) in 
the HIV-free population. 
 
5.11 Summary of independent associations 
In summary no significant associations were found between biomarkers, IMT and FMD % in the PhD 












Chapter 6: Conclusion 
6.1 Introduction 
This chapter describes the conclusion with respect to the overall aims and objectives of the PhD study 
as well as a reflection of the advantages, shortcomings, and future directions of the study.  
 
6.2 Reflection of the PhD aims 
At present, CVD is one of the major causes of death in people living with HIV. The underlying 
pathophysiological origins of many types of CVD are endothelial dysfunction and atherosclerosis, 
which can both be measured by non-invasive methods such as FMD and carotid IMT measurements. 
Both atherosclerosis (especially subclinical atherosclerosis) and endothelial dysfunction can potentially 
be prevented, if detected early. Interestingly, in the HIV-context, both the HI virus and ART have been 
implicated in the development of endothelial dysfunction and atherosclerosis. Additionally, circulating 
biomarkers of inflammation, endothelial activation and dysfunction are known to be associated with 
endothelial dysfunction and atherosclerosis, which can be screened and measured to predict 
cardiovascular outcomes in the HIV-infected population. Furthermore, the interaction between 
traditional cardiovascular risk factors, HIV, ART and endothelial dysfunction and atherosclerosis is 
vastly complex, and not well researched in South African populations, particularly not in the Western 
Cape Province. Hence, the current study aimed to investigate the putative relationship between 
subclinical atherosclerosis, endothelial dysfunction, biomarkers of CVD, and HIV-infection in a South 
African population from the Western Cape Province. 
 
6.3 Final conclusion 
The current PhD study successfully addressed its overarching aim by conducting a clinical cross-
sectional study in the HIV-context as well as by conducting an exploratory longitudinal study to assess 
the 12-month temporal progression of selected CVD outcomes, including endothelial function and 
subclinical atherosclerosis, in a sub-group of HIV-free participants. 
The longitudinal study showed that measurements of visceral obesity, fasting blood glucose, and blood 
pressure, including the prevalence of hypertension, increased over the period of 12-months. None of 
the other risk factors, nor subclinical and endothelial function measurements showed any changes 
between the two time points of the study, suggesting that the 12-month follow up period may have been 
too short to observe differences in the cohort. 
Findings from the cross-sectional study showed a significantly lower prevalence of traditional 





infected population in comparison to HIV-free population. In contrast, other markers of cardiovascular 
risk and future CVD, such as anaemia, ACR, creatinine and GGT were significantly elevated in the 
HIV-infected group in comparison to HIV-free group. What is more, our study demonstrates key 
differences between HIV-infected without ART group in comparison to HIV-infected receiving ART 
group. For instance, viral load and VCAM-1 levels were significantly higher in the HIV-infected 
without ART group in comparison to HIV-infected receiving ART group. In contrast, CD4 count, total 
cholesterol, HDL, LDL, haemoglobin, GGT, creatinine levels were higher in the ART group in 
comparison to the without ART group. Collectively, these findings suggest a mixed cardiovascular risk 
profile in the HIV-infected participants of this cohort. Overall, although there were no differences in 
sub-clinical atherosclerosis and endothelial function between the two main study groups (HIV-infected 
vs HIV-free), endothelial function (as measured by FMD) was better and subclinical atherosclerosis 
(measured by IMT) reduced in the ART group in comparison to no ART group. The results demonstrate 
that, in the cohort of the current study, ART was associated with a more favourable cardiovascular risk 
profile, reduced subclinical atherosclerosis, and improved endothelial function.   
A key aim of the PhD study was to investigate the relationships between subclinical atherosclerosis and 
serum biomarkers of endothelial dysfunction and vascular inflammation in HIV-infected (with or 
without ART) and HIV-free participants. Interestingly, our study demonstrated no relationship between 
subclinical atherosclerosis and the serum biomarkers measured. Additionally, biomarkers showed no 
associations with endothelial function in this cohort. With regards to independent associations, the 
current study confirms that age, systolic hypertension, obesity, and LDL-cholesterol levels are 
independently associated with subclinical atherosclerosis in the total cohort, even after adjusting for 
HIV status. The study shows that age was the only factor that independently associated with subclinical 
atherosclerosis in the HIV-infected group, even after adjusting for ART. With regards to the FMD 
analyses, the study findings showed that, in the HIV-free context, creatinine is an independent predictor 
of impaired endothelial function, even after adjusting for brachial artery diameter. In the HIV-context, 
viral load was an independent, inverse predictor of endothelial function even after adjusting for brachial 
artery diameter, HIV and ART duration, suggesting that endothelial function was associated with viral 











In conclusion, our study demonstrates a more cardioprotective and immune-protective effect of ART in 
HIV-infection, while a relatively higher presence of cardiovascular risk parameters in the HIV-free 
population. It is important to note that our study comprised of more females than males and although, 
no significant differences were noted in gender between the HIV-infected and HIV-free groups of the 
cross-sectional study, several findings were only found in the female groups when gender analysis was 
conducted, suggesting that many of the findings may have been driven by the female participants rather 
than their male counterparts. Similarly, the longitudinal study also noted findings in females rather than 
males when gender analysis was conducted, further suggesting the relevance of the current study’s 
descriptive findings to the female population. 
 
6.4 Advantages, limitations, and future directions 
The study has several advantages. The total sample size in the cross-sectional study of n= 347, is higher 
than many studies in the literature such as Ross et al., 2009, exploring similar research questions. The 
current study further used two separate epidemiological methodologies in addressing its aims, namely 
cross-sectional and longitudinal approach. In addition, the study utilized, for the first time, two non-
invasive ultrasound-based vascular assessment methods (IMT and FMD) in identifying subclinical 
atherosclerosis and endothelial function in a Western Cape study population of people living with HIV. 
Additionally, the current study included both males and female adults from the Western Cape 
population of South Africa and to the best of our knowledge we are the first to report on endothelial 
function as measured by FMD% and subclinical atherosclerosis as measured by IMT, in a study 
population representative of the Western Cape’s largest demographic group.  
Furthermore, although it was concerning to report that not all HIV-infected individuals were receiving 
ART, we were able to include these individuals and conduct HIV subgroup analyses to compare the 
HIV-infected group receiving treatment with the HIV-infected group without treatment. This provided 
the present study with a unique opportunity to evaluate the role of ART in the HIV context.  
However, the current study also has some limitations. The lack of temporal changes in subclinical 
atherosclerosis, endothelial function, biomarkers and cardiovascular risk parameters in the longitudinal 
study suggests that the 12-month follow up period may not have been sufficient in the current setting, 
and thus a longer follow up period is recommended to evaluate the progression of these parameters in 
the general population. Furthermore, the current study did not include HIV-infected individuals in the 
longitudinal study, thus cause and effect conclusions cannot be made in the HIV context. The cross-
sectional study is also limited due its observational nature and can only address associations, not 
causality. Thus, longitudinal studies, of longer follow-up duration and including HIV-infected 





low with only n= 57, which may have influenced the statistical power and results. Thus, overall a larger 
sample size with a longer follow-up period is recommended.  
Additionally, in both the cross-sectional and the longitudinal study, it was difficult to recruit equal 
number of male and female participants. Although there was no significant difference in gender in the 
cross-sectional HIV-infected and HIV-free groups, and although all regression models were adjusted 
for gender, many of the findings found were seemingly driven by the female participants (as 
demonstrated in the gender analysis). Similarly, many of the longitudinal study findings were 
apparently driven more by the female gender. Thus ideally, it would be valuable to either include equal 
participants from each gender group or rather study the research question in male and female 
populations separately in order to make specific conclusions in each sub-population. The current study, 
however, benefited from our attempts to analyse gender differences in each finding even though it was 
not specified as one of the original aims of the PhD study.  
Furthermore, the method of measuring FMD% has been debated in the literature for its operator 
dependencies and lack of reproducibility. However, we did mitigate this risk to best of our ability by 
selecting only a few highly trained and experienced researchers (which included the author of this 
dissertation) to measure FMD%. Additionally, each operator was assigned specific tasks in the 
assessment which remained constant throughout the study. For quality control purposes, FMD results 
were also randomly selected and assessed by blinded experts. However, research on standardization in 
the FMD method is recommended. Similarly, with regards to the IMT measurement, standardization is 
required for the categorization of subclinical atherosclerosis and plaque. There are different cut off 
values present in the literature, thus standardization of these cut-offs in specific populations is 
warranted. Equally, endothelial dysfunction, measured by FMD% has not been defined clearly in 
clinical research. Literature largely evaluates relative FMD% measurements, thus clear standardization 
and definition are required to conclusively identify endothelial dysfunction. Finally, the current study 
measured common carotid IMT while many studies have also measured internal carotid IMT and 
bifurcation IMT. Thus, it would be valuable to measure IMT at different anatomical locations to 
conclusively identify subclinical atherosclerosis, and its associations with biomarkers and 
cardiovascular risk factors. 
With regards to the biomarker analysis, the current study’s biomarker analysis was based on a relatively 
small sample size as not all samples were included in the analysis due to budgetary restrictions, but 
rather chosen by randomization. This may have influenced the statistical power and results. 
Additionally, in the literature, several other biomarkers have been identified such as asymmetric 
dimethylarginine (ADMA), IL-6 and vWF (as described in chapter 2) for endothelial dysfunction and 
atherosclerosis. Thus, it is recommended to evaluate the relevance of these other biomarkers in the HIV-





consumption by evaluating cotinine.  All lifestyle related questions were self-reported, and the 
possibility of under-reporting of lifestyle parameters is possible. Thus, it is recommended, where 
possible lifestyle data needs to be validated clinically, for instance with the measurement of cotinine to 
validate smoking. Ultimately the current study did not predict cardiovascular risk in the participants 
using known prediction and scoring methods such as Framingham risk score. Future studies are 
warranted, considering the above limitations.  
 
6.5 Role of the PhD candidate in the current study 
The PhD candidate performed all the IMT, FMD and blood pressure measurements in the participants 
of the current study. The candidate underwent intense training in both the IMT and FMD techniques. 
Additionally, as an active member of the EndoAfrica research team, the candidate also assisted in 
general laboratory work for both the studies, which included receiving blood and urine samples from 
research nurses, preparing the samples for storage as well as delivering the samples to the NHLS for 
further analyses. Some of the qualitative data was also collected by the PhD candidate, which included 
conducting the health and demographic questionnaire interviews. With regards to biomarker analysis, 
the PhD candidate prepared all serum samples according to the requirements of the Luminex analyses 
and the Division of Molecular Biology and Human Genetics, University of Stellenbosch. Meetings were 
conducted with the Luminex technician to acquire knowledge of the multiplex system and the overall 
methodology used to analyze biomarkers. Additionally, the PhD candidate captured and verified all 
data collected for the current study. Furthermore, the PhD candidate performed all statistical analysis 
for the PhD after consultation with a professional biostatistician from the Biostatistics Unit (Faculty of 
Medicine and Health Sciences, Stellenbosch University). Several engagements were conducted with 
the biostatistician to ensure the validity of the statistics and accurate interpretation of all statistical 
models completed for the PhD. Finally, the PhD candidate presented data from the current study at 
several conferences and intends to complete 2 original manuscripts for publications.  
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Appendix B: Cross-sectional study: Gender analysis 
Differences between HIV-infected and HIV-free groups in male female groups 
separately 
Table B1: All study parameters compared between HIV-infected and HIV-free in the male population 
Variable HIV-free HIV-infected P value 
N 32 (33.3%) 64 (66.7%) - 
Flow-mediated dilatation 
(%) 
5.19 ± 3.46 5.98 ± 4.59 0.391 
Mean IMT (µm) 595.08 ± 105.14 648.88 ± 133.92 0.053 
BMI 20.15 (18.13- 27.73) 20.18 (18.10- 25.10) 0.542 
Waist circumference 83.00 (68.00- 99.50) 81.50 (72.25- 91.00) 0.966 
Waist to hip ratio 0.89 (0.85- 0.96) 0.93 (0.87- 0.98) 0.201 
Systolic Blood Pressure 
(mmHg) 126.00 (108.75- 137.50) 120.00 (108.25- 130.50) 
0.451 
Diastolic Blood pressure 
(mmHg) 84.50 (71.25- 96.00) 80.00 (73.25- 90.00) 
0.408 
Heart Rate (bpm) 64.85 (59.75- 77.75) 70.50 (64.00- 83.00) 0.125 
Total cholesterol 4.31 (3.77- 5.05) 4.32 (3.80- 5.01) 0.852 
High-Density Lipoprotein 
Cholesterol (HDL) (mmol/L) 1.32 (1.07- 2.01) 1.27 (0.99- 1.59) 
0.129 
Low-Density Lipoprotein 
Cholesterol (LDL) (mmol/L) 2.29 (1.86- 2.77) 2.37 (1.92- 3.01) 
0.547 
Fasting glucose (mmol/L) 4.60 (4.30- 5.20) 5.05 (4.63- 5.48) 0.061 
Serum creatinine (μmol/L) 77.00 (69.00- 81.75) 72.00 (65.50- 82.75) 0.310 
Baseline brachial artery 
diameter (mm) 
3.76 ± 0.63 3.88 ± 0.64 0.385 
Triglycerides 1.13 (0.74- 1.40) 1.26 (0.90- 1.73) 0.309 
Glycated Haemoglobin 
(HbA1c) % 5.40 (5.23- 5.68) 5.40 (5.13- 5.60) 
0.598 
C-reactive protein 3.50 (1.30- 9.10) 4.35 (1.68- 13.18) 0.318 
GGT (U/L) 32.00 (18.50- 96.50) a 56.00 (31.75- 102.75) a 0.012 
Urine albumin (mg/L) 11.25 (1.83- 37.78) 8.10 (3.68- 37.58) 0.724 
Albumin-to-creatinine ratio 0.68 (0.17- 2.08) 0.60 (0.40- 2.50) 0.581 
CD4 - 463.86 ± 195.47 - 







ICAM-1 (ng/ml) 399.37 (241.17- 611.98) 378.47 (230.78- 834.19) 0.728 
E-selectin (ng/ml) 32.40 (25.69- 51.87) 36.58 (23.47- 46.64) 0.841 
P-selectin (ng/ml) 30.55 (25.36- 50.39) 35.48 (26.55- 47.99) 0.980 





PAI-1 (ng/ml) 102.09 (78.66- 128.35) 80.19 (47.21- 99.62) 0.065 
Data presented as mean ± SD or median with 25th and 75th percentiles for interquartile range (for 
non-normally distributed data). Means with same superscript letter: differ significantly (p < 0.05). 
Table B2: All study parameters compared between HIV-infected and HIV-free in the female population 
Variable HIV-free HIV-infected P value 
N 111 (44.2%) 140 (55.8%) - 
Flow-mediated dilatation 
(%) 
7.18 ± 5.52 7.19 ± 6.00 0.992 
Mean IMT (µm) 641.30 ± 142.95 614.57 ± 134.28 0.129 
BMI 26.60 (21.40- 33.80) 22.98 (19.30- 28.48) 0.001 
Waist circumference 94.00 (80.00- 105.00) 84.00 (75.00- 94.00) 0.000 
Waist to hip ratio 0.89 (0.83- 0.94) 0.86 (0.83- 0.94) 0.254 
Systolic Blood Pressure 
(mmHg) 
125.00 (114.00- 139.00) 
a 
118.50 (109.25- 133.50) 
a 0.021 
Diastolic Blood pressure 
(mmHg) 86.67 (78.00- 96.00) 85.00 (77.00- 91.00) 
0.076 
Heart Rate (bpm) 70.00 (61.00- 77.00) 71.00 (65.00- 80.00) 0.098 
Total cholesterol 4.30 (3.80- 4.88) 4.41 (3.87- 5.08) 0.388 
High-Density Lipoprotein 
Cholesterol (HDL) (mmol/L) 1.32 (1.10- 1.52) b 1.49 (1.13- 1.86) b 
0.007 
Low-Density Lipoprotein 
Cholesterol (LDL) (mmol/L) 2.46 (1.91- 3.04) 2.33 (1.80- 2.91) 
0.134 
Fasting glucose (mmol/L) 4.60 (4.20- 5.00) 4.70 (4.30- 5.10) 0.178 
Serum creatinine (μmol/L) 58.00 (52.00- 65.00) 57.00 (50.00- 63.00)  
Baseline brachial artery 
diameter (mm) 
3.25 ± 0.55 3.18 ± 0.47 0.283 
Triglycerides 0.93 (0.71- 1.33) 0.94 (0.76- 1.24) 0.950 
Glycated Haemoglobin 
(HbA1c) % 5.40 (5.00- 5.60) c 5.20 (4.90- 5.40) c 
0.004 
C-reactive protein 5.25 (1.93- 8.98) 5.00 (1.58- 11.50) 0.665 
GGT (U/L) 25.00 (17.00- 36.00) d 39.00 (27.00- 67.75) d 0.000 
Urine albumin (mg/L) 8.40 (3.28- 19.13) 9.50 (4.70- 30.80) 0.065 
Albumin-to-creatinine ratio 0.70 (0.40- 1.43) e 0.90 (0.50- 2.35) e 0.020 
CD4 - 529.95 ± 254.93 - 
Tnf-α (pg/ml) 22.25 (19.43- 27.57) 20.85 (17.67- 24.79) 0.130 
VCAM-1 (ng/ml) 





ICAM-1 (ng/ml) 363.48 (221.32- 635.43) 297.74 (163.69- 442.78) 0.118 
E-selectin (ng/ml) 34.15 (28.12- 43.94) 32.31 (25.12- 43.65) 0.436 
P-selectin (ng/ml) 36.60 (27.45- 40.18) 31.99 (23.64- 39.92) 0.178 





PAI-1 (ng/ml) 97.09 (78.14- 120.70) 78.73 (62.50- 115.50) 0.115 
Data presented as mean ± SD or median with 25th and 75th percentiles for interquartile range (for 





























Differences between male and female groups were analyzed in HIV-infected 
and HIV-free groups separately 
Table B3: All study parameters compared between male and female groups in the HIV-free population 
Variable Male Female P value 
N 32 (22.4%) 111 (77.6%) - 
Flow-mediated dilatation 
(%) 
5.19 ± 3.46 7.18 ± 5.52 0.055 
Mean IMT (µm) 595.08 ± 105.14 641.30 ± 142.95 0.096 
BMI 20.15 (18.13- 27.73) a 26.60 (21.40- 33.80) a 0.000 
Waist circumference 83.00 (68.00- 99.50) b 94.00 (80.00- 105.00) b 0.006 
Waist to hip ratio 0.89 (0.85- 0.96) 0.89 (0.83- 0.94) 0.304 
Systolic Blood Pressure 
(mmHg) 126.00 (108.75- 137.50) 125.00 (114.00- 139.00) 
0.550 
Diastolic Blood pressure 
(mmHg) 84.50 (71.25- 96.00) 86.67 (78.00- 96.00) 
0.301 
Heart Rate (bpm) 64.85 (59.75- 77.75) 70.00 (61.00- 77.00) 0.377 
Total cholesterol 4.31 (3.77- 5.05) 4.30 (3.80- 4.88) 0.618 
High-Density Lipoprotein 
Cholesterol (HDL) (mmol/L) 1.32 (1.07- 2.01) 1.32 (1.10- 1.52) 
0.259 
Low-Density Lipoprotein 
Cholesterol (LDL) (mmol/L) 2.29 (1.86- 2.77) 2.46 (1.91- 3.04) 
0.310 
Fasting glucose (mmol/L) 4.60 (4.30- 5.20) 4.60 (4.20- 5.00) 0.381 
Serum creatinine (μmol/L) 77.00 (69.00- 81.75) 58.00 (52.00- 65.00)  
Baseline brachial artery 
diameter (mm) 
3.76 ± 0.63 c 3.25 ± 0.55 c 0.000 
Triglycerides 1.13 (0.74- 1.40) 0.93 (0.71- 1.33) 0.347 
Glycated Haemoglobin 
(HbA1c) % 5.40 (5.23- 5.68) 5.40 (5.00- 5.60) 
0.322 
C-reactive protein 3.50 (1.30- 9.10) 5.25 (1.93- 8.98) 0.475 
GGT (U/L) 32.00 (18.50- 96.50) 25.00 (17.00- 36.00) 0.010 
Urine albumin (mg/L) 11.25 (1.83- 37.78) 8.40 (3.28- 19.13) 0.707 
Albumin-to-creatinine ratio 0.68 (0.17- 2.08) 0.70 (0.40- 1.43) 0.883 
CD4 - - - 
Tnf-α (pg/ml) 22.28 (20.04- 24.20) 22.25 (19.43- 27.57) 0.982 
VCAM-1 (ng/ml) 
688.53 (580.04- 
1253.60) 754.13 (546.42- 964.16) 
0.799 
ICAM-1 (ng/ml) 399.37 (241.17- 611.98) 363.48 (221.32- 635.43) 0.751 
E-selectin (ng/ml) 32.40 (25.69- 51.87) 34.15 (28.12- 43.94) 0.834 
P-selectin (ng/ml) 30.55 (25.36- 50.39) 36.60 (27.45- 40.18) 0.974 
VEGF (pg/ml) 79.21 (37.36- 135.34) 99.64 (70.29- 142.58) 0.298 





Data presented as mean ± SD or median with 25th and 75th percentiles for interquartile range (for 

































Table B4: All study parameters compared between male and female groups in the HIV-infected 
population 
Variable Male Female P value 
N 64 (31.4%) 140 (68.6%) - 
Flow-mediated dilatation 
(%) 
5.98 ± 4.59 7.19 ± 6.00 0.155 
Mean IMT (µm) 648.88 ± 133.92 614.57 ± 134.28 0.092 
BMI 20.18 (18.10- 25.10) a 22.98 (19.30- 28.48) a 0.004 
Waist circumference 81.50 (72.25- 91.00) 84.00 (75.00- 94.00) 0.120 
Waist to hip ratio 0.93 (0.87- 0.98) b 0.86 (0.83- 0.94) b 0.000 
Systolic Blood Pressure 
(mmHg) 120.00 (108.25- 130.50) 118.50 (109.25- 133.50) 
0.987 
Diastolic Blood pressure 
(mmHg) 80.00 (73.25- 90.00) 85.00 (77.00- 91.00) 
0.067 
Heart Rate (bpm) 70.50 (64.00- 83.00) 71.00 (65.00- 80.00) 0.863 
Total cholesterol 4.32 (3.80- 5.01) 4.41 (3.87- 5.08) 0.857 
High-Density Lipoprotein 
Cholesterol (HDL) (mmol/L) 1.27 (0.99- 1.59) c 1.49 (1.13- 1.86) c 
0.009 
Low-Density Lipoprotein 
Cholesterol (LDL) (mmol/L) 2.37 (1.92- 3.01) 2.33 (1.80- 2.91) 
0.361 
Fasting glucose (mmol/L) 5.05 (4.63- 5.48) d 4.70 (4.30- 5.10) d 0.002 
Serum creatinine (μmol/L) 72.00 (65.50- 82.75) 57.00 (50.00- 63.00)  
Baseline brachial artery 
diameter (mm) 
3.88 ± 0.64 e 3.18 ± 0.47 e 0.000 
Triglycerides 1.26 (0.90- 1.73) f 0.94 (0.76- 1.24) f 0.003 
Glycated Haemoglobin 
(HbA1c) % 5.40 (5.13- 5.60) g 5.20 (4.90- 5.40) g 
0.000 
C-reactive protein 4.35 (1.68- 13.18) 5.00 (1.58- 11.50) 0.807 
GGT (U/L) 56.00 (31.75- 102.75) h 39.00 (27.00- 67.75) h 0.004 
Urine albumin (mg/L) 8.10 (3.68- 37.58) 9.50 (4.70- 30.80) 0.546 
Albumin-to-creatinine ratio 0.60 (0.40- 2.50) 0.90 (0.50- 2.35) 0.158 
CD4 463.86 ± 195.47 529.95 ± 254.93 0.070 







ICAM-1 (ng/ml) 378.47 (230.78- 834.19) 297.74 (163.69- 442.78) 0.174 
E-selectin (ng/ml) 36.58 (23.47- 46.64) 32.31 (25.12- 43.65) 0.555 
P-selectin (ng/ml) 35.48 (26.55- 47.99) 31.99 (23.64- 39.92) 0.145 
VEGF (pg/ml) 71.07 (41.22- 163.55) 77.99 (53.23- 146.05) 0.675 
PAI-1 (ng/ml) 80.19 (47.21- 99.62) 78.73 (62.50- 115.50) 0.295 
Data presented as mean ± SD or median with 25th and 75th percentiles for interquartile range (for 





Appendix C: Longitudinal sub-study: male and female population analysis 
Table C1: Differences in all study parameter measurements between baseline and 12-month follow 
up in the male population 
Variable 
Baseline  
(time point 1) 
12-month follow 
up 
(time point 2) 
N 
Difference 
(Time point 1- 




(%) 2.24 ± 5.10 3.96 ± 3.95 
7 -1.72 0.595 
Mean IMT (µm) 668.50 ± 114.88 525.43 ± 240.64 7 143.07 0.212 
BMI 21.51 ± 6.09 23.06 ± 7.03 7 -1.54 0.160 
Waist circumference 75.00 ± 13.18 77.14 ± 17.16 7 -2.14 0.332 
Waist to hip ratio 0.85 ± 0.09 0.85 ± 0.08 7 0 0.821 
Systolic Blood Pressure 
(mmHg) 129.29 ± 16.12 140.43 ± 17.32 
7 -11.14 0.064 
Diastolic Blood pressure 
(mmHg) 88.57 ± 11.00 93.14 ± 8.69 
7 -4.57 0.219 
Total cholesterol 4.20 ± 0.67 4.27 ± 1.00 7 -0.07 0.749 
High-Density Lipoprotein 
Cholesterol (HDL) 
(mmol/L) 1.50 ± 0.41 1.55 ± 0.70 
7 -0.05 0.741 
Low-Density Lipoprotein 
Cholesterol (LDL) (mmol/L) 2.20 ± 0.61 2.21 ± 0.77 
7 -0.01 0.946 
Fasting glucose (mmol/L) 5.20 (4.40- 6.00) 4.60 (4.30- 5.20) 7 -1.99 0.046 
Serum creatinine (μmol/L) 83.86 ± 14.23 83.43 ± 18.14  0.43 0.922 
Baseline brachial artery 
diameter (mm) 4.03 ± 0.69 3.85 ± 0.64 
 0.18 0.460 
Triglycerides 0.74 (0.59- 1.96) 1.14 (0.68- 1.33) 7 -0.85 0.398 
Glycated Haemoglobin 
(HbA1c) 5.47 ± 0.34 5.61 ± 0.25 






0 -0.51 0.612 
GGT (U/L)   0 -1.52 0.128 





7 -1.35 0.176 
Albumin-to-creatinine 
ratio 0.50 (0.30- 0.80) 1.30 (0.40- 6.80) 














































3 -0.54 0.593 
Data presented as mean ± SD or n (% of group) or median with 25th and 75th percentiles for 
interquartile range (for non-normally distributed data). n, number of participants; SD, standard 





























Table C2: Differences in all study parameter measurements between baseline and 12-month follow 
up in the female population 
Variable 
Baseline  
(time point 1) 
12-month follow 
up 
(time point 2) 
N 
Difference 
(Time point 1- 




(%) 6.22 ± 4.37 7.05 ± 6.40 
47 -0.64  0.463  
Mean IMT (µm) 648.66 ± 126.90 655.53 ± 153.18 49 -6.87  0.717  
BMI 29.28 ± 8.06 29.28 ± 7.86 49  0.01  0.974  
Waist circumference 92.02 ± 16.32 93.74 ± 16.64 49 -1.72  0.053  
Waist to hip ratio 0.88 ± 0.09 0.88 ± 0.09 49  0.01  0.325  
Systolic Blood Pressure 
(mmHg) 125.52 ± 20.34 131.12 ± 21.71 
49 -5.60  0.013  
Diastolic Blood pressure 
(mmHg) 84.09 ± 11.83 88.66 ± 14.12 
49 -4.57  0.002  
Total cholesterol 4.34 ± 0.70 4.30 ± 0.88 49  0.04  0.573  
High-Density Lipoprotein 
Cholesterol (HDL) 
(mmol/L) 1.36 ± 0.28 1.32 ± 0.28 
49  0.03  0.204  
Low-Density Lipoprotein 
Cholesterol (LDL) (mmol/L) 2.46 ± 0.69 2.47 ± 0.82 
48  0.02  0.726  
Fasting glucose (mmol/L) 4.85 (4.30- 5.60) 4.65 (4.30- 5.10) 49 -1.73  0.084  
Serum creatinine (μmol/L) 61.16 ± 12.66 60.16 ± 13.38 49  1.00  0.348  
Baseline brachial artery 
diameter (mm) 3.33 ± 0.55 3.34 ± 0.63 
48 -0.02  0.747  
Triglycerides 1.00 (0.67- 1.41) 1.04 (0.74- 1.45) 50 -0.15  0.882  
Glycated Haemoglobin 
(HbA1c) 5.55 ± 1.22 5.58 ± 1.04 
50 -1.50  0.133  
C-reactive protein 
5.10 (1.25- 
10.20) 2.80 (0.80- 9.40) 






0 -1.31  0.189  





50 -0.40  0.692  
Albumin-to-creatinine 
ratio 0.60 (0.31- 1.33) 0.60 (0.38- 1.03) 














































33 -0.25  0.802  
Data presented as mean ± SD or n (% of group) or median with 25th and 75th percentiles for 
interquartile range (for non-normally distributed data). n, number of participants; SD, standard 
deviation. a Negative difference indicates an increase in the variable at 12-month follow-up. 
 
Table C3: Cross tabulation of BMI categories using McNemar-Bowker Test 
 BMI categories Time point 2 Total 







Time point 1 
Underweight  4 2 0 0 6 
Normal weight 0 14 3 0 17 
Overweight 0 1 10 2 13 
Obesity 0 0 1 20 21 
Total 4 17 14 22 57 
p value= 0.343. 
 
Table C4: Cross tabulation of Waist to hip ratio (WHR) categories using McNemar-Bowker Test 
 WHR categories Time point 2 Total 
Low Moderate High 
WHR categories 
Time point 1 
Low 13 0 0 13 
Moderate 3 6 5 14 
High 1 7 22 30 
Total 17 13 27 57 
p value= 0.228 
 
Table C5: Cross tabulation of systolic blood pressure categories using McNemar-Bowker Test 
 SBP categories Time point 2 Total 
low normal elevated high 
SBP categories 
Time point 1 
low 13 6 7 3 29 
normal 3 2 3 1 9 
elevated 0 2 1 1 4 
high 0 2 2 11 15 







Table C6: Cross tabulation of diastolic blood pressure categories using McNemar-Bowker Test 
 DBP categories Time point 2 Total 
low normal elevated high 
DBP categories 
Time point 1 
 
low 11 2 2 5 20 
normal 3 3 2 4 12 
elevated 0 2 1 6 9 
high 0 0 4 12 16 






Appendix D: Effect size categories 
Table D1: Effect size categories 
ANALYSIS EFFECT SIZE SMALL MEDIUM LARGE 
Chi-Square Independence 
Test 





0.1 0.29 0.45 
Chi-Square Independence 
Test 
Cramér's V - - - 
Chi-Square Goodness-of-
Fit Test 
Cohen's W 0.1 0.3 0.5 
Independent Samples T-
Test 
Cohen's D 0.2 0.5 0.8 
Independent Samples T-
Test 
Rpb - Point-Biserial 
Correlation 
0.1 0.24 0.37 
Paired Samples T-Test Cohen's D 0.2 0.5 0.8 
One-Sample T-Test Cohen's D 0.2 0.5 0.8 
Pearson Correlation R - Correlation 0.1 0.3 0.5 
ANOVA ω² - Omega 
Squared 
0.01 0.06 0.14 
ANOVA η² - (Partial) Eta 
Squared 
0.01 0.06 0.14 
ANOVA Cohen's F 0.1 0.25 0.4 
Linear Regression - Entire 
Model 
Model R² - R 
Squared 
0.02 0.13 0.26 
Linear Regression - Entire 
Model 
Model F² - F 
Squared 
0.02 0.15 0.35 
Linear Regression - 
Individual Predictor 




0.02 0.13 0.26 
Linear Regression - 
Individual Predictor 
Predictor F² - F 
Squared 
0.02 0.15 0.35 






Appendix E: New IMT cut off  
Table E1: Carotid IMT and subclinical atherosclerosis measurements of the total, HIV-free and HIV-
infected study groups with new cut off values 








Mean IMT (µm)  627.74 ± 135.37 631.21 ± 136.61 625.33 ± 134.79 0.69 
IMT categories    0.98 
Subclinical 
atherosclerosis a (> 
780 µm), n (%) 
33 (9.5%) 14 (9.8%) 19 (9.3%)  
Plaque b (> 1000 µm), 
n (%) 
7 (2.0%) 3 (2.1%) 4 (2%)  
Data presented as mean ± SD or n (% of group). n, number of participants; SD, standard deviation. 
Means or medians with same superscript letter: differ significantly (p < 0.05).  a Subclinical 
atherosclerosis cut off was based on guidelines by Ssinabulya et al., 2014; Sarfo et al., 2019; Schoffelen 
et al., 2015; de Groot et al., 2004 b Plaque was defined as an average IMT of more than 1000 µm, as 
suggested by Roozen et al., 2020. 
 
Table E2: Carotid IMT and subclinical atherosclerosis measurements of the HIV/ no ART and HIV with 
ART study groups with new cut off values  
Variable HIV-infected/ no ART 
 




Mean IMT (µm)  530.33 ± 92.79 a 633.24 ± 135.17 a 0.004 
IMT categories   0.33 
Subclinical atherosclerosis b (> 780 
µm), n (%) 
0 (0%) 19 (10.1%)  
Plaque c (> 1000 µm), n (%) 0 (0%) 4 (2.1%)  
Data presented as mean ± SD or n (% of group). n, number of participants; SD, standard deviation. 
Means or medians with same superscript letter: differ significantly (p < 0.05).  b Subclinical 
atherosclerosis cut off was based on guidelines by Ssinabulya et al., 2014; Sarfo et al., 2019; Schoffelen 
et al., 2015; de Groot et al., 2004. c Plaque was defined as an average IMT of more than 1000 µm, as 
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